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MicroRNAs are short non-coding RNAs that regulate gene expression at the post-
transcriptional level. Studies in mouse embryonic stem cells (mESCs) where 
DGCR8; a major protein involved in their biogenesis has been knocked out, have 
shown that the global loss of canonical miRNAs results in cell cycle defects, 
delayed and reduced expression of markers of differentiation, and an inability to 
downregulate pluripotency markers upon differentiation. By conducting a 2D-
DIGE study, comparing protein expression in wild type and DGCR8-/- mESCs, the 
aim was to study the effects that the loss of DGCR8 has on the proteome of 
mESCs when grown under proliferative conditions. The loss of DGCR8 in mESCs 
resulted in the deregulation of proteins with a chaperone function and those 
involved in glucose metabolism. Notably enzymes involved in glycolysis were 
reduced, whereas those involved in the TCA cycle were upregulated compared to 
wild type cells. mESCs are known to be highly glycolytic and the form of glucose 
metabolism used by cells has been linked to their capacity to differentiate. A 
second DIGE study was carried out on DGCR8-/- mESCs individually transfected 
with Embryonic Stem Cell Cycle specific (ESCC) miRNAs, to establish novel 
targets of these miRNAs and study their effect on the proteome. The study 
revealed that the ESCC miRNAs influence the expression of glucose metabolism 
proteins, notably Aldolase A, a key enzyme for glycolysis was identified in both 
studies as being an indirect target of the ESCC miRNAs.  High resolution nuclear 
magnetic resonance spectroscopy further revealed differences in metabolism 
between the DGCR8-/- mESCs transfected with the ESCC miRNAs and those 
transfected with a control miRNA, indicative of a switch from predominantly 
glucose metabolism in the wild type mESCs to glutaminolysis for energy 
generation in the DGCR8-/-.  Therefore the same miRNAs that control the 
embryonic stem cell cycle, also play a major role in the metabolic status of these 
cells, which may in turn play a role in the controlling the balance between 
pluripotency and differentiation. At the time of writing this is the first study 
using proteomic techniques to compare DGCR8-/- and wild type mESCs, and to 





In 2000, when the human genome was successfully decoded it was discovered 
that approximately 98% did not code for proteins (1).  One class of ncRNA that 
has been found to play an essential role for life are microRNAs (miRNAs), short 
non-coding RNAs that regulate gene expression at the post-transcriptional level.  
miRNAs have been found to influence the expression of approximately 60% of 
human protein coding genes (2) emphasizing their important role in gene 
regulation.  The loss of miRNAs in a range of cell types, has revealed their diverse 
functions including regulating the cell cycle (3), cell proliferation (4) and cellular 
stress responses (5).  
 
Embryonic stem cells (ESCs) have the unique property, of being able to 
differentiate into any embryonically derived cell type and can self renew, 
‘indefinitely’ in vitro.  Therefore, stem cell gene expression is tightly regulated to 
keep them eternally poised between pluripotency and differentiation, in 
response to external cues.  Their unique phenotype has made them an important 
resource for the study of early development and for regenerative medicine.  
Thus, it is essential that the regulation of pluripotency and differentiation in 
stem cells is thoroughly understood.  Studies have revealed that miRNAs play an 
essential role in controlling the stem cell phenotype. 
 
The importance of miRNAs in stem cells has been revealed in studies where their 
biogenesis has been impaired, resulting in the global loss of miRNAs (6,7).  
Although miRNAs affect protein expression, many studies instead focus on the 
effects of miRNAs on mRNA expression (8). 
 
5.1. Cell potency 
 
Pluripotent stem cells are defined as ‘cells with the potential to differentiate into 
any of the three germ layers; endoderm, mesoderm or ectoderm’ (9).  Three 
major types of pluripotent stem cells have been identified in fetal tissues; 
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embryonic stem cells (10), embryonal carcinoma cells (ECC) (11) and embryonic 
germ cells (EGC) (12) which share the properties of self renewal and the ability 
to differentiate into any embryonically derived cell, as well as the ability to form 
teratomas when injected in vivo (9). 
 
ECCs are derived from teratocarcinomas, which imbues them with malignant 
properties (13), therefore although they provide an excellent model of early 
development and differentiation, they are unsuitable for clinical purposes.  EGCs 
are derived from fetal gonads and eventually give rise to the gametes (14).  This 
means that of the three major types of pluripotent cells that can be directly 
derived from in vitro sources, ESCs are the most suited for regenerative 
medicine. 
 
Cells derived from earlier stages of blastocyst development than pluripotent 
cells, such as the 2-cell or 4-cell stage have the potential to develop into a total 
embryo/ whole organism and are termed totipotent (9). Cells derived from later 
stages of development, which have a more limited capacity for differentiation 
such as mesenchymal stem cells which can differentiate into osteoblasts or 
adipocytes amongst other cells, that can further develop into other cell types are 
termed multipotent. 
 
These unique properties of pluripotent stem cells have made them an important 
resource for the development of regenerative medicine, as well as a simplified 
way of studying early development and disease progression. 
 
By forcing the expression of certain pluripotency genes (15), miRNAs (16) or 
adding specific chemical cocktails to the differentiated cells (17) induced 
pluripotent stem cells (iPSCs) have also been created from mature cell types. 
iPSCs share the two unique properties of ESCs, of long term self renewal and 
pluripotency, however both human and mouse iPSCs do differ from ESCs in some 
respects. For example, particular iPSC lines display an ‘epigenetic fingerprint’, 
that is more similar to their cells of origin than ESCs and also display 
differentiation defects (18,19).  It should be noted that certain differences 
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observed between ESCs and iPSCs have been attributed to variations in genetic 
background or viral gene insertions (19). By conducting experiments on mESCs 
and iPSCs with the same genetic background, the maternally imprinted gene 
cluster; Dlk1-Dio3 was discovered to be repressed in the iPSCs, but not in the 
mESCs, this was also accompanied by differential expression of approximately 
50 miRNAs, resulting in an inability of iPSCs injected into 4n blast cysts to 
develop into successful embryos (19). 
 
5.2. Unique properties of ESCs 
 
ESCs are derived from the inner cell mass of blastocysts and have two unique 
properties; they are capable of long term self-renewal though the longer they are 
kept in culture, the more likely they are to acquire mutations (20) and they can 
remain pluripotent in vitro under defined conditions.  This unique phenotype is 
controlled by intrinsic factors regulated by extrinsic signals. The extrinsic signals 
primarily consisting of signals from neighbouring cells and the matrix that the 
cells are grown on, whereas the intrinsic factors include gene expression that is 
regulated at the transcriptional, translational, post-translational and epigenetic 
levels (21). Although hampered by ethical issues and the difficulties in 
controlling stem cell fate are yet to be completely overcome, embryonic stem cell 
research is one of the major forces driving the field of regenerative medicine 
forward and provides great insight into gene expression patterns and cellular 
behaviour both during proliferative and differentiation phases of cells. 
 
The ability to self renew ‘indefinitely’, is in part due to the prolonged expression 
of the telomerase enzyme, which maintains the lengths of their telomeres over 
successive cell divisions (22). When differentiation occurs, the expression of 
telomerase and its associated enzymes rapidly declines, so that more mature 
cells have a limited number of cell divisions and eventually succumb to 
senescence (22).  
 
Besides pluripotency and the ability to self renew, ESCs also have a very rapid 
proliferation rate, which is comparable to some cancer cell types (23) and 
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significantly faster compared to somatic cells (24).  This is due to the ESC cell 
cycle; ESCs have a persistently high activity of the cell cycle regulators cyclin 
dependent protein kinase 2 (Cdk2) and cyclin A and E, which are known to drive 
the G1 to S phase transition (23) (Figure 1). Cdk2 has also been proposed to 
drive the G2 to M phase transition in a human cancer cell line and Xenopus cells 
(25), therefore its high expression may account for both of the very short G 
phases in ESCs. Unsurprisingly, this means that at any one time, a high 
proportion of ESCs within a population is in the S-phase or M phase (23).  In 
stark contrast, the cyclin A and E proteins in differentiated cells are more tightly 
regulated and expressed at specific times during the cell cycle (23).  One possible 
reason for this unusual cell cycle is to prevent an accumulation of differentiation 
signals, until they reach a threshold level that triggers the transition from self-











Figure 1 – Embryonic stem cell cycle.  High expression of Cdk and Cyclin A/E promotes a rapid G1/S 
phase transition. 
 
In order to maintain this rapid rate of proliferation, ESCs mostly harness energy 
from aerobic glycolysis, as opposed to differentiated tissues, which derive the 
majority of their energy from oxidative phosphorylation or anaerobic glycolysis 
(28).  Although, aerobic or anaerobic glycolysis results in the formation of less 
ATPs per molecule of glucose and a higher amount lactate, aerobic glycolysis 
provides energy much more promptly than oxidative phosphorylation as it 
















Figure 2 – Schematic representation of glucose metabolism in embryonic stem and differentiated 
cells.  ESCs predominantly use the more rapid aerobic glycolysis in the cytosol for the generation of 2 
molecules of ATP and a high concentration of the waste product lactate, as opposed to differentiated 
tissues which use either oxidative phosphorylation (mitochondria) or anaerobic glycolysis (cytosol), 
which generate 36 molecules and 2 molecules of ATP, respectively.  
 
It has been suggested that as ESC proliferation is not limited by nutrients, under 
standard in vitro/vivo conditions, there has been no selective pressure to 
optimise for more efficient ATP production and that using glycolysis may have a 
protective effect on the cells, as a by-product of oxidative phosphorylation is 
increased ROS generation (28).  
 
Recently it has been shown that the primary form of metabolism used by cells 
may control the balance between pluripotency and differentiation (29,30).  
 
5.3. Mouse embryonic stem cells 
 
Mouse ESC (mESC) lines were initially first propagated in the early 1980s, either 
on mitotically inactivated mouse embryonic fibroblast (MEF) feeder layers (31) 
or in the conditioned media of ECCs (32), which led researchers to believe that 
the MEF/ECCs were secreting a substance into the medium that was aiding the 
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mESCs in maintaining pluripotency.  It was later discovered that this ‘substance’ 
was the cytokine myeloid Leukaemia Inhibitory Factor (LIF), a molecule which 
induces differentiation in M1 myeloid leukemic cells (33). The opposing effects 
of LIF on mESCs and M1 cells, is thought to be due to LIF stimulating different 
intracellular pathways in the two cell types (34). 
 
LIF is an interleukin 6 (IL6) class cytokine that promotes the pluripotent state of 
mESCs by binding a receptor complex consisting of gp130 and the low affinity 
LIF receptor, resulting in the activation of the JAK/STAT3 pathway and the 
binding of STAT3 as well as other transcription factors such as Tcf3 and Klf2 to 
the enhancer region of the Oct4 gene (35), STAT3 activation also inhibits 
differentiation towards the mesoderm/endoderm lineage (36) (Figure 3). This is 
particularly important, as Oct4 along with Nanog and Sox2 have been classed as 
pluripotent genes.  They are highly expressed in mESCs and upon their 
downregulation, differentiation ensues (37).  Interestingly, studies have shown 
that the activation of STAT3 is critical for mESC pluripotency (34).  LIF has also 
been shown to aid in the maintenance of the characteristic cell cycle of mESCs, by 










Figure 3 – Maintenance of the pluripotent state in mESCs.  The binding of LIF to the LIF receptor 
(LIFR) results in the activation of the JAK/STAT3 pathway, subsequently the three pluripotency 
markers; Oct4, Nanog and Sox2 are activated, and differentiation is blocked.  Adapted from: (36) 
 
Although LIF is widely used in mESC culture to maintain an undifferentiated 
state, studies have shown that other members of the IL6 class of cytokines can 
also bind to the receptor complex and maintain pluripotency (34). However, as 
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LIF is highly expressed by the trophoectoderm in vivo and acts upon high affinity 
receptors in the inner cell mass (ICM) to maintain pluripotency, it best 
recapitulates the in vivo state.  More recently, studies have found that LIF is 
dispensable for mESC pluripotency in vitro if it is replaced by a cocktail of 
enzyme inhibitors, which block pro-differentiative signalling such as the Map 
kinase pathway, indicating that the JAK/STAT3 pathway is not the only pro-
pluripotency pathway in mESCs (38). Notably, when LIF is added to the cocktail 
of enzyme inhibitors, pluripotency is sustained for a longer period establishing 
its important role in the maintenance of pluripotency (38).  
 
5.4. Transcription factors that regulate pluripotency 
 
Oct4, Sox2 and Nanog are three highly expressed and conserved genes that 
imbue ESCs with the key property of pluripotency. Interestingly, in the 
developing blastocyst, to maintain the embryonic phenotype, pluripotent cells 
have to express Oct4 and Nanog, though not Sox2, which is thought, be due to 
presence of stable maternally derived Sox2 protein (38). 
5.4.1. Oct4 
 
Oct4 (octamer binding transcription factor 4) also known as POU5F1 is a highly 
conserved gene that is expressed during embryonic development in the epiblast 
and in ESCs, in vitro. The downregulation of Oct4 expression results in 
differentiation, therefore it is an important regulatory transcription factor 
involved in the maintenance of pluripotency (37). This is supported by the 
inability of Oct4 null embryos to outgrow in culture and their embryonic lethal 
phenotype (39), as well as the role of Oct4 (as one of the Yamanaka factors) in 
generating iPSCs (40,41). Forced Oct4 expression accompanied by a cocktail of 
chemical inhibitors in more mature cell types such as keratinocytes and fetal 
neural stem cells, has been found to be sufficient for the reprogramming process, 
albeit at a low efficiency, highlighting the role of Oct4 as a master controller of 




Notably, of the four Yamanaka factors; Oct4, Sox2, Klf4 ad c-Myc, (43), Oct4 is the 
only factor which is absolutely crucial for iPSC formation, as the other factors can 
be substituted with homologous transcription factors (44). In order for mESCs to 
remain pluripotent, the level of Oct4 expression in mESCs is maintained within a 
threshold. Levels of expression either 50% below or above normal diploid levels 
result in differentiation either to the extra-embryonic endoderm and mesoderm 
lineages or trophoblast lineages, respectively (45). Notably, Oct4 over- or 
underexpression in ESCs directly represses the expression of transcription 
factors such as Rex1, which are associated with pluripotency, however when 
Oct4 is expressed within threshold levels, it activates Rex1 expression (46). 
Therefore Oct4 expression levels are tightly regulated in ESCs.  This is at least 
partially controlled via an autoregulatory mechanism, however levels of 
expression are also controlled by the other ‘pluripotency’ genes, Nanog and Sox2 
(47) (Figure 3) and other modulators such as miRNAs (48), in response to 
extrinsic signals.   
5.4.2. Sox2 
 
Similar to Oct4 null embryos, Sox2 null embryos are embryonic lethal (39) and 
knocking out Sox2 results in the loss of pluripotency in ESCs and differentiation 
towards the trophoectoderm lineage (49).  Contrastingly, excessively high levels 
of Sox2 expression have been shown to promote differentiation towards the 
ectoderm and mesoderm lineages (50).  This indicates that similar to Oct4, Sox2 
levels are kept within a threshold in order to maintain the pluripotent state. 
 
Studies have shown that Oct4 and Sox2 bind to enhancer sequences on each 
other (47) to form heterodimers in order to positively regulate and enhance each 
other’s expression (51). They also act in concert to increase the expression of 
other pluripotency related genes including Nanog (49) (Figure 3). Surprisingly 
the expression of many Oct4/Sox2 target genes including Nanog are not affected 
in Sox2 null cells. This is thought to be due to a redundancy of Sox2 (49), which is 
supported by the fact that Sox2 can be substituted with Sox1 or Sox3 in the 
reprogramming of somatic cells (44).  The major role of Sox2 in ESCs seems to be 
to maintain the high expression levels of Oct4, as exemplified in experiments 
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where Oct4 expression was forcibly kept at normal levels against a Sox2 null 
background resulting in maintenance of the pluripotent phenotype (49).  The 
same effect was not observed when Nanog was overexpressed in the Sox2 null 
background cells, for unknown reasons, however it should be noted that Sox2 
null cells maintain Nanog expression at similar levels to WT mESCs (49).    
 
Although Sox2 is classed as a pluripotency gene it is also expressed by cells of the 
extra-embryonic ectoderm and precursor cells of the central nervous system, 
which divide rapidly (52,53).   
5.4.3. Nanog 
 
Nanog null embryos are embryonic lethal (54), nonetheless Nanog null mESCs 
have been generated, which surprisingly can remain pluripotent as long as the 
expression levels of Oct4 and Sox2 remain high. However, Nanog null mESCs are 
more susceptible to differentiation (51), reinforcing the importance of the 
expression of all the pluripotency factors for the maintenance of pluripotency. 
 
In stark contrast to Oct4 and Sox2, overexpression of Nanog in the absence of 
LIF, results in the maintenance of the pluripotent state in ESCs, and causes them 
to be more resistant to retinoic-acid induced differentiation (37) in a dose 
dependent manner (51).  This indicates that Nanog may play a dominant role in 
the maintenance of pluripotency, possibly through the direct downregulation of 
differentiation genes such as GATA4 and GATA6 (54) as well as via interactions 
with pluripotency promoting genes. 
 
Similar to Oct4, Nanog can be used for one factor reprogramming when 
combined with chemical activators of sonic hedgehog signalling (involved in 
controlling early vertebrate embryonic development) (55). 
 
Nanog’s dominant role in maintaining pluripotency has led to the theory that it 
acts as a ‘gatekeeper’ for the onset of differentiation, as the downregulation of 
Nanog results in a concomitant downregulation of the other pluripotency genes 
Sox2 and Oct4, resulting in widespread differentiation (37). This theory is 
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supported by studies whereby Nanog RNAi has been used to forcibly repress 
Nanog expression in mESCs resulting in repression of Oct4 and Sox2 expression, 
conversely when Nanog was overexpressed, levels of Oct4 and other 
pluripotency associated genes, but not Sox2 increased (37).  These results imply 
that Sox2 may be at the bottom of a ‘hierarchy of pluripotency maintenance’ 
whereby a drop in Nanog expression levels results in cells becoming less 
resistant to differentiation signals, leading to a decrease in Oct4 transcription 
levels (37) and a subsequent reduction in Sox2 levels (47,56). This concurs with 
more recent evidence that suggests that during iPSC formation, Sox2 is the first 
of the pluripotency genes to be switched on and in a hierarchal fashion, switches 
on other genes involved in the induction and maintenance of pluripotency (57). 
  
Although, Nanog is proposed to play a major role in pluripotency, surprisingly it 
is not one of the core Yamanaka factors for reprogramming mESCs (though it is 
essential for gene based reprogramming of human ESCs) (15,41,58). However it 
has been discovered that unless murine iPSCs are expressing Nanog, they may 
not be completely reprogrammed, therefore Nanog is indispensable for the final 
stage in reprogramming (51), emphasizing its essential role in promoting 
pluripotency. 
 
Although Oct4, Sox2 and Nanog are often cited as the master regulators of 
pluripotency, it should be noted that other genes such as Foxd3 (59), FGF4 and 
STAT3 (34) are vital for the maintenance of pluripotency, when mESCs are 
grown under normal conditions.   
5.5. Embryonic stem cell glucose metabolism 
 
Metabolism is directly or indirectly, intrinsically linked to every cellular process.  
Evidence has begun to emerge that the form of metabolism predominantly 
utilised by a cell plays a major role in its differentiation potential, and this 
knowledge has been applied to mESCs, which have an unusual form of glucose 




In contrast to mature cell types, which primarily depend upon mitochondrial 
oxidative phosphorylation to generate the energy required for cellular processes, 
stem cells use the faster, yet less efficient (in terms of the amount of ATP 
generated) aerobic glycolysis (28), which occurs in the cytosol (Figure 2).  
Although a definitive reason for this is yet to be uncovered, reasonable 
hypotheses have been formulated including the high availability of nutrients for 
stem cells resulting in there being no selective pressure for the cells to use 
oxidative phosphorylation, glycolytic intermediates feeding into anabolic 
pathways that are important for cell growth and glycolysis not generating ROS, 
which can be detrimental to cell survival (28). However more recently it has 
come to light that the form of glucose metabolism used by cells may play a role in 
controlling their pluripotent phenotype (60,61), this is supported by a switch 
from predominantly aerobic glycolysis to oxidative phosphorylation upon 
differentiation in ESCs (62), as well the switching on of glycolytic genes before 
pluripotency genes during iPSC generation (57,63). It has also been shown that 
glucose deprivation can result in delayed ESC differentiation, further 
demonstrating the importance of glucose as a substrate for normal the normal 
ESC phenotype (64). 
5.5.1. Glycolysis 
 
The GLUT family of transporters is comprised of thirteen members, which 
function to control cellular glucose homeostasis, by shuttling glucose into and 
out of cells (65).  Interestingly, the expression of particular GLUT isoforms has 
been linked to the developmental status of both blastocysts and the ESCs derived 
from them (64).  Of the GLUT isoforms, GLUT1 is essential for ESC viability 
indicative of its role as the main glucose transporter in ESCs, thus it is 
unsurprising that it is ubiquitously expressed during all stages of early 
development (64).  The other GLUT isoforms are expressed sequentially over 
development, with both GLUT3 and GLUT8 showing higher expression during 
the early stages of differentiation and GLUT4 and GLUT2 displaying higher 
expression during the latter stages of development (64), which may allude to a 




Glucose can be processed via two pathways for energy generation; glycolysis or 
oxidative phosphorylation (Figure 2). Both pathways are linked by the pyruvate 
kinase enzyme, which converts phosphoenolpyruvate into pyruvate, which can 
either be converted into lactate and two molecules of ATP in the cytosol during 
glycolysis, or be shuttled into the mitochondria (66) and converted into acetyl-
CoA.  Acetyl-CoA feeds into the Tricarboxylic Acid Cycle (TCA) cycle which 
coupled to oxidative phosphorylation, eventually results in the formation of 36 
molecules of ATP, carbon dioxide and water (66) (Figure 4).  Both the TCA cycle 
and glycolysis produce byproducts which can act as precursors for amino acid 






















































Figure 4 – Glycolytic pathway in ESCs.  Enzymes in red catalyse the three rate limiting, irreversible 
steps of glycolysis  Adapted from: (68) 
 
Although both of the energy generating processes; glycolysis and the TCA 
cycle/oxidative phosphorylation can occur in the presence of oxygen, only the 
TCA cycle/oxidative phosphorylation actually requires oxygen in order to 
successfully generate energy (28) (Figure 2). The propensity of proliferating 
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cells including mESCs to use glycolysis instead of oxidative phosphorylation for 
energy generation, regardless of oxygen concentrations is termed the ‘Warburg 
effect’ (28,69).   
 
Although mESCs are highly glycolytic, they are ‘metabolically bivalent’, and 
therefore have the ability to use both oxidative phosphorylation and glycolysis 
(70), this has been supported by studies which show that growing mESCs in high 
glucose concentrations results in not only increased glycolysis rates but also 
higher ROS production, possibly due to mitochondrial overload i.e. higher TCA 
cycle/oxidative phosphorylation activity (71). 
 
Glycolysis has three rate limiting enzymes, which regulate the efficiency of the 
glycolytic pathway by catalysing the irreversible steps of glycolysis; Hexokinase 
2 (HK2), Phosphofructokinase 1 (PFK1) and Pyruvate Kinase (PK).  High 
expression of these enzymes is often indicative of active glycolysis. HK2, which 
commits glucose to the glycolytic pathway, can be positively regulated by insulin 
levels (72) and PFK1 by a number of factors including ATP and PEP (73), both of 
these enzymes predominantly play a major role in glycolysis (HK2 and PFK1). 
Whereas PK plays a major role in glycolysis but also in pathways directly 
associated with glycolysis which results in an upregulation of anabolic processes 
(74) (Figure 4). 
5.5.2. Pyruvate kinase muscle isoform 2 (PKM2) 
 
Four pyruvate kinase (PK) isoforms are present in mammals; the L and R 
isoforms which are expressed in liver and red blood cells, respectively, and the 
M1 and M2 isoforms (75), which are alternatively spliced forms of the muscle 
isoform, and have 96% similarity (76). The M2 isoform is expressed in all fetal 
tissues, but is progressively replaced by the M1, L and R isoforms in a tissue 
specific manner (77).  Both the M1 and M2 isoform are expressed in highly 
proliferating tissues/cells, however the M2 isoform (PKM2) is predominantly 
present in highly proliferative embryonic tissues (Figure 4), whereas the M1 
isoform (PKM1) is predominantly present in more mature proliferative tissues 
such as muscles and the brain (74).  Whilst, PKL, PKR and PKM1 are able to form 
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stable, highly active tetramers (78), the one exon difference between PKM1 and 
PKM2 (79) results in PKM2’s ability to intraconvert between a highly active 
tetramer and a low activity dimer. This intraconversion is under the control of 
binding partners such as amino acids (80) and substrates which are directly 
linked/involved in glucose metabolism such as Fructose 1, 6-bisphophate (FBP) 
which results in the formation of an active tetramer; (76) or ATP which results in 
the formation of a low activity dimer (81) (Figure 5).  The other PK isoforms do 
not have binding sites, which allow for external regulation by binding partners, 
therefore they are constitutively expressed (82). 
 
 
Figure 5 – Switch between tetrameric and dimeric forms of PKM2.  A) PKM2 converts into a highly 
active tetrameric form upon the binding of Fructose 1, 6-bisphophate (FBP) resulting in increased 
glycolysis, B) PKM2 converts into a low activity dimer upon the binding of ATP or tyrosine 
phosphorylated resulting in increased channelling of substrates into anabolic processes.  Adapted 
from: (83) 
 
The switch between tetramer and dimer imbues proliferative tissues such as 
ESCs with a metabolic plasticity.  In its tetrameric form, PKM2 has a high affinity 
for its substrate, phosphoenolpyruvate (PEP) resulting in the degradation of 
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pyruvate from glucose, leading to the production of lactate and two molecules of 
ATP (74), however in its dimeric form, pyruvate is instead channelled into 
anabolic pathways debranching from glycolysis, resulting in increased cell 
proliferation (74) (Figure 5).  It is the tetramer/dimer ratio within cells, which 
determines the glycolytic fate of pyruvate (74,76).  Although it has been 
established that the default state of PKM2 is as a tetramer, which allows for the 
rapid production of much needed ATP (84).  It is interesting that in cancer cells 
the predominant form of PKM2 is as a dimer, which allows for the rapid growth 
of tumours (74) (at the time of writing, studies on the dimer, tetramer ratio in 
ESCs have not been conducted/published, though this is likely due to the 
dynamic nature of the ratio).   It has been shown that when PKM2 is 
predominantly in its dimeric form, this is detected by the cell as ‘nutritional 
stress’ caused by low concentrations of glucose being converted to ATP, 
therefore glutaminolysis compensates for ATP production (74,84).  It has also 
been suggested that upregulation of the dimeric form of PKM2, under low 
glucose conditions, aids in protection from apoptosis as shown by a 
downregulation of apoptosis markers (74). 
 
Upon the receipt of signals, which inform the cell, that anabolic processes are 
required to further cell growth the intracellular balance between the dimeric and 
tetrameric forms of PKM2 is altered (74). 
 
PKM2 has at least two binding sites, one of which allows FBP (activator) to bind 
as well as another, which allows tyrosine-phosphorylated peptides to bind 
(repressor) (82). In its default tetrameric state (84), PKM2 is bound by FBP.  
However upon the binding of tyrosine phosphorylated peptides, resulting in a 
conformational change of PKM2 to its dimeric form and the release of FBP 
(Figure 5), it is the concentration of FBP in the vicinity of PKM2 which 
determines whether PKM2 remains in its dimeric state or rebinds FBP, and is 
reactivated (82). This mechanism of regulation is thought to have evolved in fetal 
tissues, so that glucose is primarily used for cell growth i.e. anabolic processes, 
when cells are activated by the appropriate growth factor receptor protein 




Though embryonic stem cells are known to be highly glycolytic and express 
PKM2, it has only recently come to light that Oct4 and PKM2 are binding 
partners, with ectopic PKM2 expression directly enhancing the expression of 
Oct4 (85).  Although it is still too early to postulate, what function this has in the 
cell and whether the two forms of PKM2 may have differing effects on Oct4 
expression, it suggests a role for glucose metabolism in the regulation of Oct4 
expression, and potentially pluripotency.  PKM2 has also been shown to play a 
role in cell cycle regulation, as its loss results in the cell cycle stalling at the G1/S 
phase transition (86). 
 
Notably, in studies on differentiated cells, when chemical inhibitors of glycolysis 
have been added, this has inhibited the reprogramming process and when 




Mitochondria are double membrane organelles, of bacterial origin that play an 
essential role in energy, amino acid and fatty acid metabolism (89).  By and large, 
ESCs do not predominantly use their mitochondria for energy production, 
instead relying on aerobic glycolysis, which occurs in the cytoplasm (28) and 
accounts for 80% of total cell glucose metabolism (30). However more recent 
studies have shown that although mESCs use aerobic glycolysis for energy 
generation, they are ‘metabolically bivalent’ and so have the ability to use either 
aerobic glycolysis or oxidative phosphorylation/TCA cycle to build precursors 
involved in cellular growth pathways and energy generation (70). 
 
On the other hand, hESCs solely rely upon glycolysis for glucose metabolism; this 
has been demonstrated most effectively, in studies where both hESCs and mESCs 
have been grown in the presence of glycolytic inhibitors. hESCs begin to 
apoptose due to their inability to switch to oxidative phosphorylation/TCA cycle, 
whereas mESCs are able to compensate for their shortfall in energy production 




Although mESCs are able to use both glycolysis and the TCA cycle/oxidative 
phosphorylation, hESCs have elongated mitochondria, with distinct cristae 
compared to mESCs, which have more oval, irregularly shaped mitochondria 
indicative of the hESC mitochondria being more mature (70). Notably it has been 
shown that hESC mitochondria are functional and consume oxygen, however 
there is a greater uncoupling between glycolysis and oxidative phosphorylation 
in hESCs compared to mESCs (90).  In stark contrast to differentiated mature 
cells, both hESCs and mESCs have underdeveloped and immature mitochondria 
(70). It has been discovered that once ESCs embark upon differentiation, they 
begin to upregulate genes associated with oxidative phosphorylation, the TCA 
cycle and ROS and reciprocally, downregulate the expression of glycolytic genes 
(63,70,91).  Notably, this has not only been observed in ESCs, but also in 
multipotent cells such as mesenchymal and hematopoietic stem cells (90,92). 
 
Although it is not well understood what controls the differences in mitochondrial 
metabolism between hESCs and mESCs, uncoupling protein 2 (UCP2), which acts 
a ‘circuit breaker’ between glycolysis and the TCA cycle/oxidative 
phosphorylation, has been implicated (61). During differentiation, UCP2 is 
repressed, resulting in increased oxidative phosphorylation (90).  Reciprocally, 
high expression of UCP2 as observed in ESCs prevents the switch from a reliance 
on aerobic glycolysis to oxidative phosphorylation, and prevents the expression 
of early differentiation genes (90,93).  However, the role of UCP2 in controlling 
the maintenance of pluripotency is still not completely certain (93). 
 
Studies have shown that although mature cell types have significantly higher 
mitochondrial activity compared to ESCs, both cells have a similar mitochondrial 
mass (when normalised to cell mass) (90,94), and that the knockdown of a 
mitochondrial DNA polymerase (89) as well as the knockdown of the 
mitochondrial protein Growth factor erv1-like (Gfer) whose function is not 
completely understood (95) result in lower expression of the major pluripotency 
markers, as well as increases in the expression of early differentiation markers. 
The importance of mitochondrial function in regulating the balance between 
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pluripotency and differentiation has also been displayed in mESCs with deletion 
of the Cited2 gene; a transcriptional modulator, which have impaired 
mitochondrial function and increased glycolytic activity, resulting in defective 
differentiation and increased expression of the major pluripotency markers (30).  
Interestingly, Cited2 has been shown to directly affect the expression of 
Hexokinase 1 (30); an ubiquitous isozyme of the regulated Hexokinase 2 enzyme. 
5.5.4. Hypoxia 
 
Although in vivo embryonic cells grow under hypoxic conditions, standard in 
vitro conditions are at atmospheric oxygen tensions, which would indicate that 
oxygen tensions have no effect on pluripotency, however there are studies that 
suggest an optimal oxygen tension is required for proper mESC behaviour (96). 
 
This is particularly interesting as mESCs contain immature mitochondria, with 
underdeveloped cristae in comparison to more mature cell types and hESCs, 
which contain more mature mitochondria (90). This may at least partially 
explain contradicting studies which show that hypoxia can either promote 
pluripotency, by activating the expression of hypoxia inducible factor 2α (HIF2α) 
which binds to and positively regulates Oct4 (96) or promote differentiation via 
the activation and binding of hypoxia inducible factor 1α (HIF1α) binding to and 
negatively regulating the LIF receptor (LIFR), preventing STAT3 activation and 
repressing pluripotency (97,98). Notably the opposing effects of oxygen on 
differentiation and pluripotency and the HIF proteins, is mirrored in other stem 
cell types, such as mesenchymal stem cells (99), pancreatic beta-cells (100) and 
hematopoietic stem cells (60). 
 
Under hypoxic conditions HIF1α also activates the transcription of glycolytic 
genes, such as fructose bisphosphate aldolase A (Aldolase A) and 
phosphoglycerate mutase 1 (PGAM1) (101,102) (Figure 4) which has been 
linked to the maintenance of the pluripotent state.  Hypoxia has also been 
implicated in increasing the efficiency of iPSC formation (103).  Therefore it is 
clear that oxygen concentrations play a major, but as yet, not a completely 
33 
 
understood role in the balance between pluripotency and differentiation in 
mESCs. 
5.5.5. Embryonic stem cell cycle 
 
ESCs have a rapid cell cycle compared to their more differentiated counterparts, 
due to their very short G phases and reciprocally longer S phases. This not only 
has a profound effect on the pace of the cell cycle, but also results in ESCs ability 
to undergo at least two independent rounds of cell division in the absence of 
nutrients (104), and in stark contrast to differentiated cell types, not go into 
quiescence due to contact inhibition (105). Conversely, differentiated cells often 
arrest in G0/G1 phase upon nutrient starvation (105).   
 
Unsurprisingly, in all cell types nutrient availability and both the pace and 
efficiency of the cell cycle are tightly intertwined. Growing mESCs in the 
presence of high glucose leads to the activation of key metabolic signal cascades 
that contain proteins such as PI3-K and Akt, which have wide-reaching roles in 
regulating glucose metabolism, cell proliferation and differentiation. This in turn 
activates Cdk complexes which enhance cell cycle function, resulting in increased 
cell proliferation (71).  There is also evidence that ATP; one of the most vital end 
products of glucose metabolism, enhances the expression of the Cdk complexes, 
increasing mESC proliferation (106). 
 
5.6. Embryonic stem cell fatty acid metabolism 
 
Due to the strong links between the forms of metabolism predominantly used by 
a cell and the balance between pluripotency and differentiation, studies on the 
metabolome of cells have become more common.  In the case of mESCs, a large 
scale unbiased study on two mESC lines and their differentiated progeny, 
showed that mESCs are characterised by an abundance of highly unsaturated 
fatty acids including secondary lipid messengers and inflammatory mediators, 
such as arachidonic acid and eicosapentaenoic acid, compared to their 
differentiated counterparts, and that the levels of unsaturated fatty acids 
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decrease upon differentiation (107).  Conversely, the mature cell types had 
increased levels of saturated fatty acids, which have been implicated in the 
transport of fatty acids to the mitochondria for fatty acid oxidation (107). This 
correlates with numerous studies that show that upon differentiation, embryonic 
cell types increase their mitochondrial function (70).  When the production of 
eicosanoids; a major group of unsaturated fatty acids involved in many processes 
including immunity and cell growth, was blocked, mESCs were unable to 
maintain pluripotency under pro-differentiation conditions (107) highlighting 
the importance of fatty acid metabolism for cell pluripotency.  The regulation of 
the pluripotent state by fatty acids, has also been shown in hESCs (107). 
 
Interestingly, linoleic acid, an unsaturated fatty acid that can be a precursor for 
eicosanoid production, has been shown to increase cell growth of mESCs by 
increasing the expression levels of the Cdk complexes and maintaining the rapid 
cell cycle (108).   
 
Carnitine palmitoyltransferase 1 (Cpt1), a mitochondrial enzyme involved in 
fatty acid metabolism, has also been shown to play a major role in fatty acid 
metabolism in mESCs (109).  In addition to impaired fatty acid metabolism, Cpt1 
knockout mESCs have reduced ATP production, abnormally shaped 
mitochondria, impaired mitochondrial function, and succumb to apoptosis under 
hypoxic or low glucose conditions, further confirming the link between fatty acid 
metabolism and the normal mESC phenotype (109). 
 
Notably UCP2, which is known to play a role in linking glycolysis to oxidative 
phosphorylation (61), has also been implicated in the mitochondria’s ‘choice’ of 
either fatty acids or glutamine as a substrate for ATP generation and has been 
shown to be responsible for the metabolic switch from glucose to fatty acid 





5.7. Embryonic stem cell amino acid metabolism 
 
Amino acids, known as the ‘building blocks’ of cells, play a vital role in the 
proliferation of all cells. Threonine in particular has been identified as an 
essential amino acid for mESC function (111) as out of the twenty amino acids, 
threonine is the only amino acid that is vital for mESC survival (111). mESCs also 
have high expression and activity of mitochondrial threonine dehydrogenase 
(TDH), which catalyses the first rate limiting step of threonine catabolism to 
glycine and acetyl-coA.  Glycine can be used as a precursor for nucleotide 
synthesis, therefore in the absence of threonine dehydrogenase, there is a 
substantial decrease in DNA synthesis (111).  Acetyl-coA can feed into the TCA 
cycle providing an alternative energy source (111). The study also showed that 
upon differentiation, there was a consistent increase in the concentration of 
guanosine, adenosine, inosine and threonine, in mature cell types (111).  In stark 
contrast to mESCs, hESCs are dependent on methionine for cell survival (112). 
This is due to hESCs expressing a TDH pseudogene making them unable to 
catabolise threonine using the same pathway as mESCs (113). 
 
The importance of threonine metabolism in mESC pluripotency has also been 
demonstrated in reprogramming studies, which have shown that the knockdown 
of TDH in cells being reprogrammed using the Yamanaka factors (41,44), lowers 
the efficiency of reprogramming (114).  The opposite effect is observed if TDH 
activity is induced, and the reprogramming efficiency is further enhanced if 
PRMT5, a methyltransferase that is known to regulate TDH is also used in the 
reprogramming process (114).   
 
Glutamine, which can be used as an alternative energy source by ESCs in the 
absence of glucose, has been linked to the rapid cell cycle in human cancer cells 
possibly providing evidence for links between glutamine metabolism and the 
rapid cell cycle, at least in mESCs (115). 
 
In order to fully understand the mechanisms underlying the pluripotent state, it 
is imperative that there is a greater understanding of not only how genes 
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interact with each other, but also how different forms of metabolism affect the 
cell and how these different forms of metabolism interact and influence each 
other.  Interestingly, both metabolism and pluripotency have been shown to 
regulated by miRNAs (48,116). 
 
5.8. Non coding RNAs (ncRNAs) 
 
In order for cells to express the correct genes both temporally and spatially in 
response to environmental or developmental cues, gene expression is tightly 
regulated. From transcription in the nucleus, to mRNA translation in the 
cytoplasm of cells and finally the action of the protein product; the ‘message’ that 
is being passed on, has to get past multiple checkpoints, can be heavily modified 
to repress or amplify the signal, and can be acted upon by small non-coding 
RNAs (ncRNAs) either activating or repressing translation (117). 
 
Regulation of gene expression using small ncRNAs is a highly conserved process, 
which is involved, in various regulatory and signaling pathways. ncRNAs have 
been observed in plants as a defence mechanism against viruses (118), and in C. 
elegans they regulate embryonic development and lifespan (119). ncRNAs bind 
to their targets in a sequence specific manner resulting in translational 
repression. This can occur through a number of mechanisms including the 
binding of ncRNAs triggering cleavage of the target sequence, ncRNAs 
destabilizing the target sequence, most often by deadenylation (120), ncRNAs 
acting to prevent ribosome binding or through the ncRNA associated proteins 
such as the Argonautes (121). In the last decade, one category of small 
(~22nucleotides (nts)) ncRNAs called microRNAs (miRNAs) have been 
discovered to play a vital role in mammalian systems. This has been 
demonstrated most convincingly in studies where the miRNA biogenesis 
pathway has been impeded resulting in embryonic lethality in mice (6,122). 
 
Although the first miRNA lin4, was discovered in 1993 in C. elegans and was 
found to negatively regulate the Lin14 protein by binding to the 3’ UTR 
(untranslated region) of the lin14 mRNA (123), it was not until 2000, when the 
37 
 
highly conserved let-7 miRNA was discovered in mammals that the field began to 
rapidly expand (124).  So far, thousands of miRNAS have been discovered (119) 
and bioinformatic predictions suggest that mammalian miRNAs regulate at least 
60% of all protein coding genes (2).  Dysregulation of specific miRNAs has also 
been implicated in many disease states; examples include miR-15 and miR-16 in 
chronic lymphocytic leukemia (125) and miR-140 in arthritis (126). 
 
5.8.1. MiRNA biogenesis  
 
MiRNA genes can be found in clusters or as single genes, either in intergenic or 
intronic regions of the genome (127) and are transcribed in the nucleus by RNA 
polymerase II or III (21).  
 
MiRNAs derived from intergenic regions of the genome are transcribed into 
primary transcripts with hairpin structures called primary miRNA (pri-miRNA) 
(21). Pri-miRNAs can contain several hairpin stem loops (128), and similar to 
mRNAs, these primary transcripts have 5’ caps and 3’ poly A tails. These pri-
miRNA, are further processed into individual hairpins called precursor miRNA 
(pre-miRNA) (~ 70 nt) by the microprocessor complex.  The microprocessor 
complex is made up of the Di-George syndrome critical region gene 8 (DGCR8) 
RNA binding protein (known as Pasha in Drosophila) in conjunction with 
Drosha, which provides a ‘catalytic centre for the cleavage’ (129) of the 5’ cap 
and 3’ poly-A tail, as well as separating multiple stem loops.  The pre-miRNA is 
then transported from the nucleus to the cytoplasm, by exportin-5 and Ran-GTP, 
where the RNAse II enzyme, Dicer removes the hairpin loop and cleaves the pre-
miRNA into a ~21 bp duplex with 2nt overhangs on its 3’ ends (Figure 6).  Of the 
two mature strands, one is known as the guide strand and is loaded onto the 
RNA-induced silencing complex (RISC) by Dicer (21). This is usually the strand 
with the weakest base pairing at its 5’ end (130) and it targets specific mRNAs in 
a sequence dependent manner. In most cases the other strand, passenger/star 
strand has no function and is degraded (21). However, 80% of human miRNAs 
have highly conserved star strands, and a smaller percentage have higher or 
similar concentrations as the guide strand, indicating that the star strand may be 
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functional, and have targets of its own (131), such as miR-233* in mammalian 
myeloid progenitor cells which targets a number of mRNAs in the insulin-like 
growth factor 1 receptor/phosphatidylinositol 3-kinase pathway (132). Both 











Figure 6 – miRNA biogenesis.  Intergenic miRNAs are transcribed in the nucleus by RNA polymerase II 
into primary miRNA (pri-miRNA), which undergoes two sequential I steps by the Drosha-
DGCR8/Microprocessor complex in the nucleus and Dicer in the cytoplasm, to form a miRNA duplex, 
which is recognised and cleaved by the RISC. 
 
Studies have shown that the majority of miRNAs (~80%) are derived from 
intronic regions of the genome and are transcribed using the endogenous 
promoter of the gene transcription unit that the intron is located in (134).  If the 
intron is within a protein coding gene, then often the intronic miRNA is found in 
an antisense orientation indicating that it is its own independent transcription 
unit, in some cases the intronic miRNA is found in the sense orientation and is 
co-transcribed with the protein coding gene (135).  Some of the host genes that 
contain intronic miRNA are non-protein coding, suggesting that they exist solely 
for miRNA production (136).  
 
The biogenesis of miRNAs derived from introns is very similar to miRNAs 
derived from intergenic regions of the genome, however due to the nature of 
introns it also involves the spliceosome (136).  Originally it was thought that 
miRNA sequences were spliced by the spliceosome before the microprocessor 
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complex cleaved the pri-miRNA (137).  However, there are studies, which 
suggest that intronic miRNAs can be processed from unspliced/partially spliced 
introns by the microprocessor complex, before splicing occurs, without any 
damage to the protein/mature mRNA sequence (136,138). Intronic miRNA 
biogenesis pathways that are not dependent on the microprocessor complex or 
its component parts and so bypass pri-miRNA production have been identified in 
C.elegans and Drosophila (139).  More recently mammalian miRNAs that are 
produced via non canonical pathways, which are not only microprocessor 
independent, but also splicing independent, therefore only requiring Drosha for 
their biogenesis have also been discovered (140). 
 
Recently, other DGCR8 independent pathways for miRNA biogenesis have been 
identified, that transcribe functional miRNAs from other sources including 
transfer RNAs (tRNAs) (141-143).  
 
5.8.2. MicroRNAs in mESCs 
 
Studies on mouse embryonic stem cells (mESCs) that no longer express the 
majority of their miRNAs due to the deletion of a protein (DGCR8) involved in 
their biogenesis (Figure 6), have an altered cell cycle, where cells accumulate in 
the G1/S phase of the cell cycle, a slow proliferation rate compared to WT cells 
and an inability to downregulate genetic markers of pluripotency (6).  This 
indicates that miRNAs play a vital role in the mESC cycle and in the 
differentiation status of the cell.   
 
By re-expressing miRNAs in DGCR8 knockout mESCs, 14 miRNAs have been 
identified that can rescue the cell cycle phenotype. However, the miRNAs 
involved in the major regulation of mESC differentiation are yet to be identified 
(6).  Large-scale transcriptomic studies have been conducted on both WT and 
DGCR8-/- mESCs and on DGCR8-/- cells transfected with the ESCC cluster of 
miRNAs amongst others, to discern potential targets of the ESCC miRNAs (144).  
GO analysis has revealed that the top pathways affected by these miRNAs are 
unsurprisingly involved in the cell cycle, epigenetic mechanisms, apoptosis and 
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immune responses (145-149).  However, as the major read out of miRNA 
function is at the protein level, this provides an incomplete picture of the targets 
of these miRNAs, and their role in the ESC phenotype.  This has been 
demonstrated most effectively in a recent study using an unbiased, large-scale 
approach to study the targets of C.elegans miRNAs, which revealed that the 
majority of miRNA interactions identified, did not have perfect seed sequence 
complementarity, and therefore would have not been easily identified using 
traditional bioinformatic, prediction methods (150).   
 
5.8.3. miRNAs and mRNA translation 
 
miRNAs are mediators of genetic repression and in rare cases, they can indirectly 
cause genetic activation during the cell cycle (117). They function at the post-
transcriptional level by binding in a sequence specific manner to mRNA. Their 
importance in gene expression has been revealed in studies where their 
biogenesis has been disrupted, resulting in early embryonic lethality in murine 
models and abnormal differentiation patterns in cellular models (6).   
 
Although the results of miRNA binding to their target sequences are known, the 
actual process of gene regulation by miRNAs is not completely understood due to 
varying experimental results showing that both the elongation and initiation 
stages of translation can be affected (151). However certain aspects of mRNA 
silencing are generally agreed upon such as the formation of the RISC being 
coupled to pre-miRNA processing by Dicer (152).  
 
The mature strand guides the RISC complex to the target sequences (6), whereby 
if the guide strand and the target sequence are completely complementary then 
in mammals, Argonaute 2 (Ago2), an RNAse enzyme will cleave the target 
sequence between bases 10 and 11 so it cannot be translated (153) (Figure 7).  
However in animals, the guide strand and target sequence are often not perfectly 
complementary (131), consequently the mRNA sequence is not destroyed rather 
it is repressed (152). In the case of imperfect complementarity, the miRNA and 
its target sequence have to base pair in specific configurations in order for 
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effective repression to take place, in many cases the miRNA needs to perfectly 
base pair to its target sequence at the miRNAs 5’ end, this area of perfect 
complementarity is known as the seed region and usually spans nucleotides 2-8 
(154).  If the seed region binding is not perfect, this can be compensated by 
strong binding between the 3’ ends of the miRNA and target sequence (154) 















Figure 7 – miRNA binding to 3’UTR of target sequence. A) Perfect complementarity at seed region 
between miRNA and 3’ UTR of target sequence results in cleaving of target, B) Weak binding at seed 
region, can be compensated by strong binding between 3’ ends of miRNA and target sequence and 
results in target repression 
 
Many miRNAs are required per target sequence for effective repression (152), 
once translation has been repressed, the target sequence and RISC are stored in 
P-bodies via an unknown mechanism (151,155). 
 
miRNAs have been shown to repress translation in number of ways, however 
there is still debate over which method, if any, is the dominant method of 
translational repression and whether these methods occur simultaneously or 
individually (151).  The methods include miRNAs interacting with the 40S and 
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60S subunits of ribosomes either preventing them from binding or causing them 
to drop off the target mRNA(131) or, RISCs competing with essential 5’ cap 
binding proteins such as eIF4G preventing translation (156). 
 
As well as directly repressing translation, miRNAs have also been shown to affect 
target mRNA levels by triggering deadenylation of the target mRNA sequence, 
resulting in decapping, disrupted translation, and eventually leading to 
degradation of the target sequence (131,157,158). 
 
Interestingly, some miRNAs have been found to reside and function in the 
nucleus, indicating that once they are cleaved by Dicer in the cytoplasm, they are 
transported back into the nucleus.  For example miR-709 is highly expressed in 
the nucleus of a number of cells including adipose derived fibroblasts and 
Human Embryonic Kidney  (HEK) cells, and represses the expression of miR-
15a/16-1 by preventing its maturation (159) and miR-122, one of the most 
abundant miRNAs in the liver (160) not only targets mRNA in the cytoplasm, but 
also targets mRNAs in the nucleus (161). 
 
5.8.4. The function of miRNAs in ESCs 
 
Studies in mouse embryonic stem cells (mESCs), have revealed that when Dicer 
is knocked out, resulting in an almost complete loss of mature miRNAs, although 
the mESCs are viable, they have a lower proliferative capacity i.e. grow much 
slower than their WT counterparts (6). Cell cycle analysis has revealed that the 
Dicer null mESCs have an altered cell cycle, where there is an accumulation of 
cells in the G1 and Go phases and a reciprocal decrease in the number of cells 
reaching the G2/M phase (162). Dicer null mESCs are able to form embryoid 
bodies (EBs) (6) but, they fail to express genetic markers of differentiation such 
as HNF4A, an early marker of endoderm and BMP4, an early mesodermal marker 
(7). 
 
In reference to their cell cycle and ability to differentiate, DGCR8-/- mESCs have a 
similar though less severe phenotype compared to Dicer knockout mESCs.  
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DGCR8-/- mESCs also fail to silence the pluripotency genes such as Oct4, Sox2 and 
Nanog (6).  This was especially apparent when differentiation was forced using 
retinoic acid, which resulted in the expression of markers of differentiation in 
DGCR8 null mESCs as well as prolonged expression of the pluripotency genes.  In 
contrast, retinoic acid was unable to force the expression of differentiation 
markers in Dicer-null mESCs (6,162). The proliferation defects in Dicer null 
mESCs can be rescued over time which has been attributed to some of the cells 
accruing mutations/stable genetic changes that can overcome the proliferation 
defects and outgrow the other cells, contrastingly DGCR8 null mESCs cannot 
overcome this proliferation defects for unknown reasons (163). 
 
By reintroducing non-canonical miRNAs into Dicer-/- mESCs; two non canonical 
miRNAs, miR-320 and miR-702 that promote the G1 to S phase transition have 
been discovered (8,164). This partially accounts for the differences in severity of 
phenotype between the DGCR8 and Dicer knockout mESCs.  It is noteworthy that 
the expression of these two miRNAs and other as yet unidentified non-canonical 
miRNAs, is insufficient to completely rescue the defects in DGCR8-/- mESCs, 
implying that canonical miRNAs play a greater role in maintaining the mESC 
phenotype than non-canonical miRNAs.   
 
These results indicate that miRNAs play a vital role in the differentiation and cell 
cycle of mESCs. In contrast to DGCR8, Dicer is involved in both the siRNA and 
miRNA biogenesis pathways. Thus the miRNA pathway plays a similarly 
predominant role in the phenotypes of the Dicer and DGCR8 null mESCs, 
whereas siRNAs may account for the difference in phenotypes between Dicer 
null and DGCR8 mutants(163). 
 
The ability of specific miRNAs to restore the cell cycle defects in DGCR8 knockout 
cells (26) suggests that there are specific miRNAs in ESCs that promote the cell 
cycle and particularly play a vital role in the transition from the G1 phase (26). 
 
The phenotype of DGCR8-/- hESCs is yet to be uncovered; nevertheless it has been 
predicted to be similar to that of mESCs.  Evidence for this has been provided by 
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hESCs and mESCs having similar miRNA profiles.  For example, a cluster of 
several mESC specific miRNAs known as the miR-295 cluster; miR-290, miR-
291a, miR-291b, miR-292, miR-293, miR-294 and miR-295, have orthologs in 
hESCs, the miR-371 cluster; miR-371, miR-372, mir-373 and miR-373* (165). 
Both clusters have the same seed sequence and share targets (122,166) (Figure 
8). Interestingly in hESCs, the miR-371 cluster is in fact expressed at relatively 
low levels, instead another cluster of miRNAs, the 302 cluster; miR-302a, miR-
302b, miR-302c and miR-302d, which also has the same seed sequence as the 
miR-295 and miR-371 clusters, is the most highly expressed cluster  (Figure 8). 
 
 
Figure 8 – Seed sequences of miRNAs that regulate the cell cycle in ESCs. A) Highly expressed mouse 
miR-295 cluster B) Highly expressed human miR-302 cluster c) Human miR-371 cluster    
 
The transcription factors Oct4, Nanog and Sox2 act together and are central to 
the establishment and maintenance of ‘stemness’, as their down regulation 
initiates and marks the beginning of ESCs differentiation program.  Therefore it 
is telling that they and one other transcription factor, Tcf3 control approximately 
20% of all known miRNAs (48) in mESCs, either by occupying the promoters of 
active miRNAs that have a role in maintaining pluripotency or, by occupying the 
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promoters with other repressive complexes of miRNAs that are normally 
upregulated in differentiated cells, but silent in ESCs (48,166). 
 
There is also a general increase in miRNA expression in hESCs and mESCs, 
following the loss of pluripotency and subsequent differentiation (166). 
 
 
5.9. The microprocessor complex 
 
5.9.1. DiGeorge critical region 8 (DGCR8) 
 
DGCR8 was first identified in humans as a protein that is deleted in patients 
suffering with a rare disease called DiGeorge syndrome (167). The disease is 
caused by de novo or autosomal dominantly inherited deletions in the 22q11.2 
chromosome region, as the genes deleted play a role in many biological systems, 
the symptoms of DiGeorge syndrome are diverse and can include cardiac 
abnormalities, hypocalcaemia and the loss of the thymus gland (167).  Unlike the 
DGCR8 null mice which are early embryonic lethal, sufferers of DiGeorge 
syndrome are heterozygous for the deletion so produce a sufficient amount of 
DGCR8 for survival, this corresponds with studies conducted on mice which are 
haploinsufficient/heterozygous (DGCR8+/-) for DGCR8 which are viable and 
develop neuronal defects postnatally (168). The neuronal defects observed in 
DGCR8+/- mice may explain some of the learning difficulties observed in some 
DiGeorge sufferers (169), however although DGCR8 maps to the deleted region 
in DiGeorge syndrome, it is yet to be confirmed whether the decrease in miRNAs 
is a direct cause of the disease symptoms(170).  DGCR8 has also been implicated 
in other diseases such as in the inherited neurodegenerative disorder; fragile X-
associated tremor/ataxia syndrome (FXTAS), in which the expanded CGG 
repeats in the fragile X mental retardation 1 (FMR1) mRNA bind to DGCR8, 





The main role of DGCR8 as a critical component of the microprocessor complex 
is to recognise the substrate pri-miRNA, in the nucleus, which is then cleaved by 
its partner Drosha (129).  DGCR8 consists of two tandem RNA binding domains 
in the C terminus, which facilitate binding to Drosha and pri-miRNA, and a WW 
domain at the N terminus which plays a role in the nuclear localisation of DGCR8 
(172).   Although the DGCR8 protein can bind RNA (single stranded, double 
stranded and random hairpin transcripts) in a non-specific manner (173), it has 
recently been discovered that DGCR8 has the ability to form a homodimer, 
creating a functional RNA binding heme domain, which resides in the central 
region of DGCR8, to specifically bind to pri-miRNA (174).  However, it is not fully 
clear whether the formation of the DGCR8 dimer is necessary for the successful 
formation of the microprocessor complex (174).  
 
DGCR8 can also undergo post-translational modifications, in order to modulate 
its function, such as deacetylation by HDAC1 of lysine residues in its RNA binding 
domains, which increases its affinity for pri-miRNAs (175) and phosphorylation 
which stabilises the protein and in the human cells studied; Human Embryonic 
Kidney (HEK) 293 and HeLa, promotes a proliferative phenotype (176). 
 
Further studies have suggested that as well as being directly involved in the 
miRNA biogenesis pathway via the Microprocessor complex, DGCR8 may also 
associate with unidentified endonucleases as part of the small nucleolar RNA 
(snoRNA) biogenesis pathway (177). 
 
Unlike Drosha and Dicer (21,178) which have been reported to have a role in 
other small non coding RNA biogenesis pathways, DGCR8 is unique to the miRNA 
biogenesis pathway, therefore knocking it out allows for studies of the effects of 
the global down regulation of miRNAs (3).  By reintroducing individual or 
clusters of miRNAs back into DGCR8 null cells, the functions of the miRNAs can 
be elucidated, without the interference of the other canonical miRNAs (3).  
 
Recent studies have revealed that although DGCR8 and Dicer do not seem to play 
a direct role in regulating or creating long (>200 nucleotides) non coding RNA 
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(lncRNA), the loss of either protein, which results in the loss of the majority of 
miRNAs also, results in decreased expression of lncRNAs, although they lack 3’ 
UTRs (177,179).  
 
Within the nucleus, Drosha and DGCR8 regulate each other. Drosha suppresses 
DGCR8 expression in the nucleus post-transcriptionally, thereby indirectly 
regulating the production of mature miRNAs (180).  Interestingly, as the 3’ UTR 
of DGCR8 is hypothesised to have miRNA binding sites and DGCR8 mRNA have a 
hairpin structure, it is wholly possible that the post transcriptional down 
regulation of DGCR8 is mediated by miRNAs (180).  The DGCR8 protein stabilises 
the Drosha protein, therefore as well as playing a functional role in miRNA 
biogenesis, DGCR8 also facilitates the successful formation of the microprocessor 










Figure 9 – Autoregulatory circuit between Drosha and DGCR8. The two components of the 
microprocessor complex regulate each other; the Drosha protein downregulates DGCR8 
posttranscriptionally, and the DGCR8 protein stabilises the Drosha protein.  Adapted from: (180) 
 
Thus, Drosha and DGCR8 are involved in a complex auto regulatory circuit, 
whereby if DGCR8 levels are high, the microprocessor complex will post 
transcriptionally down regulate it, reducing the stability of Drosha, and lowering 
the activity of the microprocessor (180) (Figure 9). Conversely in a study in 
mESCs with reduced Drosha activity, there was an increase in DGCR8 expression 
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(138).  This may be to allow for extra regulation of miRNA processing, 
preventing miRNAs from being expressed until the appropriate developmental 
signals are received (181). 
 
The microprocessor complex is also regulated extrinsically by developmental or 
environmental cues, for example in reproductive cancer cell lines, cellular stress 
has resulted in p53 (tumour suppressor gene) interacting with Drosha to 




Drosha is a class two, RNAse III endonuclease that resides in the nucleus and as 
an integral part of the microprocessor complex (along with DGCR8) aids in the 
maturation of miRNAs (183).  Structurally Drosha has tandem RNase III 
domains, and a double stranded RNA binding domain.  Akin to DGCR8, Drosha 
RNAse activity is unspecific, however unlike DGCR8, Drosha requires binding to 
DGCR8 to confer high specificity for the processing of pri-miRNAs (138,178).  
Therefore it has been suggested that Drosha may play a role in other ncRNA 
pathways. It has already been discovered that Drosha is integral to the DNA 
damage RNA (DDRNA) biogenesis pathway (184). These ncRNAs have the 
sequence of the damaged DNA locus and use this to signal the presence of DNA 
damage, so that repair can take place (185). 
 
As an endonuclease, Drosha also plays other roles outside the miRNA biogenesis 
pathway such as the processing of pre-ribosomal RNA (186).  Drosha has also 
been implicated in the processing of a murine, unspliced, polyadenylated, 
nuclear ncRNA known as meiotic recombination hot spot locus (mrhl) with a 
possible function in the nucleolus (187). 
 
5.10. Argonaute 2  
 
The Argonaute (Ago) protein family as part of the RISC complex, plays an 
integral role in RNA silencing processes, influencing both miRNA and siRNA 
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function (155). miRNAs and siRNAs guide Ago proteins as part of the RISC 
complex, to their target sequence where the ncRNAs bind via complementary 
binding, resulting in target degradation or translational repression mediated by 
Ago (188). The importance of Ago in mESCs is exemplified in studies where Ago 
has been knocked out, resulting in an inability of cells to synthesise miRNAs and 
siRNAs, and undergoing rapid apoptosis due in part to the upregulation of 
apoptotic genes due to the loss of ncRNAs (189). 
 
It should be noted that Ago proteins have been found to interact with other 
ncRNAs, including transfer RNAs (tRNAs) and ribosomal RNAs (rRNAs) (1). 
 
In humans and mice, four ubiquitously expressed Ago family members; Ago1-4, 
can function in the RISC complex interchangeably (189), though Ago2 is 
preferentially incorporated into the RISC complex for miRNA function (21). 
Although the members of the Ago family are highly similar, Ago1 and 2 are more 
effective at utilizing perfectly matched siRNAs than the other two family 
members, and there are a small percentage of miRNAs that are capable of being 
preferentially loaded onto particular Ago family members within RISC 
complexes (189,190).  There is conflicting evidence that although all of the Ago 
proteins can bind to siRNA and miRNA, only Ago2 is able to cleave target mRNA 
sequences (191,192). 
 
ncRNA interaction with Ago may be a rate limiting step for ncRNA function as 
ncRNAs can compete for Ago binding, mediating their function (133).  Ago2 
proteins are also regulated by a specific autophagic mechanism, which can 
degrade both the Ago2 and Dicer protein regulating miRNA loading into the RISC 
complex (193). 
 
Though the proteins that make up the RISC complex, are yet to be identified 
(194), it has been discovered that the minimal requirements for the RISCs 
function as a gene silencer are the Ago protein and the mature miRNA (195).  
The guide strand is not only important for the identification of the target 




As well as playing a major role in the RISC complex, Ago2 has also been shown to 
play another role in an alternative miRNA biogenesis pathway (127,188). In this 
pathway, after pre-miRNAs are exported from the nucleus to the cytoplasm, they 
are recognised by a preformed complex formed of Ago2, Dicer and the 
transactivating response RNA-binding protein (TRBP) (196), which nicks a 
section of the passenger strand, Dicer then cleaves the stem loop resulting in the 
formation of a miRNA/miRNA* duplex (127). At this point the Ago/Dicer/TRBP 
complex dissociates and it has been hypothesised that the free Ago2 is then free 
to be incorporated into the RISC complex (127).  The nicking of the passenger 
strand of the pre-miRNA by the Ago/Dicer/TRBP complex is thought to aid in the 
both the identification of the guide/mature miRNA strand by the RISC complex 
(127). 
 
5.11. DGCR8-/- mESCs 
 
Of the individual components that are involved in the miRNA biogenesis 
pathway, DGCR8 is the only one, which is unique to this particular ncRNA 
biogenesis pathway; therefore by knocking it out, researchers have been able to 
study the effects of global miRNA loss (6).  It should be noted that of course, in 
the absence of DGCR8, miRNAs generated via non-canonical pathways are still 
produced, however as these make up approximately 1% of the miRNAs produced 
by cells, that the DGCR8-/- mESCs are relatively miRNA free (197).  
 
DGCR8-/- mESCs provide a valuable resource for studying the functions and 
targets of individuals or clusters of miRNAs, via the re-expression of these 
miRNAs in DGCR8-/- mESCs, for example transfection of let-7 into DGCR8-/- 
mESCs rescued the differentiation defect, allowing the cells to effectively 
downregulate the pluripotency markers, therefore the let-7 family of miRNAs 
play a major role in the initiation of differentiation (198). 
 
Large scale transcriptomic studies on DGCR8-/- mESCs, have revealed that there 
is an upregulation of genes involved in a number of processes including cell cycle 
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signalling, epigenetic modifications and immunity (8,48), however further 
protein studies are required in order to accurately validate the individual targets 
indentified in the study. 
 
Although DGCR8 knockout (6), dicer knockout (7), drosha knockout (199) and 
argonaute 2 knockout (189) mESCs have been created among other cell lines 
with impaired miRNA biogenesis, as of yet no cell line that does not express any 
miRNAs has been created, this is in part due to the abundance of miRNA 
biogenesis pathways and due to the extensive regulatory reach of miRNAs (2), it 
is unlikely that these cell lines would be viable, particularly as mice with any one 
of these genes knocked out are embryonic lethal (200). 
 
5.12. MiRNAs and stem cell metabolism 
 
Notably, there is increasing evidence that miRNAs regulate stem cell metabolism 
(201,202). In particular the let-7 family of miRNAs, which has been implicated in 
the regulation of pluripotency(203), has also been implicated in the regulation of 
the insulin-PI3K-mTOR pathway, a pro-glycolytic pathway (116).  Furthermore, 
Lin28 a protein which is highly expressed in ESCs, and is a negative regulator of 
the let-7 family has as part of a mix of transcription factors been used to 
successfully reprogram human fibroblasts (58). 
 
Interestingly, Lin28 overexpression in mESCs results in an abundance of 
metabolites involved in the threonine catabolism pathway, and overexpression 
of let-7 miRNAs has the opposite effect, indicating these miRNAs can also play a 
direct role in regulating the TCA cycle via amino acid metabolism (201). 
 
5.13. Embryonic stem cell cycle (ESCC) regulating miRNAs 
 
It has been estimated that there are 323 distinct miRNA sequences, which make 
up the 110,000 copies of miRNAs within individual mESCs, of which the majority 
can be accounted for by six distinct loci, notably four of these loci or their human 
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homologs have been shown to play roles in cell cycle regulation and oncogenesis 
(204).  This suggests that the distinctive cell cycle of mESCs is a major aspect of 
their phenotype. 
 
As aforementioned, fourteen key miRNAs that were re-expressed in DGCR8-/- 
mESCs were able to restore the cell cycle defect (3), of these miR-291a, 291b, 
294 and 295 were studied further, as they are highly expressed in mESCs, 
representing approximately a third of the miRNAs present in mESCs (205,206).  
miR-291a, 291b, 294 and 295 are part of a cluster (miR-295 cluster) of co-
transcribed and co-expressed miRNAs that have been shown to play an 
important role in controlling the mESC cell cycle, and so have been termed 
Embryonic Stem Cell Cycle (ESCC) (3).  Due to the importance of the miR-295 
cluster for the normal mESC phenotype and for embryonic development(3,6), it 
is highly conserved having homologs in many mammalian organisms including 
humans (205,206) (Figure 8) and in other organisms such as zebrafish (207), 
which all have the same seed sequence of ‘AAGUGC’ (Figure 8).  As all of the 
members of the miR-295 cluster have the same seed sequence (with the 
exception of miR-291b which has one nucleotide difference), they are 
functionally redundant and share many of the same targets (3,8,26). 
 
Through transfection studies in DGCR8-/- mESCs, the highly conserved clusters of 
miRNAs (Figure 8) (205,206) have been shown to target cell cycle inhibitor 
mRNAs; Cdkn1a, Lats2 and Rbl2 (26), which regulate the G1/S phase transition 
resulting in restoration of the WT mESC cell cycle (3). Notably, miR-294 was the 
most efficient at restoring the normal mESC cell cycle (3).  Overexpression of the 
miR-295 cluster in mESCs results in increased resistance to differentiation and 
sustains their high proliferation rate (208). However, the ESCC miRNAs do not 
restore the differentiation defects in DGCR8-/- mESCs, indicating that a different 
subset of miRNAs is important for proper differentiation (3).  Interestingly, the 
ESCC miRNAs do act to prevent mesodermal differentiation by targeting the Dkk-
1 gene, a Wnt pathway inhibitor (209).  Notably, the miR-302 cluster (105) has 
been shown to be directly positively regulated by the pluripotency markers Oct4 
and Sox2 (210).  This is also the case with the miR-295 cluster which has been 
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shown to be positively regulated by the three key pluripotency markers; Oct4, 
Nanog and Sox2 (48). The ESCC miRNAs also inhibit the let-7 family of miRNAs, 
which are known to promote differentiation (198) and suppress cell cycle 
progression (211).  Therefore the ESCC miRNAs play an essential role in the 
mESC cell cycle and by extension in the maintenance of the pluripotency 
phenotype. 
 
As well as promoting the cell cycle and pluripotency, the miR-295 cluster has 
also been shown to play an important role in protection against apoptosis, 
studies on Dicer knockout mESCs have shown that there is an upregulation of 
cell death genes such Caspase 2 which are targeted by the miR-295 cluster. 
Notably only when the cells were exposed to DNA damaging chemicals, did the 
protective properties of the miR-295 cluster become apparent (148).  This is 
supported by murine studies on miR-295 cluster knockout mice which, display 
partially penetrant embryonic lethality (212).  The miR-295 cluster has also been 
shown to protect against autophagic cell death in human melanoma cells (213). 
 
The role of the ESCC in the maintenance of the pluripotent phenotype has been 
evidenced by their ability to replace the Yamanaka factors and reprogram 
mature cells into iPSCs, at a higher efficiency than the more traditional method 
(16,214).  In fact it has been proven that the expression of miRNAs is necessary 
for reprogramming to occur, as Dicer knockout cells are unable to undergo full 
reprogramming to iPSCs and instead reprogram into Dicer null mESCs, which 
have severe growth and differentiation defects, and only upon the re-expression 
of Dicer and therefore miRNAs, are they able to be reprogrammed (215). 
 
These studies stress the importance of miRNAs and the ESCC miRNAs in 







5.14. ESC Proteomics 
 
Proteomics is the large-scale study of proteins, with particular emphasis on their 
structures and functions. In this study we used proteomics to determine which 
proteins are not only affected by the loss of DGCR8 but also by the presence of 
the miRNAs known to be highly expressed in mESCs, thereby, providing a 
detailed and broad overview of potential mechanisms controlling the ES cell 
phenotype.   
 
Thus far, proteomic studies on ESCs have provided great insights into the 
proteomes of ESCs both under proliferative and differentiation conditions 
(216,217). By combining the results of these studies with other studies using 
transcriptomics (218), the mechanisms underlying the unique phenotype of ESCs 
can be explored.  Therefore the integration of investigative techniques is vital for 
formulating models of cell behaviour, and may allude to possible regulatory 
input such as miRNAs. This is most apparent in the few miRNAs studies using -
omics techniques, which indicate correlation between decreased protein and 




5.14.1. Sample preparation 
 
The results of any experiment depend greatly on the quality of the starting 
material, this is particularly important in molecular biology where cellular stress 
and extrinsic factors such as temperature can have major effects on the quality of 
the biological material and therefore affect any downstream results (219).  All 
proteomics studies begin with extensive sample preparation to ensure maximum 
quality of the sample. 
 
The proteins are isolated from cell lysates and solubilised in a buffer.  This buffer 
usually contains numerous denaturing agents including chaotropes and 




In order to further disrupt the cell membrane and produce homogenised cell 
lysates, the cell lysate then undergoes sonication, and centrifugation this allows 
for the separation of the solubilised total cellular protein and a cell pellet 
consisting of cellular debris and intracellular molecules such as DNA.   
 
5.14.2. 2D Difference in gel electrophoresis (2D DIGE) 
 
2D DIGE is a quantitative method for comparing whole protein expression, 
including post-translational modifications.  It allows for the routine separation of 
1000s of proteins and their isoforms in the same gel (220). 
 
A simplified summary of the 2D DIGE methods is summarised in Figure 10. 
Firstly, proteins are minimally labelled with fluorescent cyanine dyes (Cy2, Cy3 
and Cy5), which bind to surface-exposed lysines allowing for downstream 
identification of proteins.  The Cy3 and Cy5 dyes are incubated with known 
concentrations of two separate protein samples, and the Cy2 dye is incubated 
with known concentrations of a pooled sample, in order to act as an internal 
standard. Excess dye is quenched by the addition of more lysine.  Unlike methods 
that rely amino acid labelling for peptide identification, DIGE is not hindered by 
the fact that these amino acids may not always be accessible, resulting in 




























Figure 10 – Summary of 2D Difference in Gel Electrophoresis (2D DIGE) method. 
 
In order to obtain accurate representations of the samples proteomes, samples 
are loaded multiple times on different gels.  Per gel, the Cy3, Cy5 and Cy2 
samples are combined and proteins are then separated in the first dimension 
according to their isoelectric points (pI), the pH at the which the net charge of 
the protein is zero, this is known as isoelectric focusing (IEF).  This is done by 
loading the proteins onto an immobilised pH strip and applying an electrical 
field, once proteins are aligned according to their pI, the protein is immobilised 
(222).  
 
The next step is to separate the proteins in the second dimension by their 
molecule mass (Mw), in order to do this the strip is equilibrated by saturation in 
sodium dodecyl sulfate (SDS). The strip is then run on a polyacrylamide gel so 
that proteins are separated both by their pI and Mw, and this can be used to 
identify accompanying post-translational modifications (223). Once the proteins 
have completed running, they are not visible to the naked eye on the gel, 
therefore the gel is scanned and imported into software (224) in order to view 
the relative expression levels of the proteins and also to view their positions 
within the gel for downstream identification. The gel itself can be stained after 
being fixed in a solution containing acetic or phosphoric acid, which prevents 
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diffusion of the proteins (220).  Conventional staining dyes include Coomasie 
Blue and Silver nitrate, of which silver nitrate is the more sensitive (225).   
 
Multiple gels can be analysed simultaneously and aligned according to 
protein/spot position producing a protein ‘map’. Spots/proteins of interest can 
be highlighted on the software over multiple gels, aiding in the selection of spots 
for mass spectrometry (MS) analysis (Figure 10). 
 
5.14.3. Protein identification 
 
Before MS analysis, the spots on the 2D DIGE gel, are manually picked from the 
gels and digested using proteolytic enzymes such as trypsin.  The enzyme trypsin 
is a highly specific, high activity, serine protease that cleaves the C-terminal end 
of lysine (K) and arginine (R) producing tryptic peptides of appropriate lengths 




A mass spectrometer works by using magnetic and electric fields to apply forces 
to ions within a vacuum (227).  During ionization, the sample is converted into 
gas phase ions.  Two major methods are primarily used; matrix assisted laser 
desorption/ionization (MALDI) and electrospray/microspray/nanospray 
ionization (ESI), these are both similar in that they are referred to soft ionization 
techniques as they tend to produce mass spectra with little or no fragment-ion 
content, this in particular makes them optimal for the analysis of high molecular 
compounds (228).  However, MALDI produces ions by pulsed-laser irradiation of 
a sample whereas ESI produces ions by applying a high voltage to a liquid sample 
in order to produce an aerosol, this produces various multi charged ions, which 





5.14.5. Analysis and detection 
 
Once gas phase ions are formed, they are fed into a mass analyser that measures 
the mass/charge (m/z) ratio of the ions.  There are four major types of analysers; 
time-of-flight, quadrupole, ion trap and Fourier transform ion cyclotron (FT-MS) 
(227).  All of these systems use either an electric and/or magnetic field to affect 
the path and /or velocity of the ions according to their mass/charge ratios, in 
order to generate a mass spectrum of the peptides coming from the ion source 
(227).  Often this is coupled to a second MS reaction, whereby targeted ions of a 
specific m/z are separated from the remaining ions (referred to as 
parent/precursor ions) and undergo another fragmentation step to generate a 
new, more targeted mass spectrum, this increases the specificity of detection of 
known peptides (227).  There are a number of methods that are used for the 
fragmentation step including electron transfer dissociation (ETD), collision-
induced dissociation (CID) and electron capture dissociation (ECD) (230).  The 
final step in mass spectrometry is detection, this occurs via a detector which 
records either the charge or current produced when an ion passes or hits it 
surface producing a mass spectrum (230).  
 
The proteins are then identified by aligning the mass spectrum with 
comprehensive protein databases such as Uniprot (231) or NCBI.  Once the 
proteins have been successfully identified, the Mw and pI of the proteins 
provided by the databases can be compared to the Mw and pI of the 
proteins/spots on the DIGE gel, to ensure that the proteins are not correctly 
matched up but to also highlight the presence of post translational modifications. 
 





















Figure 11 – Summary of Mass Spectrometry on a 2D-DIGE gel Adapted from: (232) 
5.15. Proton nuclear magnetic resonance (H1 NMR) spectroscopy  
 
H1 NMR is technique that harnesses the magnetic properties of nuclei to identify 
molecules, in the case of H1 NMR, it focuses on particularly on molecules that 
contain hydrogen. It works because specific nuclei in a magnetic field have the 
ability to absorb and reabsorb at specific electromagnetic radiations allowing 
researchers to identify them. Due to the nature of the technique using hydrogen 
atoms as a way of identifying compounds, it is imperative that samples are pH’ed 
and adjusted to pH 7 so as to not interfere with any readings.  In this study we 
used  H1 NMR, to not only study the secretomes of the WT and DGCR8-/- mESCs, 
but also to study the intracellular metabolite composition of the cells.  
 
In order to extract soluble metabolites from the mESCs, in a way that minimised 
any alterations to metabolite concentration in the cells due to factors such as 
cellular stress, or metabolite degradation, immediately prior to harvest the cells 
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were rapidly cooled down to restrict enzymatic degradation and then they were 
harvested in perchloric acid (233).   
 
Our group has previously demonstrated that the combination of proteomics and 

































miRNAs are known to display their effects at the protein level, yet large scale 
studies focusing on miRNA function in mESCs predominantly use transcriptomic 
techniques to study their targets and functions (8).  As the major readout of 
miRNA function is at the protein level, this provides an incomplete ‘picture’ of 
the targets of these miRNAs, and their role in the mESC phenotype.   
 
1. Pathways governing mESC differentiation are controlled by miRNAs. A 
proteomic approach comparing differential protein expression in DGCR8 
knockout mESCs and WT mESCs grown in the presence of LIF will reveal 
miRNA-dependent proteins that influence pluripotency. 
 
2. DGCR8 knockout mESCs provide a relatively ‘blank canvas’ for the study 
of individual miRNA function. A proteomic approach comparing 
differential protein expression in DGCR8 knockout mESCs transfected 
with individual ESCC miRNAs grown in the presence of LIF, will reveal 
direct and indirect targets that are shared between the different miRNAs 
and affected by the individual miRNAs and potentially reveal their 


















Before stem cell-based therapies can be used for treatment, it is essential that we 
gain knowledge of the molecular mechanisms controlling pluripotency and 
differentiation towards the cardiovascular lineage. Because of their ease of 
expansion, allowing a large number of cells to be obtained, and the existence of 
the DGCR8-/- mESC cell line, mESCs will be used in the present study. 
 
7.1. Analyses comparing WT and DGCR8 knockout mESCs 
 
i) A comprehensive proteomics analyses of DGCR8 null mESCs and wild 
type mESCs. 
ii) Identify and validate miRNA-dependent proteins in mESCs.  
iii) Study the effects that the loss of DGCR8 has on the metabolome of mESCs  
7.2. Analyses comparing DGCR8 null mESCs transfected with the 
individual ESCCs 
 
iv) A comprehensive proteomics analyses of DGCR8 knockout mESCs 
transfected with the ESCC miRNAs 
v) Identify direct/indirect and validate targets of the ESCC miRNAs in 
DGCR8 knockout mESCs 
vi) Study the effects that the individual ESCCs have on the DGCR8 knockout 
mESCs on both the metabolome and proteome of the cells. 
vii) Compare the proteins identified in both of the proteomics analyses (i and 











8.1. Cell culture 
 
All cells were grown in an incubator, at 37° C in a humidified atmosphere of 5% 
CO2. 
 
8.1.1. Derivation of MEF feeder layer 
 
The clonal mouse embryonic fibroblast (MEF) cell line (SCRC-1008, ATCC) 
derived from C57BL/6 mouse embryos, was removed from liquid nitrogen and 
thawed rapidly by swirling in a 37°C water bath.  The cell suspension was then 
transferred into a falcon tube and resuspended in complete MEF medium before 
being centrifuged for 5 minutes at 1000 rpm. Next, the supernatant was 
discarded and the cell pellet was resuspended in 5ml of medium and plated in a 
sterile T25 cell culture flask. The following day the medium on the cells was 
changed to fresh medium.  Complete MEF medium consisted of DMEM (ATCC, 
Cat No. 30-2002) supplemented with 15% FBS (ATCC, Cat No. SCRR-30-2020) 
100 U/ml Penicillin and 100mg/ml Streptomycin (Life Technologies, Cat No. 
15140-122) and 5ml of 200mM L-glutamine (Life technologies, Cat No. 25030-
024).  The complete medium was allowed to reach room temperature before use.  
 
Once the cells were ≥90% confluent, they were subcultured: the medium was 
removed and, the cells were washed twice with DMEM (Life technologies, Cat No. 
10938025) supplemented with 5ml of100 U/ml Penicillin and100mg/ml 
Streptomycin (Life Technologies, Cat No. 15140-122). Next, 3ml of trypsin-EDTA 
solution (Life technologies, Cat No. 25300-054) was added to the flask and 
incubated for 90 seconds at 37°C or until cells began to detach from the flask. 
The trypsin-EDTA solution was then neutralized by the addition of 4 ml of 
complete MEF medium and the cells were transferred to a sterile falcon tube and 
centrifuged at 1000rpm for 5 minutes at room temperature.   
 
Subsequently, the supernatant was removed from the cells, and the cells were 
resuspended in 5 ml of complete MEF medium, and plated at a ratio ranging from 
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1:3 to 1:5 in T25s. Medium was changed every 1-2 days. Once the cells had 
reached 90% confluency, they were treated with 12μg/ml of mitomycin C 
(Sigma, Cat No.M4287) (2mg of mitomycin C was dissolved in 5ml of ddH2O to 
create a 0.4mg/ml stock solution of which, 30μl of mitomycin C per 1 ml of 
medium was added to the cells) in complete MEF medium for 3 hours at 37°C. 
Next, the cells were washed several times with DMEM (Life technologies, Cat No. 
10938025) supplemented with 5ml of 100 U/ml Penicillin and 100mg/ml 
Streptomycin (Life Technologies, Cat No. 15140-122) before being incubated 
overnight at 37°C in complete MEF medium.  Prior to use as a feeder layer, the 
cells were washed a further three times with DMEM (Life technologies, Cat No. 
10938025) supplemented with 5ml of 100 U/ml Penicillin and 100mg/ml 
Streptomycin (Life Technologies, Cat No. 15140-122).   
 
Feeder layers were not maintained for longer than one week and only used up to 
passage 7 to retain optimal function. 
 
8.1.2. Mouse embryonic stem cells 
 
WT (v6.5) and DGCR8-/- mouse embryonic stem cells (Novus Biologicals, Cat nos. 
NBP1-41162 & NBA1-19349, respectively) were removed from storage, thawed 
rapidly by swirling in a 37°C water bath, resuspended in complete mouse 
embryonic stem cell (mESC) medium and centrifuged at 1000rpm for 5 minutes. 
Next the supernatant was removed and the cells were resuspended in 5ml of 
complete mESC medium before being plated on a pre-treated MEF cell feeder 
layer (DGCR8-/- mESCs).  v6.5 cells were plated directly onto 0.1% gelatin (Sigma, 
Cat No. G-1393)  (8 ml of 2% gelatin was combined with 160ml of DMEM (Life 
technologies, Cat No. 10938025)) coated T25 flasks and passaged onto gelatin-
coated flasks. The mESC complete medium consisted of DMEM (ATCC, Cat No. 
30-2002) supplemented with 15% FBS (ATCC, Cat No. SCRR-30-2020), 5ml of 
100 U/ml Penicillin and100mg/ml Streptomycin (Life Technologies, Cat No. 
15140-122). 100x non essential amino acids (Life technologies, Cat No. 11140-
050), 5ml of 200mM L-glutamine (Life technologies, Cat No. 25030-024), 0.1mM 
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2-mercaptoethanol (BDH, Cat No. 441433A) and 10ng/ml recombinant 
leukaemia inhibitory factor (LIF; Chemicon, Cat No. LIF1010).    
 
The next day the medium was changed and once the cells were 70-80% 
confluent, they were passaged in a similar manner to the protocol used for the 
MEF cells. However, after the DGCR8-/- cells were centrifuged, they were 
subcultured into a ratio ranging from 1:2 to 1:5 and plated in 0.1% gelatin coated 
T25 culture flasks for 30 minutes at 37°C in order to allow for a separation of the 
mESCs and the feeder layer. Next, the supernatant containing unattached cells 
(predominantly DGCR8-/- cells) was removed, and 4 x 105 DGCR8-/- cells were 
plated on newly treated MEF cells in T25s.  The WT cells were plated directly 
onto 0.1% gelatin coated plates. Cells were subcultured every 2-3 days. 
 
Before experiments were conducted on DGCR8-/- mESCs, cells were weaned off 
the mitomycin C treated MEF layer and grown in gelatin-coated flasks. Similar to 
the subculturing procedure, cells were washed, trypsinized, centrifuged, and 
plated onto 0.1 % gelatin coated plates for 30minutes. Next, the number of cells 
in the supernatant were counted and the appropriate number of cells were 
transferred to a new gelatin coated flask, after 2-3 days, cells were passaged 
directly onto 0.1% gelatin coated flasks.  Cells were passaged at least three times 
onto gelatin-coated flasks to eliminate MEF contamination. 
 
8.1.3. Alkaline phosphatase staining 
 
DGCR8-/- and WT cells were plated at a density of 25,000 and 50,000, 
respectively, in a 0.1% gelatin-coated 6 well plate.  Medium was changed every 
two days and staining was conducted using an alkaline phosphatase detection kit 
(Millipore, Cat No. SCR004) on the fifth day of culture, as per manufacturers’ 
instructions.  Briefly, media was removed from cells and they were fixed in 4% 
paraformaldehyde in PBS for 90 seconds.  Cells were washed with PBS (Sigma 
Aldrich, Cat No. D8537) with 0.1% Tween (Sigma Aldrich, Cat No.P1379) and 
covered in staining solution in the dark, at room temperature for 15 minutes.  
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Cells were washed again with PBS-Tween, covered in PBS and stained colonies 
were observed using a light microscope. 
 
8.1.4. Cell transfection 
 
DGCR8-/- cells were transfected with the Embryonic Stem Cell Cycle (ESCC) 
miRNAs in mimic form, four from the miRNA 290 cluster; miR-291a-3p (Life 
Technologies, Cat No. mc12953) miR-291b-3p (Life Technologies, Cat No. 
mc13011), miR-294-3p (Life Technologies, Cat No. mc10865), miR-295-3p (Life 
Technologies, Cat No. mc10386) and miR-302d-3p (Life Technologies, Cat No. 
mc10927), as well as a negative control miRNA (Qiagen, Cat No. 1027280). 
Twenty four hours before the cells were transfected, the DGCR8-/- cells were 
plated in complete medium at the densities shown in Table 2. 
 
Prior to transfection, two mastermixes labelled A and B (Table 3) were made up 
as shown in transfection media consisting of DMEM (ATCC, Cat No. 30-2002) and 
10ng/ml recombinant LIF (Chemicon, Cat No. LIF1010).    
 
Mastermix A and the corresponding Mastermix B were mixed in one tube by 
gentle pipetting, and incubated at room temperature for 10 minutes before being 
added to the correct flask. 
 
Meanwhile the medium was removed from the cells to be transfected, and the 
cells were washed three times with DMEM (Life technologies, Cat No. 10938025) 
supplemented with 5ml of 100 U/ml Penicillin and100mg/ml Streptomycin (Life 
Technologies, Cat No. 15140-122).  Next 6 ml of transfection medium was added 
to the cells in the T75 flasks and, 3ml of transfection medium was added to the 
cells in the T25 flasks. Once the mastermixes had been added to the 
corresponding flasks, the flasks were placed in the incubator for five hours.  
Subsequently, 6ml and 3ml of neutralizing medium consisting of DMEM (ATCC, 
Cat No. 30-2002) supplemented with 30% FBS (ATCC, Cat No. SCRR-30-2020) 
and 10ng/ml LIF (Chemicon, Cat No. LIF1010), was added to the T75s and T25s, 
respectively.  The next morning, the medium on the cells was changed to 
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complete medium and the cells were incubated for a further 48 hours before 
harvesting. 
 




8.2.1. RNA extraction 
 
Cells were washed twice with PBS and the T25 flasks were turned on their sides 
to drain cells of all PBS.  RNA extraction was conducted using the miRNeasy Mini 
Kit (Qiagen, Cat No. 217004) following the manufacturers’ protocol.  Briefly, cells 
were scraped in 700μl of Qiazol Lysis Reagent into 1.5 ml eppendorf tubes, 
incubated at room temperature for 5 minutes, and then vortexed with 140μl of 
chloroform. The lysate was incubated for a further 5 minutes at room 
temperature before being centrifuged for 15 minutes at 12,000 rpm, at 4°C.  280 
μl of the upper aqueous phase was transferred to a new tube, mixed with  420μl 
of 100% ethanol by thorough pipetting and transferred into an RNeasy mini 
column. The remaining centrifugation steps were carried out at room 
temperature.  The column was centrifuged for 1 minute at 13,000 rpm and the 
flowthrough was discarded, next 700μl of RWT buffer was added to the column, 
it was centrifuged for 1 minute at 13,000rpm and the flow through was 
discarded.  Next 500μl of RPE buffer was added to the column before a further 
centrifugation step for 1 minute at 13,000rpm, the flow through was discarded 
and a further 500μl of RPE buffer was added to the column before it was 
centrifuged at 13,000rpm for 2 minutes.  At this point, the mini column was 
transferred into a new collection tube and centrifuged at high speed for 1 
minute, before being transferred to a new tube.  The RNA was eluted in 25-30μl 
of RNase free water, by centrifugation at high speed for 1 minute.  RNA 







8.2.2. Reverse transcription PCR prior to conventional PCR 
 
For each PCR reaction, 2.5μg of RNA was used, the total volume was adjusted to 
10μl with nuclease free water.  The RNA was then reverse transcribed into cDNA 
using reagents from the Improm-II Reverse Transcription kit (Promega, Cat No. 
A3800); the 5x Reaction buffer, MgCl2 (25mM), Random Primers, dNTPs, RNasin 
and the reverse transcriptase enzyme, as well as dNTPs (25mM) (Life 
Technologies, Cat No. 10297-018). 
 
The reverse transcription reaction was set up by mixing the 10μl of RNA with 
0.2μl of Random Primers, 5μl of 5x Reaction buffer, 3μl of MgCl2 (25mM) and 
1.25μl of 25mM dNTPs. The samples were then placed in a thermal cycler, where 
the temperature was raised to 70°C for 5 minutes, and then dropped to 4°C for 5 
minutes whilst 0.625μl of RNasin, 3.925μl of RNase free water and 1μl of reverse 
transcriptase was added to each sample, making the final reaction volume 25μl.  
The RT-PCR reaction program was as follows, samples were initially kept at 25°C 
for 5 minutes to allow the primers to anneal, then reverse transcribed for 90 
minutes at 42°C, and finally the reverse transcriptase enzyme was inactivated for 
15 minutes at 72°C.  Samples were then diluted to 10ng/μl using RNase free 
water. 
 
8.2.3. Polymerase chain reaction (PCR) 
 
Primers were designed (Table 4) and cDNA was amplified using a PCR kit (Life 
Technologies, Cat No. 18038042).  PCR reagents were mixed on ice following the 
manufacturers’ instructions; to 5μl of 10ng/μl cDNA, a mixture of 1.5μl of 10x 
PCR buffer, 0.6μl of 50mM MgCl2, 0.1μl of 25mM dNTPs, 2μl of the appropriate 
forward and reverse primers (Table 4) at a concentration of 10mM each and 
5.7μl of RNase free water was added.  Tubes were briefly centrifuged and placed 
in a thermocycler for the following program; preheat lid at 105°C, initial 
denaturation at 94°C for 4 minutes, then 30 cycles of denaturing of the cDNA at 
94°C for 1 minute, annealing of the primers at 58°C for 1 minute and elongation 
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at 72°C for 1 minute.  This was followed by a final extension step at 72°C for 5 
minutes. 
 
Samples were run on a 2% agarose gel with Safeview (NBS Biologicals, Cat No. 
NBS-SV1). 
 
8.2.4. Reverse transcription prior to quantitative PCR for genes 
 
200ng of RNA was topped up to 4.5μl with RNase free water.  The RNA was then 
reverse transcribed using the High Capacity RNA to cDNA kit (Life Technololgies, 
Cat No. 4387406), containing 20x Enzyme mix and 2x RT buffer mix. 
 
The reverse transcription reaction was set up by mixing 4.5ul of the RNA with 
0.5μl of the enzyme mix and 5μl of the RT buffer mix.  The samples were then 
placed in the thermocycler for the following program, 16°C for 5 minutes to 
allow the primers to anneal, 37°C for 60 minutes to allow the reverse 
transcription reaction to occur and 95°C for 5 minutes to inactivate the reverse 
transcriptase enzyme. 
8.2.5. Reverse transcription prior to quantitative PCR for miRNAs 
 
For each reverse transcription reaction, 200ng of RNA was used in a final volume 
of 3μl (topped up with RNAse free water).  The RNA was then reverse 
transcribed using reagents from the Taqman MicroRNA Reverse Transcription 
Kit (Life Technologies, Cat No. 4366596), containing 100mM of dNTPs with 
dTTP, 10x RT buffer, MgCl2 (25mM) and RNase Inhibitor (20Uμl).  In addition the 
Megaplex RT Primers, Rodent Pool A (Life Technologies, Cat No.4399970) and 
Multiscribe Reverse Transcriptase (Life Technologies, Cat No. 4311235) were 
added. 
 
The reverse transcription reaction was set up by mixing the 3μl of RNA with 1μl 
of the Megaplex RT primers, 0.3μl of dNTPs, 2μl of the Reverse Transcriptase, 1μl 
of the 10x RT buffer, 1.2μl of MgCl2, 0.2μl of RNase Inhibitor and 1.3μl of 
Nuclease free water.  The samples were then placed in a thermocycler, for a 
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program where for 40 cycles, the temperature was held at 16°C for 2 minutes, 
raised to 42°C for 1 minute and then raised to 50°C for 1 second.  Finally the 
samples were held at 85°C for 5 minutes.  Samples were then diluted to 2ng/ul 
with RNase free water. 
8.2.6. Quantitative PCR (qPCR) using taqman assays 
 
Samples were loaded onto a 384 well plate.  Per reaction, 1μl of 2ng/μl cDNA 
was mixed with 2.5μl of Taqman PCR Mastermix (Applied Biosystems, Cat No. 
4440049), 0.25μl of the appropriate Taqman microRNA expression assay or gene 
expression assay (Table 5) and 1.25μl of RNAse free water.  Each reaction was 
carried out in duplicate. 
8.2.7. Quantitative PCR (qPCR) using SYBR green  
 
Samples were loaded onto a 384 well plate.  Per reaction, 1μl of 2ng/μl cDNA 
was mixed with 5μl of SYBR® Select Master Mix (Life Technologies, Cat No. 
4472908), 1μl of the appropriate primer pair  (Table 4) at a concentration of 
10μM each and 3μl of RNAse free water. 
8.3. Proteomic analyses 
 
8.3.1. Cell protein extraction 
 
Cells were washed twice with chilled DIGE wash buffer (100mM, pH 8 Tris with 
1 M Magnesium acetate) and scraped in 1 ml of DIGE wash buffer, before being 
centrifuged at 4°C, at high speed for 2 minutes.  The supernatant was then 
removed and the cell pellet was resuspended in 150μl of DIGE lysis buffer (3ml 
of 1M Tris, 48g of Urea, 4g of CHAPS and 2 Protease inhibitor tablets (Roche, Cat 
no. 06538304001), before being sonicated for 15 seconds twice at 4°C.  Cell 
lysates were incubated on ice for 30 minutes, with a brief vortex at 5 minute 
intervals, before being centrifuged at maximum speed, at 4°C for 10 minutes.  





8.3.2. Protein concentration measurement 
 
Protein concentration was measured using the Biorad Protein Assay Reagent 
(Biorad, Cat No. 500-0006) following the manufacturer’s protocol.  Briefly, the 
Bradford dye was diluted in dH2O in the ratio 1:4. A BSA (bovine serum albumin) 
standard stock solution was made up at the concentration 10mg/ml with dH2O 
and serial dilutions were prepared.  For measurements, 2μl of cell lysate or 1μl of 
the standard mixed with 2μl of the DIGE lysis buffer was mixed with 998μl of the 
diluted dye, and incubated for 5 minutes before the optical density was 
measured at 595nm. Using the optical density measurements the protein 
concentrations were determined using the BSA standard curve. 
8.3.3. 2D DIGE clean up 
 
2D DIGE clean up of samples was carried out using the ReadyPrep 2-D Cleanup 
Kit (Bio-rad, Cat No.163-2130), following the manufacturers’ protocol. All steps 
were carried out on ice. Briefly, 500μg or 100μl of each protein was transferred 
into an individual standard eppendorf tube, and 300μl of precipitating agent was 
added.  The solution was then briefly vortexed and incubated on ice for 15 
minutes.  Next, 300μl of precipitating agent 2 was added to the mixture, and 
mixed by vortexing.  The samples were then centrifuged at maximum speed for 5 
minutes and the supernatant was discarded, before 40μl of wash reagent 1 was 
added to the pellet and it was again centrifuged at maximum speed for 5 
minutes.  The wash reagent was then removed, and 25μl of ultrapure water was 
added to the pellet, before 1 ml of pre-chilled wash reagent 2 and 5μl of wash 
additive 2 were added to the pellet, and the pellet was vortexed for 1 minute.  
The samples were then incubated at -20°C for 30 minutes, and vortexed every 10 
minutes for 30 seconds.  After the incubation, the samples were centrifuged at 
maximum speed for 5 minutes, the supernatant was discarded and the pellets 






Figure 12 - Summary of the proteomics workflow 
 
The fluorescence dye reaction was carried out at a dye/protein ratio of 
200pmol/50μg. 50μg of each sample was labelled with either Cy3 or Cy5 dye 
dissolved in DMF (Sigma Aldrich, Cat No. 227056) for direct comparison of the 
two samples, and 25μg of each sample was labelled with Cy2 as an internal 
standard control.  Labelled samples were incubated at 4°C in the dark for 30 
minutes, then 10mM of lysine (Sigma Aldrich, Cat No.L8662) was added to each 
sample for 15 minutes.  Per gel, samples were labelled with the CyDye DIGE 
Fluor Minimal labelling kit (GE Healthcare, Cat No. GE25-8010-65), Cy3, Cy5 and 
Cy2 were mixed and 2x DIGE buffer (8M urea, 2% v/v Pharmalyte, 2% w/v DTT 
and 4% CHAPS) was added, samples were topped up to 450μl with rehydration 
buffer  (8M urea, 0.5% w/v CHAPS, 0.2% w/v DTT, 0.2% w/v Pharmalyte and 
trace amounts of bromophenol blue).  Protein samples (two samples and one 
control per strip) were loaded onto 18cm non-linear immobilized pH gradient 
strips, pH 3-10 (GE healthcare, Cat No. 17-6003-76) on a reswelling tray, covered 
with Immobiline DryStrip cover fluid (GE Healthcare, Cat No. 17-1335-01) and 
left in the dark, overnight at room temperature.  Strips were focused in the 
Multiphor™ II isoelectric focusing system (GE healthcare) at 20°C with the 
following protocol: 150V for 2 hrs, 300V for 2 hrs, 600V for 2 hrs, 1500V for 
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8hours, 8000V for 30mins, then 8000V for 2 hrs.  Once the isoelectric focusing 
had completed, the strips were equilibrated in equilibration buffer (6M urea, 2% 
w/v SDS, 30% glycerol, 50mM Tris/HCl pH 8.8 and trace amounts of 
bromophenol blue) with 1% w/v DTT for 15 minutes on a shaker, followed by a 
further 15 minute incubation with equilibration buffer with 4.8% 
iodoacetaemide on a shaker.  The strips were briefly washed with water and 
loaded onto 12%T (total acrylamide concentration), 2.6% C (degree of 
crosslinking) polyacrylamide gels without a stacking gel.  The gels were then 
sealed with an agarose sealing solution (100ml of SDS electrophoresis buffer, 1g 
of agarose and trace amounts of bromophenol blue), before being run in the 
Ettan™ DALT six vertical electrophoresis system (GE Healthcare).  The gels were 
run at 10°C with this protocol; for 6 gels, 600V, 400mA, 12W for 15 mins, 15W 
for 30 mins and 100W for approximately 4.5 hrs, using 2x running buffer (Life 
Technologies, Cat No.LC2675) in the upper chamber and 1x running buffer in the 
lower chamber, until the bromophenol blue dye had migrated off the lower end 
of the gels.  Fluorescence images were acquired using the Typhoon variable 
mode imager 9400 (GE Healthcare). 
8.3.4. Silver staining 
 
Protein profiles of 2-DE gels were visualized by silver staining using the 
PlusOne™ Silver Staining Kit (GE Healthcare, Cat No.17-1150-01) and protocol 
with slight modifications, for compatibility with mass spectrometry.  All steps 
were performed with gentle shaking and all solutions were made with double 
distilled water.  Gels were fixed in fixing solution (40% v/v methanol, 10% acetic 
acid) overnight.  Next gels were sensitized for 30 minutes in sensitizing solution 
(30% v/v methanol, 0.2% w/v sodium thiosulphate and 0.5M sodium acetate), 
followed by 3 x 5 mins washing steps in water and silver staining for 20 minutes 
in 0.25% w/v AgNO3.  After two further 5 min washes, the developing solution 
(2.5% w/v sodium carbonate, 0.0148% w/v formaldehyde) was added and the 
gels were gently shaken until the silver spots became visible but before the 
background staining became too bright.  At this point, the developing solution 
was replaced by the stopping solution (1.46% w/v EDTA-Na22H2O) for 10 
minutes.  Next, the gels were washed 3 x 5 mins with water and placed in clear 
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plastic bags to be scanned in transmission scan mode using a calibrated scanner 
(GS-800, Bio-Rad). 
 
8.3.5. Analysis of 2-DE gels 
 
Gel images were analysed using the DeCyder software (GE Healthcare), and 
protein spots showing a statistically significant difference i.e a fold change of 1.2-
1.5, p value<0.05, were selected for manual picking. 
 
8.3.6. In gel tryptic digestion 
 
Using the information from the DeCyder software, spots were picked from at 
least 4 of the total number of gels.  In gel digestion was performed using an 
Investigator ProGest robotic digestion system (Genomic Solutions).  Briefly, 
spots were destained with destaining solution (15mM potassium ferricyanide, 
50 mM sodium thiosulfate) for 15 mins, washed with 100μl of double distilled 
water for 2 x 10 mins, then with 100μl of 25mM ammonium bicarbonate (Sigma 
Aldrich, Cat No. A6141).  All solutions were purged using Nitrogen gas, gels were 
dehydrated with 50μl of acetonitrile (Sigma Aldrich, Cat No. 27071-7), and 
neutralised with ammonium bicarbonate, before being shrunk with 100μl of 
acetonitrile.  The gels were reduced in 30μl of 10mM DTT in 50mM ammonium 
bicarbonate at 60°C before being cooled for 20 minutes and then alkylated in 
30ul of 50mM iodoacetamide in 50mM ammonium bicarbonate for 15 mins.  
After a 10 minute wash with 40μl of 50mM of ammonium bicarbonate, gel pieces 
were shrunk with 50μl of acetonitrile for 2 x 15 mins and 15μl of trypsin solution 
(10μg of trypsin in 600μl of 2mM HCl in 10% acetonitrile, and 900μl of 25mM 
ammonium bicarbonate) was added to each well, the digestion was carried out at 
37°C for 7.5 hours.  1.5 hours later, 10μl of double distilled water was added to 
each well.   
 
Subsequently, 10μl of 25mM ammonium bicarbonate, 20μl of acetonitrile and 
20μl of formic acid was added sequentially to the wells, for 10 minutes each.  
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Next 20μl of acetonitrile was added to each well for 15 minutes and 30μl more 
was added for a further 15 minutes, before all the solutions were purged into the 
collection plate and the digestion was complete.  Finally, the gel pieces were 
lyophilized and resuspended in 18μl of 0.1% formic acid in preparation for mass 
spectrometry. 
 
8.3.7. Mass spectrometry 
 
Following enzymatic digestion, tryptic peptides were separated on a nanoflow 
high-performance liquid chromatography (HPLC) (Acclaim®, Thermo Scientific) 
with subsequent analysis by tandem mass spectrometry (MS/MS) (Q Exactive 
Plus Orbitrap mass spectrometer, Thermo Scientific). For peptide separation on 
HPLC reversed phase column was used (PepMap C18, 3µM, 100 Å 50cm x 75µm) 
and eluted with a 240 min gradient and a flow of 300 nl/min (2-10% B from 0-
10 min, 10-30% B from 10-200 min, 30-40% B from 200-210 min, 99% B from 
210-220 min and eventually 2% B from 220-240 min; the mobile phase solvent 
compositions were as follows: A = 0.1% formic acid (FA) in HPLC H2O; B = 80% 
acetonitrile, 0.1% FA in HPLC H2O). The sequentially eluted peptides were then 
directly analyzed by an orbitrap mass analyzer using full ion scan mode over the 
mass-to-charge (m/z) range of 350 – 1600, resolution 70000 (at m/z 200). 
MS/MS was performed using higher energy collisional dissociation (HCD) on the 
15 most abundant ions (top 15 ions) in each full MS scan with dynamic exclusion 
(30sec).  
 
Data from the mass spectrometer was uploaded to the Mascot server and the 
Scaffold3 program with the parameters allowing for one missed cleavage per 
peptide, carbamidomethylation of cysteines, and partial oxidation of methionine.  
This allowed for accurate identification of the differentially expressed proteins 






8.3.8. Buffer exchange 
 
Buffer exchange was carried out on DIGE samples before they were used for 
immunoblotting, using the Amicon Ultra-0.5 Centrifugal Filter Devices (Millipore, 
Cat No. UFC500396), following the manufacturers’ protocol.  Briefly, the filter 
device was slotted into the provided centrifuge tube and 20-50μl of the protein 
sample was loaded into the filter device.  This was diluted 10x with double 
distilled water, and the filter device was capped and centrifuged at 14,000 g for 
25 minutes, or until only 20-50μl of liquid remained in the filter device.  Next, the 
filter device containing 20-50ul of the protein sample diluted in water was 
turned upside down into a new eppendorf tube and centrifuged at 1000 g for 
two minutes.   
 
Protein concentration was measured using the Biorad Protein Assay Reagent 
(Biorad, Cat No. 500-0006) following the manufacturer’s protocol. Using the 
optical density measurements the protein concentrations were determined using 




20-30μg of cell protein lysate was mixed with protein loading buffer (0.1mM 
Tris, 0.1% of 1M SDS, 10% glycerol, 0.25% beta-mercaptoethanol and trace 
amounts of bromophenol blue) and denatured at 96°C for 10 minutes before 
being briefly centrifuged and loaded onto a 4-12% Tris-Glycine pre-cast gel (Life 
Technologies, Cat No. EC60385BOX) or a 12% Tris-Glycine pre-cast gel (Life 
Technologies, Cat No. EC60055BOX) in NuPage Mops SDS Running Buffer 20x 
(Life Technologies, Cat No. NP0001) diluted with distilled water.  Samples were 
run at 160v for 70 minutes, before being transferred to nitrocellulose 
membranes (GE healthcare, Cat No. RPN2020D) in ice-cold transfer buffer 
(25mM Tris Base (3g) and 200mM Glycine (14g) dissolved in 800ml deionized 
water and 200ml Methanol).  The membranes were then blocked in 5% milk in 
PBS (PBS, Lonza, Cat No. 17-517Q) with 0.1 %Tween for one hour on a shaker at 
room temperature, briefly washed in PBS-Tween and then incubated with the 
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appropriate primary antibody (Table 6) diluted in 5% BSA (Sigma Aldrich, Cat 
No. A2153) with 0.01% sodium azide (Sigma Aldrich, Cat No. S2002) overnight 
at 4°C on a shaker.  
 
The next day, the membrane was washed 3 times for 15 minutes with PBS-
Tween on a shaker and then incubated with the appropriate secondary antibody 
(Table 6) diluted in 5% milk dissolved in PBS-Tween at a dilution of 1/2000 for 
90 minutes at room temperature.  The membrane was then washed a further 
four times with PBS-Tween for 15 minutes each time before ECL Western 
Blotting Detection Reagent (GE Healthcare, Cat No. RPN2209) was applied for 1 
minute and proteins were detected using X-ray films (FUJIFILM, Cat No.AUT-
300-040D). 
 
8.4. Cell death (apoptosis) assay 
 
The cell death detection assay was carried out using the Cell Death Detection 
ELISAPLUS kit (Roche Applied Science, Cat No. 11774425001) per the 
manufacturers’ instructions, the optimal number of cells required for the assay 
was determined by a titration experiment.  5,000 DGCR8-/- and 2,500 WT cells 
were plated in a gelatin coated 96 well plate in 100μl of complete mESC medium 
in triplicate.  48 hours after plating, the medium was removed, 200μl of the 
provided lysis buffer was added to each well and the plate was incubated at 
room temperature for 30 minutes.  The plate was then centrifuged at 200 x g for 
10 minutes and 20μl of each cell lysate, the provided positive control and 
background control were pipetted into individual wells of the provided 
streptavidin coated microplate.  80μl of the Immunoreagent was added to each 
well, and the plate was placed on a shaker at 300rpm for 2 hours at room 
temperature, before each well was washed three times with Incubation buffer.  
Next 100μl of the ABTS solution was added to each well, and the plate was 
placed onto a shaker at 250rpm for approximately 15 minutes or until the green 
colour had developed enough for proper analysis.  Absorbance was measured at 
405nm, reference wavelength; 490nm.  Absorbance values were normalized to 






8.5.1. Perchloric acid (PA) extraction of cells 
 
PA extraction was undertaken on cells grown in T25s.  The medium was 
removed from the cells, and immediately placed on ice, before being centrifuged 
for ten minutes at 5000g to pellet any cellular debris.  The supernatant was then 
transferred to a new tube and placed at -80°C until it could be analysed.  The 
cells were washed twice with 10ml of saline, which was removed completely 
after each wash.  Subsequently 4ml of ice cold PA (Sigma Aldrich, Cat No. 
244252) was added to each flask, and tilted back and forth to ensure that all the 
cells were covered.  Next the cells were scraped into the PA, and the lysate was 
transferred into a clean tube on ice.  The flask was further washed with 1 ml of 
PA to ensure that all cells had been collected and the final wash was added to the 
remainder of the lysate.  The cell lysate and PA residue were centrifuged for 15 
minutes at 10000rpm for 15 minutes.  The supernatant was removed and placed 
in a fresh tube, to be pH’ed and neutralised to pH 7 with the addition of 1% 
potassium hydroxide, 10% potassium Hydroxide and 1% PA.  The cell pellet was 
immediately stored at -80°C.  Once the supernatant had been pH’ed it was frozen 
at -80°C, freeze dried and then stored at -80°C again before it underwent 
metabolic analysis. 
 
8.5.2. Proton nuclear magnetic resonance (H1 NMR)  
 
H1 NMR was carried out by Dr. Yuen Li Chung of the Institute of Cancer Research 
on medium taken after 48 hours of cell growth as previously described. 
 
8.6. Seahorse bioscience  
 
The Seahorse bioscience XFE24 analyzer was used to measure the Oxygen 
Consumption Rate (OCR) and Extracellular Acidification Rate (ECAR) of both WT 
cells and DGCR8-/- mESCs, according to the manufacturers’ instructions.  Briefly, 
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the provided 24 well microplates were coated with 0.1% gelatin, and 10,000 WT 
and 15,000 DGCR8-/- mESCs were plated in triplicate into each well, to ensure 
approximately 90% confluence at the time of analysis.  Four of the twenty wells 
did not contain any cells acting as a background control.  All cells were grown in 
complete mESC medium for 24 hours, before being washed 3 times with DMEM 
(Life technologies, Cat No. 10938025) supplemented with 5ml of100 U/ml 
Penicillin and100mg/ml Streptomycin (Life Technologies, Cat No. 15140-122), 
and placed in 450μl of complete mESC media either in the presence or absence of 
LIF for a further 48 hours before mitochondrial function was studied using the 
Seahorse Bioscience Analyser. 
 
The afternoon prior to analysis, a separate plate containing the drugs ports and 
probes was rehydrated using the supplied XF Calibrant solution (Seahorse 
Bioscience, Cat No. 100840-000), this was carried out by pipetting 1ml of the 
calibrant solution into each well, putting the lid containing the probe and drug 
ports on top, sealing the plate with parafilm and placing it in a 37°C incubator 
without CO2.  The next day, both the unsupplemented XF media (Seahorse 
Bioscience, Cat No. 102365-100) and the XF media supplemented with 25mM 
glucose (Sigma Aldrich, Cat No. G7021) and 2mM pyruvate (Sigma Aldrich, Cat 
No. P5280) were warmed to 37°C and adjusted to pH 7.  The cells were carefully 
washed with the unsupplemented media twice, before 450μl of the 
supplemented media was added to each well.  The cells were then placed in an 
incubator without CO2 for approximately 45 minutes.  Meanwhile, individual 
stock solutions of 10μM of oligomycin A (Sigma Aldrich, Cat No.75351), 5μM of 
FCCP (Sigma Aldrich, Cat No. C2920), 10μM of antimycin A (Sigma Aldrich, Cat 
No. A8674) and 10μM of Rotenone (Sigma Aldrich, Cat No. R8875) were 
prepared in the unsupplemented medium to provide a final concentration of 
1μM of oligomycin A, 0.5μM of FCCP and 1μM of antimycin A/rotenone in each 
well.  The individual drugs were pipetted into each port of the hydrated plate 
(Antimycin A and rotenone were pipetted into the same port), in a sequential 
order (oligomycin A, FCCP, antimycin A/rotenone), and the hydrated plate now 




Once the cells and Seahorse machine were ready, the cells were placed in the 
machine, for the following programme; mix the medium for three minutes, wait 
for two minutes, measure the OCR and ECAR over three minutes, inject from the 
first port containing oligomycin, this protocol was repeated for the three ports 
containing drugs.  Drugs were injected in the order oligomycin, FCCP and 
antimycin A/Rotenone.   
 
To normalize the values provided by the Seahorse software to cell number, the 
cells were fixed using 4% paraformaldehyde (PFA) (Sigma Aldrich, Cat No. 
158127) and stained with DAPI (Sigma Aldrich, Cat No.D8417); briefly, the cells 
were washed carefully with PBS, 450μl of 4% PFA was added to each well and 
the cells were incubated at room temperature for 15 minutes, before being 
washed again with PBS.  The PBS was then removed and the cells were incubated 
in the dark for 15 minutes with 6μg/ml of DAPI dissolved in PBS.  The cells were 
washed twice with PBS and kept hydrated in 50μl of PBS whilst being 
photographed using an inverted fluorescence microscope.  Open CFU software 
(235) was used to quantify the number of cells in each well. 
  
Cell density titration experiments were carried out to determine the optimal 
number of cells for the Seahorse analysis 
 
8.7. Statistical analysis 
 
Data are shown as ± standard deviation from the mean, represented as error 
bars.  Differences from the mean were calculated using the Students’ unpaired t-
test for comparisons between two samples, and ANOVA for comparisons 
between more than two samples using the GraphPad Prism software (236) to 
determine if there were any significant differences in expression.  If the p-value 
was less than 0.05, then further posthoc t-test were conducted.  Differences were 
considered significant if the p value was ≤ 0.05 represented by *,  ** represents p 







9.1. WT and DGCR8-/- mESCs 
 
All experiments in this chapter consisted of three biological replicates (three 
separate passages of each cell type).  Each biological replicate was repeated 
twice, i.e. two flasks of the same cell type were plated and harvested at the same 
time therefore there were two technical replicates per passage. N=3 represents 
the number of biological replicates. 
9.1.1 Characterisation 
 
Initially, the DGCR8-/- mESCs were grown on a MEF feeder layer and expanded 
onto gelatin-coated plates, whereas the WT mESCs were grown directly on 
gelatin-coated plates. Therefore it was vital to characterise both cell types to 
ensure that they remained pluripotent. 
 
DGCR8-/- and WT cells were grown for 5 days, fixed and stained for alkaline 
phosphatase. The number of cells that stained positively for alkaline 















Figure 13 - Alkaline Phosphatase staining. The top row of images (A, B) are WT mESCs and the 
bottom row of images (C, D) are DGCR8
-/-
 mESCs.  Line represents 200μm 
 
Although after 5 days in culture both cell types had begun to differentiate around 
the outer edges of their colonies, (Figure 13) they displayed 90-95% positive 
staining for alkaline phosphatase. The WT formed rounder, more compact 




PCRs and immunoblotting were used to confirm the expression of the three 
































































Figure 14 – Expression of pluripotency markers. A) Conventional PCR and densitometry normalised 
to loading control β-actin, B) QPCR normalised to positive control, β-actin, C) Immunoblot and 
densitometry normalised to loading control β-tubulin.  p value <0.05 (t-test), n=3 
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The pluripotency markers Oct4, Nanog and Sox2 showed similar expression 
levels in both the DGCR8-/- and WT cells using both the conventional (Figure 14a) 
and quantitative PCR methods (Figure 14b).  In accordance with the PCR data 
(Figures 14a, b) the two pluripotency markers Oct4 and Nanog were expressed 
at similar levels in both cell types at the protein level. Unexpectedly, Sox2 
showed differential expression at the protein level (Figure 14c). 
 
DGCR8 is a key protein in the miRNA biogenesis pathway, therefore its loss 




Figure 15 – Genotype of WT and DGCR8
-/- 
mESCs and expression levels of miRNAs involved in the 
embryonic stem cell cycle. A) DGCR8 mRNA expression levels were normalized to β-actin.  Wild type 
expression levels were set to 1, B) miRNA expression levels were normalized to U6 (n=3 independent 
experiments). MiRNA expression in wild type cells was set as 1.   P(t-test) < 0.05 
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DGCR8-/- mESCs are known to express significantly higher levels of cell cycle 
inhibitors compared to WT cells (6), therefore we also evaluated the expression 
of the cell cycle inhibitors (Figure 16). 
 
 DGCR8 was undetectable in the knockout cells (Figure 15a) and this resulted in a 
significantly lower expression of the four canonical miRNAs (miR-291a, miR-
291b, miR-294 and miR-295) in the DGCR8-/- mESCs compared to the WT mESCs 
(Figure 15b).   
 
Further experiments were conducted on the cells to confirm previous findings, 
which showed that the DGCR8-/- mESCs displayed a slower proliferation rate 
compared to the WT cells (3,6). The specific loss of the miRNAs tested in 
Figure15, is consistent with the derepression of their targets, such as Cdkn1a, 
Rbl2 and Lats2 (Figure 16). 
 
 
Figure 16 – mRNA expression levels of cell cycle inhibitors. Conventional PCR and densitometry 
normalised to loading control.  QPCR was conducted on Cdkn1a and normalized to positive control.  
Wild type expression levels are set to 1.  P(t-test) < 0.05,n=3 
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Lats2, Rbl2 and Cdkn1a are highly expressed inhibitors of the G1/S phase 
transition in WT mESCs, however the results suggest that only Lats2 and Rbl2 
have significant differential expression in the two cell types (Figure 16).  
However using qPCR, which is a more sensitive and accurate gene quantification 
method, Cdkn1a showed a significantly higher expression in the DGCR8-/- 






















As reported previously, the DGCR8-/- cells were displaying the expected 
phenotype of a slow proliferation rate compared to WT cells (6). Figure 17 
indicates that although half the number of WT mESCs compared to DGCR8-/- 
mESCs were plated, after 48 hours of growth under identical conditions, there 
were significantly more WT mESCs compared to DGCR8-/- mESCs. 
 
To ensure that the differences in cell number were solely due to proliferation 
defects as opposed to cell death via apoptosis, a cell death detection assay was 
conducted, which quantified the release of nucleosomes released by the cells into 
the growth medium (Figure 18).  
 
 
Figure 17 – Cell numbers.  Analysis was 
conducted after 48 hours in culture. 
n=4 (two technical replicates in two 
independent experiments).  T-test was 
conducted between WT and DGCR8
-/-
 

















Figure 18 - Cell death detection assay.  The number of nucleosomes released into the medium by the 
WT and DGCR8
-/- 
mESCs, after 48 hours of growth was taken as an indication of the amount of cell 
death.  Values were normalised to cell number after 48 hours.  n=4  (two technical replicates in two 
independent experiments), error bars represent standard deviation. P(t-test) < 0.05. NS denotes not 
significant. 
 
The cell death assay (Figure 18) demonstrates that the loss of canonical miRNAs 
does not result in increased apoptosis. 
 
9.1.2 DIGE  
 
2-D DIGE provides a quantitative method of comparing proteomes, by 
differentially labelling the samples with different fluorescent dyes (Cy3 (red) and 
Cy5 (green)), and separating the proteins from two samples plus a pooled 
standard (Cy2) on the same two-dimensional gel which allowed for reliable 
quantification of proteins between gels. 2-D DIGE analysis was carried out on 
DGCR8-/- and WT whole cell protein lysates, to compare differential protein 
expression (Figure 19). Proteins are separated by molecular weight (Mw) and 





























Figure 19 - Representative DIGE gel image.  DCGR8
-/-
 cells were labelled with Cy3 (red) and WT mESCs 
with Cy5 (green).  A sample pool was labelled with Cy2 as an internal standard.   Proteins were 
separated by molecular weight (Mw) and isoelectric point (pI). Spots that are orange or green 
represent proteins that are differentially expressed, yellow spots represent proteins that are 
expressed to the same level in both samples. Spots were excised if they showed at least a 1.5 fold 
change between cell types with a p-value of <0.05 (t-test), as determined by the Decyder software 
(GE Healthcare).  Mw=mass of protein, pI= isoelectric point. Protein names are listed in Table 7.  
 
96 spots that were differentially expressed in the two cell types were selected for 
LC-MS/MS analysis based on the parameters, of having at least a 1.5 fold change 
between the cell types at a significance level of p<0.05 (Figure 19).  Of the 96 
spots, 84 unique proteins were identified and from these 48 were upregulated in 
the  DGCR8-/- cells compared to the WT cells, as would be expected for putative 
direct targets of the canonical miRNAs (Table 7). 
 
Results from an Ingenuity pathway analysis software (237) to screen for any 
common pathways between proteins or any networks that the proteins may be 
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involved in are summarized in Figure 20.  The two largest groups of proteins that 
showed differential expression between the two cell types were those involved 









Figure 20 – Pathway analysis.  Pathways affected by the loss of DGCR8 in mESCs as determined by REACTOME within the bioprofiling software (238,239)  Pathways are 
ordered by level of significance, as determined by a hypergeometric test, which tests the ‘probability of seeing n or more genes by chance’, only proteins with a p-value less 
than 0.01 are shown.  The ratio represents the number of proteins found in the DGCR8
-/- 
vs. WT dataset that are present in the pathway divided by the total number of 
proteins in that pathway.  
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The biggest group of pathways affected by the loss of DGCR8 in mESCs were 
those with a chaperone function, however the top pathways are involved in 
glucose metabolism (Figure 20).  
9.1.3 Validation of DIGE analysis (and associated proteins) of wild type 
and DGCR8-/- mESCs 
 
In order to validate the results from the DIGE analysis (Figure 19 and Table 7) as 
well as the accompanying common pathway analysis (Figure 20); Western blots 
(Figure 21) and qPCRs (Figure 22) were conducted not only analysing the 
proteins identified in the DIGE study but those in associated pathways, such as 























Figure 21 - Protein expression profile.  Immunoblotting was conducted on 3 consecutive passages of 
WT and DGCR8
-/-
 mESCs, labelled as experiment 1, 2 and 3. Protein targets were chosen based on 
their differential expression between the two cell types (Table 7) and their relationship with identified 
proteins.  β-tubulin was used as a loading control. Abbreviations- ALDOA: Fructose-bisphosphate 
Aldolase A, PKM2: Pyruvate kinase muscle isoform 2, IDH2: Isocitrate dehydrogenase 2, MDH2: 
Malate dehydrogenase 2 PDI: Protein disulphide isomerase, , PPARα: Peroxisome proliferator-







Figure 22 – Densitometry.  A) Glycolytic enzymes, B) TCA enzymes, C) Chaperone proteins, D) Fatty 
acid metabolism, E) Antioxidants, n=3, P(t-test) <0.05.  Abbreviations- ALDOA: Fructose Bisphosphate 
Aldolase A, PKM2: Pyruvate Kinase muscle Isoform 2, PPARα: Peroxisome proliferator-activated 










































Figure 23 - Quantitative PCR profile. Expression of glycolytic genes in WT and DGCR8
-/-
 mESCs.  
Expression levels were normalised to the loading control β-actin.  Expression in WT mESCs was set as 









Figure 24 - Quantitative PCR profile (2). Gene expression in WT and DGCR8
-/- 
mESCs. A) Associated 
with glycolysis, B) TCA cycle, C) Antioxidant and chaperone, D) Fatty acid metabolism, E) Associated 
with energy metabolism.  Expression levels were normalised to the loading control β-actin.  
Expression in wild type mESCs was set as one.  n=3,P(t-test) < 0.05 
 
The RNA and protein analysis revealed differences in the expression of glucose 
metabolism enzymes between the DGCR8-/- and WT mESCs, with the DGCR8-/- 
mESCs displaying lower expression of glycolytic enzymes (Figures 21, 23) and a 
reciprocal higher expression of TCA cycle enzymes such as Malate 
Dehydrogenase 2 and Isocitrate Dehydrogenase 2 (Figures 21, 24b), the opposite 




In agreement with the pathway analysis presented in Figure 20, eight out of the 
twelve enzymes involved directly in glycolysis displayed lower expression in the 
DGCR8-/- mESCs compared to the WT (Figure 23). 
 
Other proteins including those with antioxidant function; Sod1 and a chaperone 
protein; Serpin H1, were also identified as having differential expression 
between the two cell types and were validated at both the protein and RNA 
levels (Figures 22, 24).   
 
9.1.4 Metabolic analysis 
 
As glycolytic and TCA cycle enzymes were differentially expressed between the 
two cell types, the Seahorse XFe analyzer was used to further study glucose 
metabolism in the WT and DGCR8-/- mESCs (Figure 25). 
 
The Seahorse XFe analyzer, allows for the simultaneous measurement of the 
amount of mitochondrial respiration that occurs within cells/tissues through a 
parameter termed the Oxygen Consumption Rate (OCR) and the number of 
protons produced by the cells/tissues via parameter termed the Extracellular 
Acidification Rate (ECAR).  The OCR and ECAR provide readouts for the amount 
of oxidative phosphorylation and glycolysis occurring in cells, respectively.  The 
analyzer not only allows for the simultaneous measurement of the ECAR and 
OCR over a defined period of time, but also for chemical modulators to be 
directly added to the cells, permitting the study of mitochondrial function and 







Figure 25 – Seahorse analysis of WT and DGCR8
-/- 
mESCs. A) Representative OCR (Oxygen 
Consumption Rate) of WT and DGCR8
-/- 
mESCs in the presence of three mitochondrial modulators; 
Oligomycin (ATP synthase inhibitor), FCCP (mitochondrial uncoupler) and Rotenone/Antimycin A 
(Complex I/Complex IV inhibitor), B) Summary of OCR measurements, C) Representative ECAR 
(Extracellular Acidification Rate) of WT and DGCR8
-/- 
mESCs in the presence of three mitochondrial 
modulators; Oligomycin (ATP synthase inhibitor), FCCP (mitochondrial uncoupler) and 
Rotenone/Antimycin A (Complex I/Complex IV inhibitor), D) Summary of OCR measurements.  n=3, 
P(t-test) <0.05 
 
Although both cell types, had a similar basal and residual glycolytic rate, the WT 
cells had a significantly higher glycolytic capacity (Figure 25c, d), which is line 
with their higher mRNA and protein expression of glycolysis-associated enzymes 
(Figures 21, 23).  At baseline, the DGCR8-/- cells had a significantly lower OCR 
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(Figure 25b).  This was also the case upon the addition of Oligomycin A, an ATP 
synthase inhibitor. 
 
The inhibition of ATP synthase by Oligomycin A led to a fall in ATP production 
and a reciprocal increase in the ECAR, as the cells attempted to compensate for 
the shortfall in ATP production, indicative of the higher glycolytic capacity of the 
WT cells compared to the DGCR8-/- cells (Figure 25d).  The maximal respiration 
rate (Figure 25b) was calculated using the OCR values upon the addition of FCCP 
minus the non-mitochondrial respiration (values collected upon the addition of 
Rotenone and Antimycin A), the WT cells tended to show a higher maximal 
respiration rate overall, however the difference was not significant (Figure 25c).  
 
The metabolite concentrations of WT and DGCR8-/- mESCs were studied (Figure 
26) in their conditioned medium.  The values of the metabolites quantified using 














Figure 26- Metabolites in cell culture supernatants.  Values represent percentages and have been 
normalised to cell numbers after 48 hours of growth. P (t-test) < 0.05 
 
The metabolomic studies revealed that after 48 hours of growth, in both cases 
glucose was taken up at a higher proportion than any other metabolite and 
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lactate was excreted the most (Table 8).  Alanine, a transamination product of 
pyruvate and a precursor for glutaminolysis, was the only metabolite that 





To further explore the role of miRNAs we transfected the DGCR8-/- mESCs with 
four miRNAs from the 295 cluster; miR-291a, miR-291b, miR-294 and miR-295, 
and miR-302d from the 302 cluster. The efficiency of transfection was confirmed 
via qPCR (Table 10).   
 
9.2.1 Characterisation after transfection 
 
PCRs and immunoblotting were used to confirm the expression of the three 
pluripotency markers, Oct4, Nanog and Sox2, in WT and DGCR8-/- mESCs 
transfected with miRNAs from the 295 cluster and miR-302d (Figure 27).  





































Figure 27- Expression of pluripotency markers and cell cycle inhibitor in DGCR8
-/-
 mESCs transfected 
with the ESCC miRNAs.  Pluripotency (Oct4, Nanog and Sox2) and cell cycle inhibitor (cdkn1a) genes.  
Gene expression levels were normalised to the loading control β-actin, n=3, P(ANOVA)<0.05. 




The pluripotency markers, Oct4, Nanog and Sox2 remained unaffected by the 
over expression of the ESCC miRNAs (Figure 27). 
 
Cdkn1a (G1/S phase cell cycle regulator) that has previously been identified as a 
target of the ESCC miRNAs (3), was used a positive control to ensure that the 
expression of the ESCC in the DGCR8-/- mESCs resulted in its downregulation 
(Figure 27). 
 
The cells were also counted just before they were harvested to ensure that the 
transfection was not detrimental to cell viability (Figure 28b).  Although on 
average the cell numbers before harvest were similar between transfections, 
individually, the transfection of miR-291b resulted in a significantly lower final 
cell number (Table 11), therefore it was eliminated from some of the further 
analysis. 
 
On average after 48 hours of transfection with the ESCC miRNAs there was no 
significant difference in cell number (Figure 28b), this is supported by the photos 
of DGCR8-/- transfected with the ESCC miRNAs (Figure 28a).  The transfected 
mESCs looked similar except for the mESCs transfected with miR-291b, which 
displayed less round colony formation and more elongated cells around the 














































Figure 28a- Representative photos of transfected DGCR8
-/-  
mESCs.  Photos were taken 48 hours post 














Figure 28b - Average cell numbers of transfected DGCR8
-/-
 mESCs. Cells were individually transfected 
with the ESCC miRNAs and counted 48 hours post-transfection.  Error bars represent standard 
deviation, P(ANOVA) < 0.05, none of the differences were found to be significant.  n=6 
 
9.2.2 Transfection DIGE   
 
In order, to gauge the effects that the individual ESCC miRNAs have on the 
proteome of mESCs, comparative 2-D DIGE analysis was conducted on the 
transfected cell lysates(Figure 29).  Protein changes upon transfection with 



































Figure 29 – Representative DIGE gel image comparing the differences in protein expression 
between DGCR8
-/-
 mESCs transfected with miR-302d and the Control miRNA .  The 58 numbered 
proteins represent proteins that show differences in protein expression above the threshold level 
between the DGCR8
-/- 
transfected with each of the ESCC miRNAs and those transfected with the 
control miRNA. Cells transfected with the control miRNA were labelled with Cy3 (red) and DGCR8
-/-
 
cells transfected with miR-302d were labelled with Cy5 (green).  Both transfected cells were 
labelled with Cy2 as an internal standard.  Spots that are orange or green represent proteins that 
are differentially expressed, yellow spots represent proteins that are expressed to the same level in 
both samples.  Spots were excised if they were within the parameters of a 1.2 fold change between 
cell types and a p value of <0.05, as determined by the Decyder software. Mw=mass of protein, pI= 
isoelectric point.  Proteins are summarised in Table 9. 
 
A representative DIGE gel of the DGCR8-/- mESCs transfected with the ESCC 
miRNAs is shown in Figure 29.  Proteins expressed in the DGCR8-/- mESCs 
transfected with the control miRNA were labelled with Cy3, and those DGCR8-/- 




58 of the differentially expressed spots were selected for LC-MS/MS analysis 
based on the parameters, of having at least a 1.2 fold change between the 
transfections at a significance level of p<0.05.   The fold change threshold was set 
lower than in the initial DIGE comparison between the wild type and DGCR8-/- 
mESCs, to increase the power of the DIGE analysis and the chances of identifying 
real targets, as the five miRNAs have the same seed sequence and have many 
similar targets (3). 
 
Of the 58 spots picked, 51 unique proteins were identified, of those 11 were 
identified in the first 2-D DIGE study as differentially expressed between the 
untransfected and DGCR8-/- mESCs (Table 14). Of these 11, 9 were upregulated 
in the DGCR8-/- mESCs compared to the WT mESCs, indicating that they may be 
targets of the ESCCs (Table 14). 
 
Although 12 DIGE gels were run, encompassing all the individual transfections 
(two technical replicates and two biological replicates per transfection), only 
eleven gels were used for principal component analysis (Figure 30).  This was 
due to the uneven running of one gel (containing a comparison between DGCR8-
/- mESCs transfected individually, with a control miRNA and miR-302d).  The 
technical artefact would have introduced greater experimental variability into 










Figure 30 –Principal Component Analysis (PCA).  PCA was conducted based on targets identified in 
the DIGE study as being affected by the ESCC miRNAs.  a) PCA of the DGCR8
-/-
 mESCs transfected with 
miR-291a, 291b, 294, 295, 302d and a control miRNA, b) PCA of the DGCR8
-/- 
mESCs transfected with 
miR-291a, 291b, 294, 295 and 302d (n=3 or 4). 
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By conducting PCA on the DGCR8-/- mESCs transfected with the ESCC, it was 
established that the cells transfected with the control miRNA were distinct from 
the cells transfected with the ESCC miRNAs (Figure 30a) in terms of their effect 
on protein expression.  For closer inspection of the differences between ESCC 
miRNAs, the DGCR8-/- mESCs transfected with the control miRNA, were omitted 
in the PCA analysis (Figure 30b).  In particular miR-291b and miR-294, clustered 




Figure 31 – Venn diagram of proteins from DIGE study. Proteins were selected based on significantly 
differential expression compared to cells transfected with the control miRNA.  Proteins were selected 
based on having a fold expression difference of 1.2, with a significance level of p(ANOVA) <0.05.  
Proteins in bold represent proteins that were also identified as having differential expression 
between the wild type and DGCR8-/- mESCs at baseline using DIGE. Proteins are named using Uniprot 
nomenclature for mouse proteins (231).  
 
Of the miRNAs studied (excluding miR-291b due its detrimental effect on cell 
number), miR-295 shared the most targets with the other miRNAs and also had 
the highest number of targets identified in both DIGE studies (Figure 31). miR-
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291a, had the least number of targets of which three out of four of them were 
directly associated with transcription and translation (Table 14). 
 
Twenty-three proteins were identified as being influenced by the expression of 
the ESCC miRNAs (Figure 31). Of these approximately a third were affected by 
the expression of at least two miRNAs, highlighting the high number of shared 
targets between miRNAs from the same family.  Of these proteins, three were 
also identified in the initial DIGE study comparing baseline protein expression 
between the WT and DGCR8-/- mESCs; Peroxiredoxin 1 (PRDX1), Glyceraldehyde 
3-phosphate dehydrogenase (GAPDH) and Eukaryotic translation initiation 
factor 5A-1 (IF5A1) (Figure 31, Table 14).  
 
The identified proteins (Table 9) were searched in five different miRNA target 
predication databases, Targetscan (240), microRNA.org (241,242), DIANA 
(243,244), miRwalk (245) and miRNAmap (246) to uncover any predicted 
targets (Table 9). 
 
Using the results from the DIGE analysis, we used Ingenuity pathway analysis 
software (237) to screen for any common pathways between proteins or any 


























Figure 32- Pathway analysis.  Only significant values are shown  as determined by the DAVID software using a one-tailed Fisher's Exact test, with a cut-off value of p<0.05. 
A) Highly enriched pathways for proteins, which are differentially expressed upon individual transfections of the ESCC miRNAs.  Only proteins with significant changes are 
represented as determined using a one-tailed Fisher’s exact test, with a cut-off value of p<0.05.  Image was created using the DAVID software (247), B)  Proteins affected by 
the individual transfection of the ESCC miRNAs classified by GO terms  B) Proteins affected by the individual transfection of the ESCC miRNAs, classified by GO terms. Height 
of bars is indicative of the number of significantly affected proteins classified by the GO term. Odds ratio=(no. of genes in input list/total list)/(no. of genes in the whole 
genome classified by the GO term/no. of genes in the whole genome).   
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The pathway analysis revealed that the most enriched pathways based on the 
transfection of the ESCCs, were those involved in redox reactions, proton 
transport and ATP metabolism (Figure 32a), which confirms the top GO term 
observed in Figure 32b, of ‘Mitochondrion’, and also the top odds ratio being 
aligned to the GO term, ‘Cell redox homeostasis’.   
 
In order to validate the results from the DIGE analysis (Figure 29, Table 9) as 
well as the accompanying common pathway analysis (Figure 32), western blots 
(Figures 33, 34) and qPCRs (Figure 35) were conducted on selected targets 
identified by proteomics, as well as associated mRNAs/proteins. 
 
Initially, one way ANOVA tests were conducted on the mRNA and protein 
analysis of the transfected cells using GraphPad Prism (236) to determine if 
there were any significant differences in expression.  If the p-value was less than 
0.05, then further posthoc t-tests were conducted between the DGCR8-/- mESCs 
transfected with the individual ESCC and those transfected with the control 
miRNA to further assess any differences (Figures 32 -35).  
9.2.3 Validation of  proteins from DIGE analysis and associated proteins in 
transfected cells 
 
Using ANOVA and individual t-tests to compare protein expression levels of 
DGCR8-/- mESCs transfected with the individual ESCCs and the mESCs 
transfected with a control miRNA, we were able to identify proteins influenced 
by the expression of the ESCC miRNAs (Table 9). Due to the similarities between 
the ESCC miRNAs particularly their shared seed sequence, many of the targets 
tested, were similarly affected (Figures 33- 35). 
 
In order to validate the results from the DIGE analysis (Figure 29 and Table 14 ) 
as well as the accompanying common pathway analysis (Figure 32 ); Western 
blots (Figures 33 and 34 ) and qPCRs (Figure 35) were conducted not only 
analysing the proteins identified in the DIGE study but those in associated 




Of the twelve mRNAs analysed due to their direct role in glycolysis, eight of 
them; displayed significant differential expression in the presence of the ESCC 
miRNAs compared to the DGCR8-/- mESCs transfected with the control miRNA 
(Figure 35a).  Aldolase A in the presence of the ESCCs was further validated at 
the protein level (Figure 34a).  
 
 
Figure 33 - Protein expression of DGCR8
-/-
 mESCs transfected with the ESCC miRNAs.  
Immunoblotting was conducted on 3 consecutive passages of transfected cells.  Analysed proteins 
were chosen based on their differential expression between the transfected cells (Table 9) and their 

























Figure 34 - Densitometry analysis of DGCR8
-/- 
mESCs transfected with the ESCC miRNAs.                  A) 
Glycolytic proteins, B) TCA cycle enzymes, C) Chaperone proteins, D) Fatty acid metabolism and 
antioxidant protein.  Protein expression levels were normalised to Ponceau staining.  n=3, 
P(ANOVA)<0.05. Abbreviations: ALDOA- Fructose bisphosphate aldolase A, PKM2- Pyruvate kinase M2 
isoform, PDI- Protein disulfide isomerase, PPARα- Peroxisome proliferator-activated receptor α, 

















Figure 35 - Quantitative PCR profile of DGCR8
-/-
 mESCs transfected with the ESCC miRNAs.       A) 
Glycolytic genes, B) Gene associated with glycolysis, C) TCA cycle genes, D) Antioxidant genes,    E) 
Fatty acid metabolism genes, F) Genes associated with energy metabolism.  Gene expression levels 
were normalised to the loading control β-actin.  n=3, P(ANOVA)=0.05. Abbreviations- Aldoa- Fructose 
bisphosphate aldolase A, GAPDH-Glyceraldehyde-3-phosphate dehydrogenase, PGAM1- 





The ability of the ESCC miRNAs to restore the expression of some of the 
glycolytic/TCA transcripts/proteins led us to further investigate the 
metabolomic status of the transfected cells, using 1H-NMR techniques. 
9.2.4 Metabolomics  
 
 
In order to probe the effects of the individual ESCC on the metabolic status of 














Figure 36– Secretome analysis of DGCR8
-/- 
mESCs transfected with the ESCC miRNAs Metabolites 
were secreted into the media. Values were normalized to cell number n=3, P(ANOVA)<0.05 
 
Although the DGCR8-/- mESCs were individually transfected with five miRNAs; 
miR-291a, miR-291b, miR-294, miR-295 and miR-302d, the secretome analysis 
revealed that metabolites showed the most significant differences upon the 
expression of miR-294 and miR-302d (Figure 36), which correlated with the 
principal component analysis of the proteomics data which displayed distinct 
separation from the other ESCC miRNAs (Figure 30). The analysis revealed 
numerous metabolites that are summarised in Table 12. Although miR-294 and 
miR-302d were the only significant miRNAs, all of the miRNAs tested affected 
alanine and lactate in a similar way, albeit not at a significant level. Therefore 
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further intracellular H1 NMR analysis was conducted on the DGCR8-/- mESCs 




























Figure 37 - Intracellular concentrations of metabolites in DGCR8
-/- 
mESCs transfected with a control 
miRNA, miR-294 and miR-302d. Analysed metabolites highlighted in red.  n=3,  p(ANOVA)<0.05 
The intracellular metabolite analysis showed that the DGCR8-/- mESCs 
transfected with the ESCC miRNAs; miR-294 and 302d, had increased 
intracellular concentrations  of lactate and decreased levels of alanine compared 
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to the DGCR8-/- mESCs transfected with the the control miRNAs  (Figure 37).  
Notably, glutamate which can be metabolized in the mitochondria, into α-
ketoglutarate (which can feed into the TCA cycle) displayed a higher intracellular 
concentration, in the transfected cells compared to the cells transfected with the 
control miRNA (Figure 37).   
 
This is indicative of a possible switch from glycolysis to glutaminolysis for 
energy production (248) in the DGCR8-/- mESCs, which is shown to be partially 
reversed by the transfection of the ESCC miRNAs (Figures 32, 33).   
 
In order to verify whether there is a switch from glucose metabolism to 
glutaminolysis in the DGCR8-/- cells for energy production, the gene expression 
of hypoxia inducible factor 1 α (HIF1α) (Figure 38) which can act as a master 
regulator for a switch from glycolysis to glutaminolysis (249,250) and glutamic 
pyruvate traminase 2 (gpt2), the key enzyme which catalyses the reversible 









Figure 38 – mRNA expression of HIF1α.  A) Expression in wild type and DGCR8
-/- 
mESCs.  Wild type 
expression levels were set to one, n=3, P(t-test)<0.05  B)  Expression in DGCR8
-/- 
mESCs transfected 
with ESCC miRNAs relative to DGCR8
-/- 





Figure 39 – Role and mRNA expression of glutamic pyruvate transaminase 2 (gpt2) in DGCR8
-/- 
and 
WT mESCs.  A) Summary of glutaminolysis pathway in DGCR8
-/-
 mESCs (arrows represent intracellular 
metabolite levels relative to DGCR8
-/- 
mESCs, B)  Baseline gene expression levels of gpt2 in both 
DGCR8
-/- 
and WT mESCs, relative to the WT cells, n=3, P(t-test)=0.05,  C)  Quantitative PCR profile of 
gpt2 in DGCR8
-/- 
mESCs transfected with ESCC miRNAs relative to DGCR8
-/- 
mESCs transfected with a 
control miRNA.  n=3, P(ANOVA)<0.05 
Both Hif1α and Gpt2 showed significantly higher expression in the DGCR8-/- 
mESCs compared to the WT, and in the case of Gpt2 this was enhanced by the 
overexpression of the ESCC miRNAs (Figure 34). 
 
Taken together, the results of this study indicated that the absence of ESCC 
miRNAs in DGCR8-/- mESCs led to a metabolic switch from predominantly 







10 . Discussion 
 
In this study, we combined proteomics, metabolomics and RNA analysis 
techniques, to investigate the effect of the loss of DGCR8 and therefore miRNAs 
on mESCs.  Using mass spectrometry techniques, we discovered a range of 
protein expression differences between the DGCR8-/- and WT mESCs, most 
notably there were consistent differences in the expression of glucose 
metabolism enzymes.  Protein and RNA validation experiments, revealed there 
to be a distinct trend in the expression of glycolytic enzymes which displayed a 
lower expression in the DGCR8-/- mESCs compared to the WT with a reciprocal 
decrease in the expression of TCA cycle enzymes.  This was supported by 
functional metabolic analysis, which revealed the WT mESCs to be more 
glycolytically active than the DGCR8-/- mESCs.  By overexpressing highly 
conserved, mESC specific miRNAs, that are known to play an direct role in 
controlling the cell cycle and also play a role in the regulation of pluripotency, 
the expression of the majority of glycolytic enzymes was restored, indicating that 
the miRNAs tested influence the metabolic status of mESCs. 
 
As miRNAs regulate gene expression at the post-transcriptional level, their effect 
is most keenly observed at the protein level, however studies on DGCR8-/- 
mESCs, predominantly focused on the transcriptome of these cells both at 
baseline and upon the transfection of specific miRNAs (8). No study to date has 
explored either the baseline proteome of DGCR8-/- mESCs, or the effects on the 
proteome of cells transfected with the ESCC miRNAs (miR-291a, miR-291b, miR-
294, miR-295 and miR-302d).  The over expression of these miRNAs in DGCR8-/- 
mESCs is sufficient to restore the cell cycle defects, yet it is unable to reverse the 
differentiation defects (3), however as there are clear links between the cell cycle 
and pluripotency, uncovering targets and networks affected by these miRNAs 
may provide insight into the regulation of the balance between pluripotency and 
differentiation (208). 
 
It should be noted that proteomic techniques have been previously applied to the 
DGCR8 protein, in order to elucidate characteristics of its structure; tandem 
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mass spectrometry has been used to identify phosphorylation sites, which 
depending on the site in question, when phosphorylated can increase or 
decrease the stability of the DGCR8 protein, thereby acting as a regulatory 
mechanism for the successful formation of the microprocessor complex (176).  
Mass spectrometry has also been used to identify ribosomal proteins that bind to 
the 5’ end of DGCR8 RNA, which may result in internal translation of DGCR8 in a 
cap-dependent manner (251). 
 
10.1 Characterization studies 
10.1.1 DGCR8-/- mESCs may display increased differentiation  
 
Although both cell types displayed a similar genotype (Figure 14) ,after they had 
been cultured for 5 days, the cells displayed a distinctly different phenotype as 
indicated by not only their appearance but the different degrees of alkaline 
phosphatase staining (Figure 13). These results suggest that there is a profound 
difference in the cells underlying differentiation capacity, which is supported by 
Wang’ seminal study on DGCR8-/- mESCs (3).  This is supported by the initial 
DIGE analysis which indicated that as well as the DGCR8-/- mESCs expressing the 
pluripotency markers (Figure 14), but also expressing some early differentiation 
markers such as Calponin 3 and Vimentin, at a higher level than in the wild type 
cells (Table 7). 




In concordance with previous studies the WT and DGCR8-/- mESCs displayed 
similar levels of pluripotency, as defined by comparable levels of alkaline 
phosphatase staining and the high expression of the pluripotency markers; Oct4, 
Nanog and Sox2 in both cell types at the mRNA level (6).  Yet only Oct4 and 
Nanog mirrored this trend at the protein level whereas, Sox2 displayed 
significantly lower expression in the DGCR8-/- mESCs compared to the WT. A 
possible reason for the discrepancy between the mRNA and protein expression 
of Sox2 may be the genetic structure of Sox2, which only consists of one exon. 
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Primers are usually designed to span at least two exons, in order to prevent DNA 
contamination from masking any results.  
 
At the time of writing, there are no other studies, which compare pluripotency 
protein expression between DGCR8-/- and WT mESCs.  DGCR8-/- mESCs were first 
characterized in the seminal study by Wang et al., 2007, which concluded that the 
three major pluripotency markers showed similar mRNA expression levels 
between the DGCR8-/- and WT mESCs under conditions that promote self 
renewal.  Although the RNA samples were treated with DNase to prevent 
genomic DNA contamination, the primer set used to detect Sox2 was not specific 
and detected both Sox1 and Sox3, as well as Sox2 therefore any differences in 
Sox2 expression were not apparent (6). 
 
Recently, a study comparing Sox2 protein expression between miR-295 cluster 
knockout and WT mESCs, has shown that the Sox2 protein is expressed at a 
similar level in both cell types, possibly signifying that miRNAs other than the 
ESCC miRNAs play a role in the regulation of Sox2 expression (252).  This is 
supported by the protein analysis in this study that implies that Sox2 is not 
directly or indirectly regulated by the ESCC miRNAs, and studies, which show 
that although Oct4, Nanog and Sox2 bind to the promoter regions of the ESCC 
miRNAs sustaining their high expression, they are not targeted by the ESCC 
miRNAs (26).  Notably, the miR-295 cluster has been implicated in the regulation 
of DNA methyltransferases (Dnmts), which upon differentiation aid in the 
permanent repression of Oct4 (253), therefore the ESCC miRNAs play an indirect 
role in maintenance of pluripotency by aiding in the onset of differentiation. This 
is supported by DGCR8-/- mESCs inability to downregulate markers of 
pluripotency even under differentiation inducing conditions (6). 
 
The downregulation of Sox2 in the DGCR8-/- mESCs is at odds with the known 
phenotype of delayed or reduced differentiation rates in the DGCR8-/- mESCs 
(6,254).  Particularly as Sox2 is known to maintain high levels of Oct4 
expression, (49) and no difference is observed in the expression of Oct4 between 
both the WT and DGCR8-/- mESCs or upon the overexpression of the ESCC 
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miRNAs. As Sox2 shares redundant functions with other Sox proteins (44), and 
the downregulation of Sox2 in the DGCR8-/- mESCs does not have an effect on 
Oct4 levels as would be expected, it may indicate that the other isoforms of Sox2 
may be playing a compensatory role or that miRNAs play a role in regulating the 
interaction between Oct4 and Sox2. 
 
In WT mESCs, the expression of the pluripotency markers is tightly regulated to 
maintain the pluripotent state, this has been most reliably observed in studies 
where the expression of the pluripotency markers has been enhanced or 
repressed resulting in varying degrees of differentiation (37,45,49,50). In the 
particular case of Sox2, its downregulation results in differentiation towards the 
trophoectoderm lineage (53), however no difference was observed in 
spontaneous differentiation rates as confirmed by alkaline phosphatase staining 
or a decrease in Nanog or Oct4 expression levels, further highlighting the 
important role of the ESCC miRNAs in the maintenance of the balance between 
differentiation and pluripotency.   
 
Interestingly, of the three major pluripotency markers, Sox2 is the only one, 
which is not specific to ESCs and is expressed by cells of the extra-embryonic 
ectoderm (52) and embryonic neural stem cells (53). 
 
10.1.3 DGCR8-/- mESCs display a slower proliferation rate 
 
mESCs have an unusual cell cycle structure that lack a G1/S phase restriction 
point, caused in part by the high expression of the ESCC miRNAs (3).  Due to the 
loss of miRNAs in DGCR8-/- mESCs, in particular the ESCC miRNAs, they have a 
significantly higher expression of cell cycle inhibitors of the G1/S transition, 
including Rbl2, Lats and Cdkn1a (3). This results in a significantly slower 
proliferation rate compared to WT mESCs (3,6).  We confirmed that the DGCR8-/- 
mESCs used in this study were displaying a slow growth phenotype and that the 
differences in cell number were not due to apoptosis which is in agreement with 




Recently studies have shown that the forced expression of the miR-295 and 302 
clusters in DGCR8-/- mESCs, is enough to reverse the cell cycle/proliferation 
defect (3).  In this study, the final cell numbers of WT and transfected DGCR8-/- 
mESCs was counted, and indicated that there was no significant difference 
between the two cell types, demonstrating that although the transfection 
efficiency levels were sufficient enough to affect known targets of the ESCC, it 
had no effect on the proliferation of the cells.   
 
Initially conventional PCR was used to test the RNA expression levels of the cell 
cycle inhibitors, which revealed that Rbl2 and Lats2, displayed significantly 
higher expression in the DGCR8-/- mESCs compared to the WT.  However, in stark 
contrast to the other tested cell cycle inhibitors and previous studies (3), 
although cdkn1a trended towards displaying lower expression in the DGCR8-/- 
mESCs, there was too much variability between the three technical replicates for 
there to be a significant difference between the two cell types.  To eliminate any 
variability introduced by the insensitivity of the conventional PCR method, qPCR 
for the Cdkn1a mRNA was conducted on the same samples, and revealed that 
there was a significant difference in Cdkn1a expression between the two cell 
types. This was supported by the transfection studies, which confirmed that 
Cdkn1a is a direct target of the ESCC miRNAs. 
 
Although all of the miRNAs had a similar effect in restoring the expression levels 
of cdkn1a, it should be noted that previous transfection studies have shown that 
of the ESCC miRNAs, miR-294 has the greatest effect on restoring the ESC cycle 
(3).  This has led to it being termed a representative miRNA for the miR-295 
cluster and it has been used as such, in transfection experiments studying the 






10.1.4 The overexpression of miR-291b in DGCR8-/- mESCs results in 
increased cell death 
 
The downregulation of DGCR8 results in increased susceptibility to cell death, 
limited proliferation and limited differentiation capacities, to varying degrees, in 
a range of cell types (256-259). Therefore changes in its expression levels have 
profound effects on cell phenotype.  Nowhere, is this more distinct than in the 
DGCR8-/- mESC line, where the complete loss of DGCR8 results in 
reduced/delayed differentiation, slow proliferation and prolonged expression of 
the pluripotency genes, particularly; Oct4, Sox2 and Nanog under differentiating 
conditions (3,6).  However studies have revealed that cell death rates do not 
differ between WT and DGCR8-/- mESCs (6), and this was confirmed in this study. 
 
The miR-295 cluster has been shown to play an important role in protection 
against apoptosis; studies on Dicer knockout mESCs have shown that there is an 
upregulation of cell death genes such as Caspase 2, a direct target of the miR-295 
cluster (148).  However only when the Dicer knockout mESCs were exposed to 
DNA damaging chemicals, did the protective properties of the miR-295 cluster 
become apparent (148).  Interestingly, DGCR8-/- mESCs do not downregulate 
pro-survival, C-terminal binding proteins due to the loss of miRNAs, when 
treated with an apoptotic reagent such as Staurosporine, therefore the loss of 
miRNAs can protect against apoptosis (260), thus miRNAs are not only 
important for controlling mESC proliferation via the cell cycle but also for 
regulating mESC apoptosis (3,208). 
 
Although, there were no differences in cell death between the WT and DGCR8-/- 
mESCs at baseline, and on average post-transfection of the ESCC miRNAs there 
were no differences in cell number, in two of the four replicates used to study 
cell proliferation in the cells transfected with miR-291b, there was a 5% loss of 
cells compared to other transfections (Table 11).  This may have explained the 
phenotypic differences between the cells transfected with miR-291b, which 
displayed less round colony formation and more elongated cells around the 
edges of colonies. This correlates with a previous study, which shows that the 
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remaining miRNAs in the 295-cluster with the specific seed sequence ‘AAGUGC’, 
have a protective effect with regards to cell death when re-introduced into 
miRNA deficient mESCs (148).  Another contributing factor may have been the 
considerably higher transfection efficiency of miR-291b in the DGCR8-/- mESCs 
compared to the other transfections, as well as the one nucleotide difference in 
seed sequence in miR-291b compared to the other tested miRNAs possibly 
indicating that as well as miR-291b targeting the same mRNAs as the other 
ESCCs, it also has other distinct mRNA targets, which result in the morphological 
and cell number differences.   
 
The characterization experiments conducted on the WT and DGCR8-/- mESCs 
indicate that the loss of DGCR8 results in lower protein expression of Sox2 and a 
slower proliferation rate in comparison to WT cells, which has been attributed at 
least in part to the loss of miRNAs from the miR-295 cluster, resulting in 
decreased expression of the cell cycle regulators (3). These results concur with 
the seminal study by Wang et al., which show that the differences in proliferation 
observed between DGCR8-/- and WT mESCs is solely due to a decreased 
proliferation rate, at least in part caused by an accumulation of cells in the G1/S 
phase of the cell cycle. (6),  
 
10.2 Proteins influenced by the ESCC miRNAs  
 
We chose to study the targets and effects of the miRNAs from the miR-295 
cluster; miR-291a, miR-291b, miR-294 and miR-295 and a human homolog miR-
302d (ESCC miRNAs), as the miR-295 cluster is the most abundantly expressed 
group of miRNAs in mESCs (48), is known to control the ESC cycle and has also 
been instrumental in increasing the efficiency of iPSC formation, in comparison 
to the Yamanaka factors (16,214), and therefore play a major role in the 
maintenance and regulation of pluripotency (3).  Due to the importance of the 
ESCC miRNAs for the stem cell phenotype and their high abundance in mESCs, it 




Of the miRNAs studied (excluding miR-291b, due to it occasionally promoting 
cell death in our study), miR-295 shared the most targets with the other miRNAs 
and also had the highest number of targets identified in both DIGE studies.  miR-
291a, had the least number of targets of which three out of four were directly 
associated with transcription and translation indicative of miR-291a playing a 
general role in regulating gene expression.   
 
Fifty-eight proteins showed differential expression between the different 
transfections and of these twenty-three proteins were identified as showing 
significantly differential expression compared to the mESCs transfected with the 
control miRNA. Of these approximately a third were affected by the expression of 
at least two miRNAs, highlighting the high number of shared targets between 
miRNAs from the same family.  Furthermore three of these proteins; Aldolase A, 
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and Peroxiredoxin 1 were 
also identified in the initial DIGE study comparing baseline protein expression 
between the WT and DGCR8-/- mESCs.  Interestingly, both Aldolase A and GAPDH 
are key enzymes for glycolysis, and upon overexpression of the ESCC miRNAs, 
the expression of both of the enzymes was restored at the mRNA. 
 
Interestingly, there is emerging evidence alluding to the fact that metabolism 
may play a role in the control of differentiation/maintenance of pluripotency 
(24,60,87,261,262).  Although the proposed links between glucose metabolism 
and ESC pluripotency have not been directly identified, studies have shown that 
pluripotent cells predominantly use glycolysis as their primary form of energy 
generation, and upon differentiation switch to predominantly using oxidative 
phosphorylation (28,62).  Also, during the reprogramming process from mature 
cell types to iPSCs, glycolytic genes are switched on before pluripotent genes, 
indicating that the switch in glucose metabolism may be a trigger for the onset of 
pluripotency (57,63,70).  However these studies do not directly and definitively 
uncover the mechanisms that connect pluripotency and metabolism, the results 
of the DIGE analysis potentially indicate that it is miRNAs that control glucose 




In the following chapter, I will discuss glucose metabolism in DGCR8-/- mESCs, 
focusing on glycolysis (Aldolase A, Phosphofructokinase 1, PKM2 and Fructose-
1,6-bisphosphate) and the TCA cycle (Succinate dehydrogenase 2, Isocitrate 
dehydrogenase 2 and Malate dehydrogenase 2). 
 
 
10.3 Glucose metabolism 
 
10.3.1 DGCR8-/- and WT mESCs display differential expression of glucose 
metabolism enzymes 
 
The DIGE analysis revealed that one of largest groups of proteins that showed 
differential expression between the WT and DGCR8-/- mESCs, were those 
involved in glucose metabolism.  This was supported by the principal component 
analysis, which indicated that the top three pathways containing the most 
differentially expressed proteins were involved in glucose metabolism related 
pathways; ‘Gluconeogenesis’, ‘Glucose metabolism’ and ‘Glycolysis’.  Another 
metabolic pathway that was identified was the ‘Citric acid cycle (TCA cycle)’.  The 
differential expression of enzymes involved in both glycolysis and the TCA cycle 
was validated at both the RNA and protein levels.  Strikingly, the differences 
observed in the expression of the glucose metabolism genes were more 
pronounced at the protein level compared to the RNA level suggesting that 
glucose metabolism genes may also be regulated at the post translational level.  
This was also supported by the common pathway analysis conducted on the 
DGCR8-/- mESCs transfected with the ESCC miRNAs, which revealed that the top 
three enriched pathways were those involved in redox reactions, proton 
transport and ATP metabolism, which is tightly interlinked to glucose 
metabolism (Figure 32). 
 
As well as the top three pathways, the pathway analysis also identified 
‘Translocation of GLUT4 to the plasma membrane’ and ‘Translocation of GLUT4 
vesical and docking at the plasma membrane’ as common pathways for the 
differentially expressed proteins between the WT and DGCR8-/- mESCs, which 
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corresponds to the mRNA expression pattern of the glucose transporters GLUT1 
and even more importantly, GLUT4.  Among the well-characterized family of 
glucose transporters, only GLUT1 and GLUT4 were analysed as they specifically 
shuttle glucose into cells (263) and both displayed significantly lower mRNA 
expression in the DGCR8-/- compared to the WT mESCs.   
 
The pathway analysis was mirrored with eight of the twelve glycolytic enzymes 
analysed, which all showed significantly lower mRNA expression in the DGCR8-/- 
compared to the WT mESCs, suggesting that they are indirect targets of the ESCC 
miRNAs.  Of the four glycolytic mRNAs that did not show significantly different 
expression between the two cell types, Phosphofructokinase 1 (pfk1) was the 
most notable, as it fully commits cells to glycolysis by catalysing the second 
irreversible step (Berg, Tymoczko et al. 2002), and the remaining rate-limiting 
enzymes; hexokinase 2 and pyruvate kinase 1/2 were expressed at lower levels 
in the DGCR8-/- mESCs.  This indicates that pfk1 is not affected by the ESCC 
miRNAs and this is confirmed in the transfection experiments, possibly alluding 
to the fact that pfk1’s activity is regulated by a number of binding factors 
including a high ATP/AMP ratio, a low pH as can be caused by high lactate 
production and high citrate production which act as inhibitors and fructose-2, 6-
bisphosphate which acts as an activator (68).  The binding of these proteins 
results in a conformational change, affecting the activity of the enzyme, however 
the mRNA analysis only provides data on gene expression not enzymatic activity.   
 
PKM2 which also exists in two states, as both a low activity dimer and high 
activity tetramer form (264), which could not be distinguished between using 
PCR or immunoblotting, displayed lower expression in the DGCR8-/- mESCs.  
Interestingly, although the M2 isoform is predominant form of the PKM2 enzyme 
in mESCs (74), the M1 form also showed significantly differential expression 
between the two cell types, supporting a higher rate of glycolysis in the WT cells 
compared to the  DGCR8-/-. 
 
This was further supported by Seahorse analysis, which provided a functional 
read out of the glycolytic rates of the DGCR8-/- and WT mESCs, and revealed that 
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although at baseline both cell types had a similar ECAR (indicative of the rate of 
glycolysis), upon the introduction of Oligomycin, an ATP synthase inhibitor, 
which forces the cells to maximally use glycolysis for energy generation; the WT 
cells displayed a higher glycolytic capacity. This coupled with the RNA and 
protein analysis, possibly indicates that although at baseline both cells conduct 
glycolysis at a similar rate, when mitochondrial function is impaired, the WT 
cells are poised (via the higher expression of glycolytic enzymes) to use 
glycolysis more effectively for energy generation.  
 
Lactate, which is an end product of glycolysis, was secreted in higher quantities 
upon the overexpression of the ESCC miRNAs in comparison to the DGCR8-/- 
mESCs transfected with the control miRNA, which correlated with the higher 
expression of LDHA in the WT cells compared to the DGCR8-/-.  These results 
suggest that the ESCC miRNAs play a role in positively controlling the rate of 
glycolysis in wild type mESCs. 
 
To verify this a wide range of glycolytic enzymes were analysed upon the 
overexpression of the ESCC miRNAs in the DGCR8-/- mESCs.  Seven of the twelve 
mRNAs analysed, expression was restored near to or to WT levels.  Notably both 
Aldolase A and PKM2 displayed restoration of mRNA expression to WT levels, 
and strikingly this was mirrored at the protein level for Aldolase A.  Interestingly 
studies have shown that nuclear PKM2 acts in a positive feedback loop to 
promote the higher expression of glycolytic enzymes, such as GLUT1 and lactate 
dehydrogenase (86,265).   
 
Although not all of the miRNAs were able to restore expression to levels that 
were significant compared to the mESCs transfected with the control miRNA, 
they all followed a similar trend, confirming that due to the shared seed 
sequences of the miRNAs, they share a large number of targets.   
 
The metabolic analyses accompanied by the lower expression of glycolytic 
proteins and mRNA in the DGCR8-/- cells, indicate that the DGCR8-/- cells are less 
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glycolytic than the WT cells, and that this is influenced by the expression of the 
ESCC miRNAs. 
 
10.3.2 Aldolase A’s substrate FBP regulates PKM2 expression  
 
PKM2, the rate-limiting enzyme for the final step of glycolysis, exists in either a 
less active dimeric form or a highly active tetrameric form that promote anabolic 
processes which debranch from glycolysis or glycolysis, respectively (80).  
Although the qPCR and protein analysis do not indicate what form of the PKM2 
enzyme is most dominant in either of the cell types, they do indicate that overall 
PKM2 is expressed at lower levels in the DGCR8-/- compared to the WT cells, and 
that PKM2 is an indirect target of miR-291b, miR-294, miR-295 and miR-302d, at 
the mRNA level.  However, the upregulation of PKM2 in the presence of the 
ESCCs at the RNA level, was not mirrored at the protein level for reasons that are 
yet to be elucidated.   
 
The intraconversion of PKM2 between its dimeric and tetrameric forms is 
controlled by the binding of activators such as fructose-1, 6-bisphosphate (FBP) 
and repressors, including tyrosine-phosphorylated peptides. Notably, FBP is a 
major substrate for Aldolase A during glycolysis, therefore the expression of 
higher expression of Aldolase A in the WT mESCs compared to the DGCR8-/- 
coupled to a higher amount of lactate production in the presence of the ESCC 
miRNAs in the transfected DGCR8-/- mESCs, further supports a higher rate of 
glycolysis in the WT cells compared to the DGCR8-/- (Figure 40). 
 
The differential expression of Aldolase A between the DGCR8-/- and WT mESCs, 
as well as the restoration of Aldolase A to WT levels upon the introduction of the 
ESCC miRNAs into the DGCR8-/- mESCs suggests that the expression of Aldolase A 
may be indirectly regulated by the ESCC miRNAs. Notably, high levels of Aldolase 







Figure 40- Simplified representation of glycolytic pathway in WT mESCs A) Green arrows represent 
mRNA expression compared to DGCR8
-/- 
mESCs.  Red arrow represents protein expression compared 
to DGCR8
-/- 
mESCs.  Blue arrow represents lactate secretion compared to DGCR8
-/- 
mESCs.  B) Binding 
of FBP to PKM2 results in higher glycolysis via higher expression of Aldolase A. 
 
10.3.3 The DGCR8-/- mESCs display a higher expression of TCA cycle 
enzymes 
 
Reciprocal to the expression pattern of the glycolytic genes, the DIGE analysis 
revealed that the TCA cycle proteins showed a trend of being more highly 
expressed in the DGCR8-/- mESCs compared to the WT, with only one out of the 
six proteins identified being expressed at higher levels than in the DGCR8-/- 
mESCs.  This was reflected in the common pathway analysis, which indicates that 
within DGCR8-/- mESCs, the individual ESCCs may play a role in the regulation of 
proteins involved in the TCA cycle and also in the regulation of oxidative stress. 
Succinate dehydrogenase assembly factor 2 which aids in the assembly of the 
succinate dehydrogenase 2 enzyme complex (267) was the one TCA cycle 
associated protein that was identified as showing higher expression in the WT 
mESCs compared to the DGCR8-/-, this was mirrored by RNA analysis for 
succinate dehydrogenase 2.  Interestingly, succinate dehydrogenase 2 couples 
the TCA cycle to oxidative phosphorylation, possibly indicating that although 
there is an upregulation of TCA cycle proteins, the coupling between oxidative 
phosphorylation and the TCA cycle is weaker in the DGCR8-/- mESCs, suggesting 
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that the DGCR8-/- mESCs may be using another metabolic pathway for energy 
generation. 
 
The DIGE analysis revealed that Isocitrate Dehydrogenase 2 (Idh2); which 
catalyses the sole rate limiting step of the TCA cycle (268) showed one of the 
largest fold changes of 2.25 higher in the DGCR8-/- than the WT mESCs and this 
was confirmed at both the RNA and protein levels.  However, in this study Idh2 
was not identified as a target of any of the miRNAs, though the qPCR analysis 
revealed it to be downregulated upon transfection of miR-291b, with a p-value 
on the cusp of significance at 0.051.   
 
Malate dehydrogenase 2 (Mdh2), another TCA cycle enzyme which also showed 
significantly higher expression in the DGCR8-/- in comparison to the WT mESCs 
at the protein level, was directly affected by the expression of the ESCC miRNAs, 
further alluding to a role of the ESCC miRNAs in controlling the metabolic 
phenotype of mESCs.  Although all of the miRNAs downregulated the expression 
of Mdh2 at the RNA level, miR-295 had the most obvious effect on Mdh2 
expression at the protein level, possibly indicating that although Mdh2 is 
expression is downregulated by all of the ESCC miRNAs, miR-295 has the 
greatest effect on its expression.  This is supported by miRNA target prediction 
databases that show Mdh2 to be targeted by miR-291a and 291b (245). 
 
Seahorse analysis was used to provide functional data to support the mRNA and 
protein expression data. At baseline, the DGCR8-/- cells had a significantly lower 
OCR indicative of a lower rate of mitochondrial respiration at baseline, which 
may be representative of their slower proliferation rate compared to the WT 
mESCs.  This was also the case upon the addition of Oligomycin A, an ATP 
synthase inhibitor, which indicated a lower amount of ATP production by the 
DGCR8-/- mESCs.   
 
The maximal respiration rate was calculated using the OCR values upon the 
addition of FCCP minus the non mitochondrial respiration (values collected upon 
the addition of Rotenone and Antimycin A), however although the WT showed a 
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higher maximal respiration rate overall, the difference was not significant 
indicating that both cell types have the capacity for similar mitochondrial 
function. 
 
Overall, these results indicate that although both the WT and DGCR8-/- mESCs are 
still reliant on glycolysis, as indicated by a similar basal glycolytic rate, the lower 
expression of the glycolytic enzymes accompanied by the higher expression of 
some TCA cycle proteins indicates that the DGCR8-/- mESCs may also be using an 
alternative form of energy generation. 
 
10.4 DGCR8-/- mESCs may use an alternative energy generation pathway 
to glycolysis 
 
This study suggests that DGCR8-/- mESCs are less glycolytic than their WT 
counterparts.  Metabolic techniques were used to discover whether the DGCR8-/- 
mESCs were using an alternative pathway for energy generation.  The analysis 
showed that the DGCR8-/- mESCs displayed a lower expression of glycolytic 
enzymes, and the expression of the majority of glycolytic enzymes studied was 
restored upon the expression of the ESCC miRNAs in the DGCR8-/- mESCs.  This 
was supported by both NMR based secretome and intracellular analysis, which 
revealed the DGCR8-/- mESCs to contain and secrete less lactate, and also secrete 
less alanine, which was reversed by the expression of the ESCC miRNAs.  
Threonine secretion was also increased in the presence of the ESCC miRNAs. The 
analysis suggested that similar to cancer cells, the DGCR8-/- mESCs may be using 
glutaminolysis as a compensatory energy source and that changes in threonine 
metabolism may be playing in role in the survival of DGCR8-/- mESCs. 
 
Glutaminolysis is defined as ‘...a series of biochemical reactions by which 
glutamine is lysed to glutamate, aspartate, CO2, pyruvate, lactate, alanine and 
citrate...’ (269), thereby producing intermediates such as glutamate and 
aspartate which can be used as precursors for nucleic acid and serine synthesis, 
respectively (270).  It is a key energy source for proliferative cells, particularly 
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cancer cells, as it allows them to produce ATP under low glucose conditions 
(271).  
 
In comparison to the WT mESCs, the DGCR8-/- cells displayed a lower expression 
of glycolytic enzymes and a reciprocal higher expression of TCA cycle enzymes.  
The metabolic analyses, show that the transfected DGCR8-/- mESCs have a lower 
intracellular concentration of alanine and a higher intracellular concentration 
and lactate compared to the DGCR8-/- mESCs transfected with the control 
miRNAs and reciprocally secrete less alanine and more lactate. Notably, 
glutamate and alanine displayed a lower and higher intracellular concentration, 
respectively, in the transfected cells compared to the cells transfected with the 
control miRNA.  Glutamate can be metabolized in the mitochondria, into α-
ketoglutarate which can feed into the TCA cycle. This is indicative of a switch 
from glycolysis to glutaminolysis for energy production (248) in the DGCR8-/- 
mESCs, which is shown to be partially reversed by the transfection of the ESCC 
miRNAs.   
 
Figure 41- Glutaminolysis via the ‘reverse TCA cycle’ in rare cancer cells. Glucose is converted into 
pyruvate, which is converted into acetyl Co-A that feeds into the reverse TCA cycle.  Glutamine is 
metabolized into α-ketoglutarate (α-KG) and alanine, and then Isocitrate via the high expression of 





Interestingly, studies have shown that cancer cells (Figure 41) which are similar 
to mESCs in terms of the expression of pluripotent genes and their ability to use 
aerobic glycolysis for energy generation, can in specific cases undergo metabolic 
changes which result in them using glutaminolysis via ‘the reverse TCA cycle’ 
aided by the ability of the Isocitrate dehydrogenase enzymes to catalyse 
reversible reactions, for energy generation, thereby producing less lactate and 
also resulting in higher fatty acid production (273).  
 
This is supported by the higher baseline expression of TCA cycle proteins, most 
significantly Idh2 in the DGCR8-/- mESCs compared to the WT, which correlates 
to the higher expression of the Idh isoforms in certain cancer types (271,273), 
the increased protein expression of fatty acid related proteins as identified by 
the DIGE analysis, as well as the higher expression of HIF1α in the DGCR8-/- 
mESCs, which under hypoxic conditions has been found to be a master regulator 
of the switch to glutaminolysis in some rare cancer types (249).   
 
To aid with the verification of this, the expression of Pparα, a transcription 
factor/ master regulator, which upon activation promotes uptake, utilization and 
catabolism of fatty acids (274) was analysed at the protein and RNA levels. The 
blot shows that there is a consistent trend of Pparα being more highly expressed 
in the DGCR8-/- mESCs compared to the wild type, with the p-value being close to 
significance, at 0.06, at the RNA level the difference is significant (p-value= 
0.021).  Aldehyde dehydrogenase 2, another protein involved in fatty acid 
metabolism, of which two isozymes were identified in the DIGE analysis as being 
differentially expressed between the wild type and DGCR8-/- mESCs is a 
predicted target of the ESCC miRNAs as identified in three miRNA data 
prediction databases (240,243,244) and was more highly expressed in the 
DGCR8-/- compared to the WT cells.  However both Pparα and Aldehyde 
dehydrogenase 2, were unaffected by the presence of the ESCC miRNAs. 
 
Triosephosphate Isomerase  (TPI) which is also involved in glycolysis and is 
known to reversibly catalyse the conversion of Glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) to Dihydroxyacetone phosphate (DHAP) exhibited 
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similar expression in both the WT and DGCR8-/-, notably DHAP is known to be a 
precursor for fatty acid synthesis.  However the expression of TPI was similar 
across both cell types, possibly indicating that if fatty acid metabolism rates have 
increased in the DGCR8-/- mESCs, then this is due to an alternative pathway such 
as the reverse TCA cycle summarized in Figure 41. 
 
Most importantly the NMR analysis revealed that at baseline, alanine is excreted 
at higher concentrations in the DGCR8-/- mESCs compared to the WT and upon 
the overexpression of ESCC miRNAs, the secretion levels decreased indicating 
the miRNAs have a direct effect on alanine metabolism.  Lactate displayed higher 
secretion levels upon overexpression of ESCC miRNAs in the DGCR8-/- mESCs. 
 
Although the DGCR8-/- mESCs were individually transfected with five miRNAs; 
miR-291a, miR-291b, miR-294, miR-295 and miR-302d, the secretome analysis 
revealed that the metabolites displayed the most significant differences upon 
overexpression of miR-294 and miR-302d compared to cells transfected with the 
control miRNA, which correlated with the principal component analysis.  
Therefore intracellular H1 NMR analysis was conducted on the DGCR8-/- mESCs 
transfected with miR-294, miR-302d and the control miRNA.   
 
10.4.1 HIF1α expression in DGCR8-/- mESCs  
 
Notably although HIF1α is a predicted target of the ESCC miRNAs (except miR-
291b, possibly due to the one nucleotide difference in seed sequence), it was 
unaffected by the presence of the ESCC miRNAs, indicating that the activation of 
PKM2 via HIF1α is independent of the ESCC miRNAs.  Interestingly, studies have 
shown that HIF1α is a direct target of miR-17-92 cluster of miRNAs, which are 
highly expressed in ESCs and have a similar seed sequence to the ESCC miRNAs 
of ‘AAAGUG’, therefore share targets with the ESCC miRNAs such as cdkn1a 
(148,275).  Thus the loss of miRNAs particularly, the miR-17-92 cluster may 
account for the significantly higher expression of HIF1α in the DGCR8-/- mESCs, 
and may potentially explain the loss of the link between the expression of HIF1α 
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and the glucose metabolism enzymes (70).  This awaits further experimental 
confirmation. 
 
Interestingly, a high expression of HIF1α has been implicated in the induction of 
glutaminolysis in cancer cells (249) and HIF1α was shown to be consistently 
expressed at higher levels in the DGCR8-/- mESCs compared to the wild type in 
this study. 
 
10.4.2 Glutamic pyruvate tranaminase 2 (Gpt2) and Isocitrate 
dehydrogenase 1 (Idh1) are both indirectly regulated by the ESCC 
miRNAs 
 
In order to verify whether there was a switch from glucose metabolism to 
glutaminolysis in the DGCR8-/- cells for energy production, the gene expression 
of glutamic pyruvate transaminase 2 (gpt2), the key enzyme which catalyses the 
reversible conversion of glutamate to alanine and α-ketoglutarate was analysed. 
 
Gpt2 showed significantly higher expression in the DGCR8-/- mESCs compared to 
the WT, and this was enhanced by the overexpression of the ESCC miRNAs. This 
was also the case with the cytosolic Isocitrate Dehydrogenase 1, which showed 
similar expression at baseline between the two cell types, but was indirectly 
targeted by the ESCC miRNAs resulting in expression levels that were above WT 
levels.  Notably, both Idh1 and Gpt2 catalyse irreversible reactions, therefore, the 
higher expression of Idh1 and Gpt2 in the presence of the ESCC miRNAs coupled 
to the lower intracellular concentration of alanine and higher intracellular 
concentration of lactate indicate that the presence of the ESCC miRNAs may push 
mESC metabolism towards glycolysis and in the absence of these miRNAs, the 
cells utilize more glutaminolysis.  This is supported by studies which show that 




10.4.3 Threonine is secreted at higher levels by the transfected DGCR8-/- 
than those transfected with the control miRNAs 
 
Threonine is an essential amino acid for mESC pluripotency and survival and is a 
precursor for glycine synthesis, which in turn is a precursor for purine 
biosynthesis (114).  mESCs have a distinctively high rate of threonine catabolism 
into glycine and acetyl Co-A, of which the latter can feed into the TCA cycle, 
providing an alternative energy source for mESCs (111). Interestingly, threonine 
displayed increased secretion upon the transfection of the individual ESCC 
miRNAs, with miR-295 causing a significantly higher secretion compared to the 
DGCR8-/- mESCs transfected with the control miRNA (data not shown). 
 
The lower secretion of threonine into the medium in the presence of the ESCC 
miRNAs may be indicative of more threonine retention within the transfected 
DGCR8-/- and may provide a metabolic mechanism for the differentiation defects 
observed in the DGCR8-/- mESCs.  However, as the focus of this study was on 
mESCs under proliferative conditions, this would require further exploration.  
Studies have shown that high threonine dehydrogenase activity promotes 
cellular pluripotency and low activity promotes differentiation (111), so it would 
be interesting to study the DGCR8-/- under differentiative conditions in this 
context.  The increased retention of threonine in the presence of the ESCC 
miRNAs, also supports a higher rate of glycolysis in the transfected DGCR8-/- and 
WT mESCs, as less catabolism of threonine would result in a lower activity of the 
TCA cycle. 
 
There was no difference in the mRNA expression level of threonine 
dehydrogenase 2 at baseline between the two cell types, or upon the transfection 
of the ESCC miRNAs into the DGCR8-/- mESCs. Notably, when Lin28a, a protein 
which is highly expressed in ESCs and has been successfully been used as part of 
a cocktail of transcription factors to reprogram human fibroblasts (58), is 
overexpressed in mESCs, this results in an accumulation of metabolites involved 
in the threonine-purine biosynthesis pathway (276).  Whereas overexpression of 
the pro-differentiation let-7 family of miRNAs which is usually negatively 
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regulated in the wild type mESCs by Lin28 proteins (198), reduces the 
abundance of the metabolites in pathway, indicates that this pathway is 
regulated by a combination of protein/miRNA interactions that play an 
important role in the balance between pluripotency and differentiation (276).   
 
Adenylate kinase 2 (closely related to adenylate kinase 4 (Table 7) regulates ATP 
homeostasis within cells and is therefore linked to purine biosynthesis (277) and 
was differentially expressed between the WT and DGCR8-/- mESCs at both the 
protein level and RNA level displaying lower expression in the DGCR8-/- mESCs, 
which was restored to WT levels in the presence of the ESCC miRNAs further 
supporting the role of the ESCC miRNAs in purine biosynthesis. 
10.5 DGCR8-/- mESCs display higher expression of antioxidant proteins 
 
The comparative DIGE analysis between the DGCR8-/- and WT, with three out of 
four identified proteins displaying higher expression in the knockout cells.   
 
Of these, Sod1 which showed higher expression in the WT cells compared to the 
DGCR8-/- in the DIGE analysis, however the at the mRNA level, the opposite 
pattern of expression was observed.  The expression of Sod1 at the RNA level 
corresponded to the expression pattern observed with the other antioxidant 
genes; Peroxiredoxin 3 and Thioredoxin-interacting protein 1 (txnip); which 
both displayed higher expression in the DGCR8-/- mESCs, though the difference 
observed in txnip gene expression was not significant.  Notably, Peroxiredoxin 3 
and txnip are predicted targets of the ESCC miRNAs (245), and studies indicate 
that txnip is an important regulator of cellular glucose and fatty acid metabolism 
(278), further implicating miRNAs in the regulation of mESC metabolism.  The 
downregulation of txnip has been shown to result in increased rates of 
glycolysis, as observed in the WT mESCs (278).  Txnip’s expression was lowered 
in the presence of the ESCC miRNAs, significantly by miR-294. 
SOD1 and Peroxiredoxin 3, are both antioxidant genes, which were expressed at 
a significantly higher level in the DGCR8-/- cells compared to the WT, and at the 
qPCR level were shown to be influenced by the expression of the ESCC miRNAs; 
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SOD1, indirectly by miR-291a, miR-295 and miR-302d, and Peroxiredoxin 3 
directly by miR-295. The targeting of Peroxiredoxin 3 by miR-295, would have to 
be confirmed by luciferase assays. 
 
Of the metabolites which are associated with both the TCA cycle and glycolysis, 
both alanine and NAD(H) displayed differences upon the transfection of the 
miRNAs, not only suggesting a possible change in substrate utilization for energy 
generation, but also changes in the redox status of the cells transfected with the 
miRNAs.  Due to the nature of the analysis NAD+ and NADH were taken as one 
measurement, therefore we cannot definitively determine the redox status of the 
transfected cells, and this is also the case with the measurement of ADP+ATP.   
 
10.6 Chaperone proteins 
 
Overall, the largest groups of proteins that was identified as being differentially 
expressed in DGCR8-/- mESCs at baseline were chaperone proteins whose major 
function is to transport and fold proteins post-translation into their final 
configurations (279).  The miRNA walk database (245), which cross references a 
number of miRNA target prediction databases was used to identify potential 
targets of the highly expressed miR-295 cluster of miRNAs (48). It revealed two 
of the chaperone proteins; peptidyl-prolyl cis-trans isomerase FKBP4 and the 
mitochondrial 60kDa heat shock protein as putative targets of members of the 
ESCC cluster (241,242,280).  The majority of chaperone proteins identified 
displayed higher expression in the DGCR8-/- compared to the WT mESCs, 
suggesting that their expression may be regulated by miRNAs.  Notably the loss 
of miRNAs in mESCs has been linked to autophagy associated with an increased 
expression of chaperone proteins (281).   
 
The common pathway analysis comparing the WT and DGCR8-/- mESCs also 
supports the finding that the chaperone proteins may be altered as pathways 
including ‘Binding of Erp57’ (Erp57 interacts with calreticulin and calnexin to 
promote their function of folding glycoproteins (282)), ‘Activation of chaperones 
by ATF6-alpha’ and ‘Protein folding’ have been highlighted as being important in 
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the DGCR8-/- cells.  ‘Binding of Erp57’ even had the highest ratio of proteins 
identified to be part of that pathway compared to any other pathway, further 
supporting a role for chaperone proteins in DGCR8-/- mESCs .   
 
Two of the chaperone proteins identified in the DIGE study were validated at the 
protein level; the expression levels for Serpin H1 were in agreement with the 
data from the DIGE analysis however, the expression levels for PDI, another 
chaperone protein, were not, most likely because, PDI is a redox regulated 
chaperone protein, and therefore has different oxidation states (283).  Thus the 
discrepancy between the differential expression of PDI observed on the DIGE gel 
and the similar expression of PDI in both the WT and DGCR8-/- cells at the 
protein level, most likely represents the ability of the DIGE technique to detect 
different post translational modifications of the same protein, whereas the 
antibody used in the western blot was not specific for different oxidation states.  
 
Serpin H1, a chaperone protein for collagen, which at the protein level was 
consistently expressed at a lower level in the DGCR8-/- mESCs compared to the 
WT, was unaffected by the expression of the ESCCs at the protein level.  However 
ANOVA analysis revealed there to be a highly significant difference (p-value = 
0.0021) between the transfected cells at the mRNA level, further t-tests revealed 
that the mESCs transfected with miR-291b and miR-294 showed significantly 
higher and lower expression of Serpin H1, respectively compared to the cells 
transfected with the control miRNA. 
 
Notably, the loss of miRNAs in mESCs has been linked to autophagy coupled with 
an increased expression of chaperone proteins (281) as observed in this study.  
Other potentially contributing factors to this trend could be the loss of miRNAs 
indirectly regulating chaperone protein expression, or resulting in a need for 
higher chaperone protein expression to deal with the increased number of 
proteins being translated such as is observed during the unfolded protein 
response (UPR) (279).  In order to test this, the expression of master regulators 
of the UPR such as PERK, CHOP and ATF6 was analysed, however the results 
were inconsistent (data not shown). 
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11 Limitations of the study and future work 
 
11.1 Cell characterization 
 
The cells were characterised at baseline using PCR, Western blots and 
morphological analysis (Section 9.1),which revealed that both cell types were 
undifferentiated.  However, the alkaline phosphatase staining revealed that once 
the cells were kept in culture for longer (5 days), differences were revealed both 
in terms of morphology as shown by the differences in colony formation and the 
degree of staining (Figure 13).  This may suggest a difference in the 
differentiation status of the cells , which is supported by the DIGE analysis which 
reveals a higher expression of markers of early differentiation such as Calponin 3 
and Vimentin (Table 9 ) in the DGCR8-/- mESCs compared to the wild type.  In 
order to verify this, both cell types would have to be grown under the same 
differentiative conditions.  Although the cells were counted immediately prior to 
harvest, to ensure that a similar number of cells had survived and a cell death 
assay (Figure 18) was also conducted to verify this, however the cell death assay 
measured the number of nucleosomes released from the cells so only focused on 
one type of cell death; apoptosis, at one-time point, therefore it would be useful 
to carry out assays focusing on other forms of cell death at a range of time points. 
11.2 Technical difficulties 
 
Although DIGE analysis provides a robust and accurate method to study and 
compare the proteome of a number of samples, once the proteins have been 
identified, they need to be validated in order to ensure that the DIGE analysis is 
accurate.  The proteins were run on a gel over a size range of 15-100kDa and a pI 
ranging from 3-10, which gives an overview of abundant proteins, but only 
within this mass and pI range.  Using common pathway analysis allows for the 
identification of networks of proteins that may be affected aiding in the 
identification of proteins missed by DIGE analysis .  Therefore, it was vital to 
integrate a number of approaches in order to obtain the most accurate and in-
depth analysis of the mESC phenotype.  This is especially true when studying 
miRNAs effects on protein expression, as miRNAs can act as ‘rheostats’ for 
protein expression, so any subtle differences in protein expression may not be 
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identified by DIGE analysis.  For example, although it is clear that Aldolase A 
expression is influenced by all of the ESCC miRNAs, the DIGE analysis indicated 
that miR-295 was the only miRNA that had a significant influence on Aldoa 
expression, miR-294 had a near to significant effect on Aldoa expression, with a 
p-value at 0.08, while the remaining miRNAs failed to induce a change that 
reached statistical significance.   
 
11.2  Future work 
 
 
To further increase the understanding of the underlying mechanisms of the 
balance between pluripotency and differentiation and to fully study the 
metabolism of ESCs, it would be imperative to study the cells over a timecourse. 
 
Based on the metabolic differences observed between the DGCR8-/- and WT 
mESCs, with the DGCR8-/- possibly using glutaminolysis for their energy 
generation.  An important next step would be to provide WT mESCs with 
glutamine as their major substrate and identify what effect this would have their 
balance between pluripotency and differentiation.  However due to the mESCs' 
obvious reliance on glucose metabolism for energy production as well as the 
formation of amino acids and metabolites for cell growth and other intracellular 
processes, it can be difficult to study any direct effects of altering metabolism 
which would of course be tightly intertwined with cell survival.  
 
As aforementioned the DGCR8-/- mESCs provide a relatively ‘clean’ background 
for the study of miRNA function and targets (252).  Thus, studying a highly 
related set of miRNAs, which are known to have a large number of redundant 
targets (8,26), does not provide a full representation of the large number of 
interactions occurring in mESCs.  This study focused on the miR-295 cluster and 
miR-302d due to their highly conserved nature, and universality in ESCs. It has 
been established that although these miRNAs can be used to reprogram cells, 
when transfected into DGCR8-/- mESCs they are only able to restore the cell cycle 
and not any of the differentiation defects.  Therefore it would be useful to study 
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other miRNAs such as the let-7 miRNAs, which are known to have the ability to 
downregulate the pluripotency markers in DGCR8-/- mESCs (198), either on their 
own or in conjunction with the ESCC miRNAs. 
 
mESCs are continually poised between differentiation and pluripotency, 
therefore to fully understand the mechanisms controlling the obvious links 
between pluripotency, metabolism and miRNA regulation, it would be 
imperative to conduct the same study but under differentiation conditions.  
However, this would introduce more questions, as in culture of mESCs, although 
the majority of cells are undergoing self renewal, a small percentage of cells will 
be spontaneously, randomly differentiating, therefore the mere removal of LIF 
would result in a differentiation into a variety of cell types, which would 
confound any downstream metabolic and proteomic study. Thus a method of 
differentiation such as growing the mESCs on a collagen IV matrix in the absence 
of LIF, which would force the majority of cells to differentiate towards the 
smooth muscle cell lineage (284), would provide a more coherent overview of 
differentiation, albeit in relation to one lineage.  The spontaneous differentiation 
of mESCs is a major reason for using mESCs of early passages for any 
experiments, particularly those focused on pluripotency.   
 
 
12 . Conclusion 
 
Increasingly, metabolism and glucose metabolism in particular have been shown 
to play a direct role in the regulation of the onset of differentiation 
(29,30,60,63,67).  Using a range of combined –omics techniques, we were able to 
show that DGCR8-/- mESCs which are known to have impaired differentiation (6), 
not only display lower expression of glycolytic enzymes, but also have a lower 
glycolytic function than their WT counterparts, which may at least in part 




Upon the re-introduction of the ESCC miRNAs into the DGCR8-/- mESCs, not only 
was the expression of the glycolytic genes restored to WT levels, most strikingly 
for Aldoa, but NMR analysis showed that the DGCR8-/- cells secreted more lactate, 
indicative of a higher rate of glycolysis.  Therefore the same miRNAs that control 
the ESC cycle also influence the metabolic status of the ESCs.  Of the miRNAs 
studied, miR-295 had the most indirect/direct targets in the DIGE studies, and 
had the greatest effect upon the glucose metabolism enzymes.  The lower 
glycolytic activity of the DGCR8-/- mESCs compared to the WT indicate that the 
DGCR8-/- may be using a compensatory mechanism for energy generation. Using 
metabolomics, we discovered potential pathways that the DGCR8-/- mESCs may 
be using and formulated a putative model for DGCR8-/- cell metabolism, using 
glutamine as their main source of energy production as opposed to glucose . 
 





Figure 42-  Summary figure of possible glutaminolysis in DGCR8
-/-
 mESCs.  Red arrows represent protein expression, green arrows represent mRNA expression and blue 
arrows represent metabolite changes in DGCR8
-/-
 mESCs in relation to wild type
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Summary of denaturing agents in protein solubilising buffers 
 
Class Common reagents General characteristics 







Disrupt disulfide bonds 
between cysteine residues 
Detergents  










Cell densities for transfections 
 
 Per transfection Number of cells per flask 
Protein 2 T75 1.2 x 106 
RNA 2 T25 4 x 105 




Mastermixes for transfections 
 
Flask size T25 T75 
Mastermix 
A 
198ul of Transfection 
medium 
 
1.5ul of mimic/control  
(25μM) 
397ul of Transfection 
medium 
 




200ul of Transfection 
medium 
 
8ul of Lipofectamine 
RNAiMAX* 
400ul of Transfection 
medium 
 
16ul of Lipofectamine 
RNAiMAX* 
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Table 4 






















































FGF5 TG TCTCAGGGGATTGTAGGA 
 



























Taqman microRNA/gene expression assays 
 
 
Gene expression assay Cat No. 
Aldehyde dehydrogenase 2 (Aldh2) Mm00477463_m1 
Cyclin dependent kinase inhibitor (Cdkn1a) Mm04205640_g1 
Fructose bisphosphate aldolase A (Aldoa) Mm00833172_g1 
Hypoxia-inducible factor 1-α (Hif1α) Mm01198376_m1 
Isocitrate dehydrogenase 2 Mm00612429_m1 
Nanog Mm02384862_g1 
Oct4 Mm00658129_gH 
Peroxisome proliferator-activated receptor α 
(PPARα) 
Mm00440939_m1 
PTEN-like mitochondrial phosphatase (PTPM1) Mm00458631_m1 
Serpin h1 Mm00438058_g1 
Smooth muscle actin (SMA) Mm01546133_m1 
SM22 Mm00441661_g1 
Superoxide dismutase 1 (SOD1) Mm01344233_g1 
Sox2 Mm03053810_s1 
Vimentin Mm01333430_m1 
























Table   
Primary antibodies Company (Catalogue 
Number) 
Anti-Oct4 (mouse monoclonal IgG) Santa Cruz (sc-5279) 
Anti-Nanog (rabbit polyclonal IgG) Abcam (ab80892) 
Anti-Sox2 (rabbit polyclonal IgG) Millipore (ab5603) 
Anti-Serpin/hsp47 (rabbit polyclonal IgG) Abcam (ab13519) 
Anti-SOD1 (rabbit polyclonal IgG) Santa Cruz (sc-11407) 
Anti-mnSOD (rabbit polyclonal IgG) Upstate (06-984) 
Anti-Peroxiredoxin 3 (mouse monoclonal IgG) Abcam (ab16751) 
Anti-Malate dehydrogenase (rabbit polyclonal IgG) Abcam (ab96193) 
Anti-Pyruvate dehydrogenase E1α (rabbit polyclonal IgG) Abcam (ab92696) 
Anti-Protein disulfide isomerase (mouse monoclonal IgG) Stressgen (SPA-891) 
Anti-ALDOA (rabbit polyclonal IgG) Sigma Aldrich (av48130) 
Anti- Isocitrate dehydrogenase (rabbit polyclonal IgG) Abcam (ab154932) 
Anti-Tubulin (rabbit polyclonal IgG) Abcam (ab4074) 
Secondary antibodies 




Anti-mouse IgG, HRP-linked 
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Table 7 
 
DIGE analysis of wild type and DGCR8-/- mESCs at baseline 
 
 



































9 NADH dehydrogenase 
[ubiquinone] 1 alpha 







100.0% 2 3 6 1.63 1.10E-02  CDS 
15 Succinate 
dehydrogenase 








99.0% 1 1 1 -1.52 1.60E-04   









100.0% 6 7 15 1.68 3.00E-05  






























100.0% 19 27 48 1.77 9.40E-06  
Glycolysis   



































57.1/6.2 100.0% 10 15 25 -1.57 1.20E-04  








































100.0% 2 2 2 2.35 2.00E-05 3'UTR 
Energy i.e ATP 









100.0% 5 6 11 1.57 6.60E-04 3' UTR 


















100.0% 10 13 21 1.75 1.80E-05 3'UTR 
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component of branched-













95.0% 1 1 1 -1.51 6.50E-05  








100.0% 2 2 2 1.57 1.30E-02 CDS 
 Cytosolic 















100.0% 2 2 4 -1.57 3.00E-03  








100.0% 3 3 6 -2.08 6.80E-05  
51 DnaJ homolog subfamily 





39.6/5.5 100.0% 7 10 16 -1.59 1.20E-04  






100.0% 3 4 5 -1.53 6.20E-06  




















100.0% 26 31 54 1.73 1.30E-05  
73 DnaJ homolog subfamily 














100.0% 11 11 17 1.96 1.70E-03  
84- 78 kDa glucose- GRP78_M 70.4/5.0
1 
73.3/5.3 100.0% 32 51 88 1.74 2.20E-05  
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85/
87 











100.0% 28 33 56 1.55 2.30E-04  
88-
89 








100.0% 8 8 11 1.74 1.1E-02  








100.0% 31 40 63 1.53 3.30E-02  
Aid Chaperone function 


































100.0% 12 13 24 2.08 2.10E-02  








100.0% 4 4 5 1.65 6.80E-05  






17.8/5.7 100.0% 4 6 12 -1.75 7.80E-04  








95.0% 5 5 9 1.69 2.10E-05 3'UTR 










100.0% 3 3 5 1.5 3.90E-
03 
 
28 Mediator of RNA 
polymerase II 







100.0% 3 3 5 -1.63 1.80E-
02 
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100.0% 7 8 14 -1.65 6.20E-
06 
 






100.0% 11 14 22 1.55 1.00E-
04 
 
91 Far upstream element-























RNA Processing  
4 U6 snRNA-associates 







100.0% 2 2 3 -1.59 2.30E-
04 
CDS 
24 Transcription factor 







100.0% 3 3 5 -1.8 1.60E-
02 
 
76 Cleavage stimulation 































































100.0% 9 16 26 -2.11 9.50E-
06 
 
31 Eukaryotic translation 







100.0% 5 6 11 -1.83 3.90E-
06 
 










100.0% 4 4 8 -1.65 6.20E-
06 
 








90.0% 1 1 1 2.03 6.70E-
04 
 








100.0% 10 12 19 1.75 1.80E-
05 
 









100.0% 14 19 28 1.78 9.20E-
03 
 
CELL CYCLE ASSOCIATED 










































100.0% 4 9 17 -1.74 6.20E-
06 
 








100.0% 2 2 3 -1.91 9.40E-
06 
 















72.5/5.3 100.0% 25 32 50 1.71 7.30E-
04 
 









100.0% 3 6 11 -1.53 8.80E-
06 
 
ACTIN ASSOCIATED  




100.0% 4 5 6 -1.54 5.40E-
04 
 










100.0% 10 18 36 1.64 1.10E-4  
78 Adenylyl cyclase-







100.0% 6 7 10 0.89 1.90E-
05 
 


















65 CD2 antigen cytoplasmic 





67.1/4.5 100.0% 5 5 7 1.65 3.10E-
03 
3' UTR 
CALCIUM SIGNALLING  
2 Protein S100-A6 S10A6_M
OUSE 
10.1/5.3 10.1/5.3 95.0% 1 1 2 1.89 1.30E-
02 
 
33 Calcineurin B 



















100.0% 3 4 7 1.63 1.10E-
02 
 




18.0/5.3 100.0% 4 5 6 -1.59 1.50E-
03 
 








100.0% 4 5 6 -1.57 1.10E-
04 
 








100.0% 6 7 12 -1.5 9.80E-
05 
 

















100.0% 14 19 33 1.56 7.90E-
05 
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Table 8 
 
Average percentages (± standard deviation) of metabolites produced by 




Negative values indicate that metabolites are excreted, whereas positive values 
indicate that metabolites are taken up by the cells.  Values have been normalised 
to cell numbers after 48 hours of growth.  Metabolites with a significant 
difference between the two cell types are highlighted in red.  p-values were 
calculated using an independent student’s t-text, a value of less than 0.05 was 
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Table 9 
 
DIGE analysis of DGCR8-/- mESCs transfected with ESCC miRNAs 
 











































22.60% 4 4 6 1.08 5.00E-
01 
  






32.90% 5 7 12 1.16 4.60E-
02 
1 ** 


















49.30% 15 22 40 1.13 1.70E-
01 
2 ** 







60.00% 16 24 42 1.47 2.20E-
04 
4 * 






28.20% 7 9 14 1.21 1.70E-
02 
  






57.40% 17 23 50 1.36 2.50E-
02 
1 * 






40.60% 14 20 33 1.07 3.10E-
01 
  
42 Propionyl-CoA PCCB_M 58.4/6.53 54.3/7.5 20.20% 9 10 17 1.36 2.70E-   
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carboxylase beta chain, 
mitochondrial 


















73.90% 26 39 65 -1.47 5.90E-
03 
1 * 
36 Pyruvate dehydrogenase 
E1 component subunit 



















42.60% 24 29 45 -1.17 2.60E-
01 
  



























25.30% 7 8 11 1.41 5.00E-
03 
1 * 
50 Peroxisomal targeting 





8.14% 4 4 6 1.18 3.00E-
02 
1 ** 
Energy i.e ATP  metabolism 
19 GTP:AMP KAD4_ 25.1/7.02 27.3/8.3
9 
15.20% 4 6 8 1.21 6.20E-
02 
2 ** 




















66.50% 18 30 56 -1.12 2.70E-
01 
  
8 60S ribosome subunit 






57.20% 7 11 20 -1.1 2.20E-
01 
  
25 DnaJ homolog subfamily 





33.80% 10 15 25 1.5 1.70E-
04 
4 ** 
37 DnaJ homolog subfamily 












10.40% 7 7 10 -1.05 8.6E-01   






41.30% 30 46 75 -1.22 5.80E-
01 
  










Mitochondrial  Transport 
7 Mitochondrial import 



























26.90% 17 20 31 1.04 7.20E-
01 
  
























28.1/5.73 24.1/5.4 28.80% 8 12 22 1.27 1.10E-
01 
1 *** 






13.00% 4 5 9 1.15 8.10E-
01 
  
ASSOCIATED WITH TRANSCRIPTION/TRANSLATION 
DNA processing 






38.10% 4 4 5 -1.01 9.10E-
01 
  




































25.20% 17 20 32 1.1 3.40E-
01 
1 * 







22.80% 15 20 33 -1.17 1.70E-
01 
  






13.90% 6 6 9 -1.2 1.20E-
02 
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6 Eukaryotic translation 



































38.00% 23 31 49 -1.05 5.70E-
01 
  
CELL CYCLE   
7 S-phase kinase-















16.90% 8 9 13 -1.2 1.20E-
02 
  












16 Meiotic nuclear division 





27.80% 6 6 10 1.15 1.80E-
02 
  
APOPTOSIS          
46 Apoptosis-inducing AIFM1_ 66.8/7.27 61.7/8.7 36.80% 20 28 44 1.13 1.60E- 1 ** 
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37.5/5.94 39.5/5.4 26.10% 10 10 16 1.08 3.10E-
01 
1 * 







24.70% 29 33 57 -1.21 6.90E-
02 
  
57 LIM domain and actin-





21.20% 16 19 30 -1.03 8.90E-
01 
  







39.10% 19 31 51 1.23 2.30E-
01 
  








51.30% 14 15 25 1.23 3.90E-
02 
3 * 













26.30% 9 12 19 1.16 5.20E-
02 
2 * 






52.80% 19 21 33 1.07 1.80E-
01 
3 * 
40 V-type proton ATPase 





14.50% 8 9 16 1.22 1.60E-
01 
1 * 








* denotes p<0.05, ** denotes p<0.01, *** denotes p<0.001 p-values were calculated using an one-way ANOVA




Efficiency of transfections based on average Ct values from qPCR(n=6) 
 
 
  Average Ct values 








1 21.805 33.929 17.703 
2 21.762 30.791 17.312 




1 28.492 33.943 21.333 
2 28.362 34.368 22.696 
3 28.269 36.144 21.671 
 
miR-294 
1 24.138 34.938 19.497 
2 24.049 35.338 21.320 
3 24.227 37.641 19.625 
 
miR-295 
1 21.272 32.580 17.272 
2 21.335 31.912 17.995 




1 39.425 Undetermined 27.961 
2 Undetermined Undetermined 29.607 
3 38.465 Undetermined 28.227 
 
U6 
1 20.544 19.137  
2 20.389 19.975  
























Average cell numbers of the DGCR8
-/-
 mESCs transfected with the ESCC miRNAs 
 





 (x 10⌃6) 
Standard 
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Table 12 
 
Secretome analysis of DGCR8-/- mESCs transfected with the ESCC miRNAs 
 Untransfected Control miR-291a miR-291b miR-294 miR-295 miR-302d  
 
ANOVA 







Choline 0.18 0.06 0.13 0.08 0.21 0.05 0.26 0.08 0.23 0.07 0.25 0.11 0.26 0.07 0.272 
 
Glucose 1.41 1.22 1.19 1.00 1.44 1.36 1.48 1.58 1.87 0.98 1.19 0.62 2.09 2.05 0.957 
Glutamine 1.23 0.39 1.41 0.07 1.03 0.69 1.24 0.75 1.29 0.49 0.94 0.46 1.31 1.00 0.951 
Histidine 0.04 0.02 0.05 0.02 0.04 0.05 0.05 0.04 0.06 0.02 0.03 0.02 0.05 0.06 0.942 
Iso-Leucine 0.16 0.10 0.16 0.07 0.14 0.14 0.14 0.14 0.17 0.06 0.11 0.06 0.23 0.21 0.899 
Leucine 0.22 0.09 0.22 0.09 0.22 0.16 0.23 0.17 0.26 0.10 0.20 0.11 0.30 0.23 0.97 
Phenylalani
ne 
0.07 0.05 0.04 0.06 0.05 0.08 0.05 0.08 0.06 0.04 0.04 0.04 0.09 0.11 0.953 
Pyruvate 0.34 0.05 0.38 0.14 0.42 0.12 0.46 0.08 0.46 0.10 0.43 0.14 0.46 0.06 0.585 
Tyrosine 0.06 0.05 0.06 0.04 0.05 0.08 0.05 0.07 0.07 0.03 0.05 0.03 0.09 0.09 0.962 






Acetate 0.30 0.09 0.26 0.01 0.32 0.05 0.36 0.18 0.32 0.11 0.32 0.15 0.32 0.09 0.958 






























Lactate 6.20 1.69 5.90 1.12 8.94 1.95 10.1
4 
1.79 9.74 1.82 9.88 1.80 8.53 1.31 0.01 
Threonine 0.08 0.14 0.09 0.24 0.27 0.29 0.57 0.28 0.37 0.24 0.49 0.16 0.29 0.26 0.072 
s.d represents standard deviation 
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Intracellular metabolite analysis of DGCR8-/- mESCs transfected with the ESCC miRNAs 
 
 Control miR-294 miR-302d ANOVA 
Mean s.d. Mean s.d Mean s.d. 
Acetate 0.89 0.55 1.36 1.02 1.22 0.89 0.73 
ADP+ATP 1.41 0.34 2.37 0.81 2.07 0.57 0.13 
Alanine 3.70 1.13 2.72 1.17 2.01 0.53 0.01 
Asparate 0.31 0.16 0.24 0.09 0.25 0.20 0.80 
Choline 0.08 0.02 0.09 0.03 0.11 0.10 0.79 
Creatine 0.83 0.07 1.27 0.41 1.29 0.31 0.10 
Formate 0.72 0.50 1.06 0.53 0.84 0.37 0.60 
Fumarate 0.05 0.01 0.11 0.07 0.08 0.04 0.25 
Glucose 5.65 2.31 6.75 2.83 5.03 2.51 0.64 
Glutamate 5.17 0.57 8.60 2.65 6.94 0.88 0.05 
Glutamine 4.48 1.01 5.23 1.66 4.41 0.72 0.58 
Glycine 4.19 2.41 2.24 0.65 1.86 0.65 0.11 
Glyerophosphocholin
e 
0.35 0.23 1.04 0.69 0.73 0.22 0.14 
Lactate 7.56 2.61 19.87 5.92 17.78 6.01 0.02 
NAD(H) 0.14 0.02 0.28 0.13 0.36 0.12 0.04 
Phosphocholine 2.93 0.24 4.18 1.23 4.06 1.52 0.28 
Phosphocreatine 0.77 0.17 1.25 0.70 1.06 0.08 0.31 
Succinate 0.23 0.04 0.45 0.15 0.36 0.11 0.06 
s.d represents standard deviation 
 





Proteins identified in both DIGE studies 
 
 
Protein name  Accession 
Number 
DGCR8-/- vs Wild Type Targeted by miRNAs 
based on proteomics 
Predicted 
target of...*  
METABOLISM  
Oxidative phosphorylation 
Electron transfer flavoprotein subunit beta ETFB_MOUSE 1.68 miR-291b, 294, 295, 
302d 
 





Glyceraldehyde-3-phosphate dehydrogenase G3P_MOUSE 1.59 miR-291a, 291b, 
294, 295, 302d 
miR-302d5 
Fructose-bisphosphate aldolase A ALDOA_MOUSE 1.58 miR-295  
Fatty Acid Associated 
Delta (3,5)-Delta(2,4)-dienoyl-CoA isomerase, 
mitochondrial 
ECH1_MOUSE 1.67 miR-295  
CHAPERONE 
Peptidyl-prolyl cis-trans isomerase A PPIA_MOUSE -1.58   
Heat shock cognate 71kDa protein HSP7C_MOUSE 1.74   
REDOX SIGNALLING 
Peroxiredoxin-1 PRDX1_MOUSE 2.08 miR-291a, 291b, 295, 302d 
ASSOCIATED WITH TRANSCRIPTION/TRANSLATION 
DNA processing 
Histone H4 H4_MOUSE 1.5  miR-291b1 
Protein synthesis 
  190 
Eukaryotic translation initiation factor 5A-1 IF5A1_MOUSE -2.11 miR-291a, 291b, 
302d 
 
SMOOTH MUSCLE ASSOCIATED    




Cytosol aminopeptidase AMPL_MOUSE 1.62  miR-
291a4,291b4,29
44, 2954, 302d4 
 
Information taken from five different microRNA databases, Targetscan1, MicroRNA.org2, DIANA3, mirwalk4 and mirnamap5.  Dec, 2013
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